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                                                      SUMMARY 
Cancer is one of the leading causes of death around the world, with lung, breast 
and prostate cancer being the most commen cancers. Most of current cancer treatments 
are associated with various side effects such as depression, fatigue, hair loss, nausea, 
infection, fertility problems, anemia, and myelosuppression. Therefore, there is an unmet 
need to develop new and more potent anticancer therapeutic agents with less off-target 
toxicities. This thesis documents efforts at the design and synthesis of different classes of 
HDAC inhibitors (HDACi) as promising therapeutic agents in cancer therapy. These 
HDACi are anticpated to accumulate at the site of tumor due to selective tissue/cell 
distribution conferred on them by ligands, known to accumulate in certain tissues or 
target receptors that are overexpressed on tumor cells, incorporated into their the cap 
group. 
FDA approved macrolide, azithromycin, is known to accumulate in macrophage 
cells. Macrophage cells are known to have a high concentration in lung, hence, 
azithromycin has the potential to target and acuumulate in lung tissue. An unpublished in 
vivo data in our lab, showed that azithromycin maintains its lung accumulation after 
being modified and attached to HDACi moiety. Thus, we hypothesized conjugating the 
HDACi to azithromycin can lead to their delivery to lung tissues. To this end, in the 
second chapter, we designed and synthesized three different classes of azithromycin 
conjugated hydroxamic acid derived HDACi and evaluated their HDAC inhibitory 
potency and anti-proliferative activity in lung (A549) and breast (MCF-7) cancer cell 
lines.  
It is believed that isoform selective HDACi may be endowed with less off-target 
toxicities and better therapeutic outcome and efficacy compared to pan HDACi which 
have no selectivity toward different HDAC isoforms. To evaluate this hypothesis, in the 
third chapter, we designed and synthesized isoform selective azithromycin conjugated 
 xx 
HDACi, by replacing the hydroxamic acid zinc binding group with the N-(2-amino-5-
(thiophen-2-yl)phenyl)acylamide  zinc binding group which is a HDAC1 and HDAC2 
selective. Additionally to determine these compounds ability to target lung tissue and 
protect it from metastasis, we tested the lead compound in a model of lung metastasis of 
breast cancer using spontaneous mouse mammary tumor model MMTV-PyMT-Tg. The 
in vivo study results showed that there was a greater tumor regression in mice that were 
treated with N-(2-amino-5-(thiophen-2-yl)phenyl)acylamide derived HDACi compared to 
hydroxamic acid derived HDACi. Additionally this class of HDACi was able to protect 
the lung tissue from metastasis better than its hydroxamic acid analogue.     
 The fourth chapter focuses on continuation of prior SAR study on design 
multiple ligand compounds with selective estrogen receptor modular (SERM) and 
HDACi activities. In this study tamoxifen, an estrogen receptor (ER) antagonist, with a 
high binding affinity for ER, was used as the HDACi cap group. These antiestrogen 
equipped HDACi are expected to be better uptaken by ER positive breast cancer cells 
possibly due to tamoxifen affinity for binding to ER. This selective uptake is anticipated 
to eventually lead to an improved antiproliferative activity. MTT assay results confirmed 
the hypothesis. Hydroxamic acid derived HDACi showed about 4 fold more cytotoxicity 
toward ERα positive breast cancer cells compared to ERα negative breast cancer cells. 
Two of these SERM HDACi conjugates are currently being studied in animal models.   
The fifth chapter illustrates bifunctional STAT3/HDAC inhibitors for treating 
STAT3 activated cancers, such as acute myeloid leukemia. In this study, pyrimethamine, 
a selective STAT3 inhibitor was used as the HDACi cap group. We hypothesized that 
design multiple ligand compounds comprising STAT3 inhibitor and HADCi will 
integrate direct STAT3 and HDAC inhibition, and downregulation of Mcl-1 within a 
single molecular template. These bifunctional compounds can be potential inhibitors of 







               Cancer is one of the leading causes of death worldwide and is the second cause 
of death after cardiovascular diseases in the United States [1], [2]. According to National 
Cancer Institute there will be approximately 1,685,210 new cases of cancer, and 595,690 
cancer deaths which is equal to 1600 deaths per day only in United States in 2016 [3]. 
 Cancer develops when there is an environmental or inherited mutation or damage 
in the genetic materials of cells such as proto-oncogenes that are responsible for coding 
for proteins involved in cell proliferation and differentiation or tumor suppressor genes 
inhibit cancer cell growth or induce apoptosis. Normal cells grow, divide, die, and 
eventually are replaced by new cells. However, cancer is an uncontrollable cell growth, 
division and proliferation that is resistant to normal cell death, consequently leading to 
the formation of an abnormal cell mass or tumor [4]. Cancerous cells can become 
metastatic with time and migrate to other parts of body as well [5]. In fact tumor cells 
ability to sustain proliferating signaling and replicative immortality helps them to evade 
tumor growth suppressors, activate invasion and metastasis, induce angiogenesis and 
finally resist cell death, which is why it is difficult to eradicate tumor growth and cure 
cancer [6].  
The most common cancers in US are that of the lung, bronchus, colorectal and 
prostate (in men), and breast (in women). Together, these cancers account for about 46% 
of cancer prevalence with the lung cancer being the most prevalent with 27% occurrence 
[1]. Moreover, cancer mortality is higher for men rather than women and it has its highest 
rate for African American men and lowest rate for Asian/Pacific Islander women [7].   
 2 
Surgery, chemotherapy, and radiation are the most common cancer treatments [8], 
with hormone therapy, immunotherapy or targeted therapy serving as other choices of 
treatment. Surgery is used to remove the tumor as well as other cells or parts of the body 
that were affected by tumor cells. For example, a common surgical procedure is the 
removal of part or all of breast or prostate gland in the case of breast and prostate cancers. 
Chemotherapy on the other hand is the administration of drugs orally or intravenously to 
kill tumor cells or to slow their growth [9]. Additionally, radiation is another choice of 
treatment used in combination with other treatments or as a standalone therapy to treat 
cancer. Surgery and radiotherapy are the most effective therapy for non-metastatic 
cancers that are limited to certain areas of the body and has not yet spread to other 
tissues, whereas, chemotherapy and hormone therapy are the only treatments for 
metastatic cancers since they can reach all the organs in the body through blood 
circulation [10]. Unfortunately, these treatments are accompanied with side effects such 
as nausea, vomiting, fatigue, anemia, and lymphedema due to their off-target toxicities to 
healthy cells. Furthermore, emergence of multi-drug resistance in addition to cytotoxicity 
of current anticancer agents brings up the critical need for developing targeted cancer 
drugs.                        
1.2. Epigenetics 
Epigenetics is mitotically and meiotically heritable changes in DNA expression 
and histone modification without alteration to gene sequences that regulate cell function. 
Epigenetic silencing is caused by RNA- associated silencing, chromatin remodeling and 
most importantly DNA methylation, and histone modifications such as methylation, 
acetylation, phosphorylation, ubiquitination and sumoylation. These processes are 
associated with dysfunctions in transcriptional activation. Aberrant regulation of the 
epigenome results in dysfunction in the control of gene expression which can present in 
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various physiological conditions. Disruption of these regulating systems can lead to 
various diseases including cancer [11]. 
 Nucleosomes are the basal units of chromatin, and are made of five histone 
proteins. Nucleosome core consists of the core histone octamers H2A, H2B, H3 and H4. 
Core histones are involved in both histone-histone interactions as well as histone-DNA’s. 
H1 on the other hand, is a linker histone and is responsible for chromatin compaction and 
maintaining chromosome structure.   The state of chromatin is very important for many 
cellular mechanisms such as transcription, translation and repair. Chromatin state is 
determined by changes in amino terminal tails of the histones.  Around 30-40% of core 
histone amino acids are positively charged lysine and arginine. The high density of 
positive charge, along with the undetectable secondary structure of free histones, led to 
the presumption that N-termini of histones operate by binding as unstructured coils to 
DNA components in nucleosome [12].   
The histone amino tail groups are believed to interact with negatively charged 
DNA backbone or other chromatin related proteins. The DNA interaction with chromatin 
can facilitate or hinder cellular processes like transcription, translation and apoptosis 
[13]. Histone tail post-translation modifications such as methylation, acetylation, 
phosphorylation, and ubiquitination have been the subject of many studies [14].  
The focus of this thesis is on histone deacetylation, the link between aberrant 
histone deacetylation tumorigenesis and design of small molecules which promote 
histone acetylation through inhibition of the deacetylase activities of various histone 
deacetylase isoforms. The sections below are focused on histone deacetylation and its 
inhibition in efforts aimed at identifying tumor selective histone deacetylase inhibitors.  
Additionally, it focuses on different methods for HDACi specific tissue delivery to 
enhance their potency and lower their off-target toxicities.   
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1.3. Histone acetylation 
Nucleosome consists of 146 base pairs of DNA wrapped around core histone 
octamer [15]. Nucleosome has two copies of each core histone. All four core histones in 
nucleosome are subject to post acetylation of their terminus amino groups of specific 
lysine residues (Figure 1.1) [16].  Core histones H2B, H3 and H4 each has 16 possible 
isoforms including 1 non-acetylated, 4 mono-acetylated, 6 di-acetylated, 2 tri-acetylated 
and 1 tetra-acetylated. H2A only has 2 isoforms: 1 non-acetylated and 1 mono-acetylated. 
Thus altogether there are 16 x 16 x 16 x 2 = 8192 possible combinations within every 
single nucleosome [14]. Furthermore, H1 histone protein is associated with each 
nucleosome and plays an important role in DNA level of condensation [17].  
The idea of histone acetylation and its relation with gene transcription was suggested 
about five decades ago [18]. Histones are acetylated by histone acetyl transferase enzyme 
(HAT) which transfers the acetyl group from acetyl coenzyme (acetyl CoA) to the 
terminal amine group of histone lysine residues. Histone acetylation revamps the 
structure of chromatin and therefore influences transcription as well as DNA replication. 
Acetylation affects initiation and elongation of transcription by diminishing the 
interactions between DNA and histone leading to an open chromatin and more accessible 
transcription factors [19]. In vitro studies have revealed that acetylation of lysine residues 
of histone promotes binding of particular transcription factors to DNA and therefore 






Figure 1.1. Nucleosome consists of 4 core histones, H2A, H2B, H3, H4, and the linker 
histone H1. Histones are the main proteins of chromatin which DNA winds around. 
These core histones are subject to post-translation modifications, one of which is 
acetylation of the amine group of specific terminal lysine residues by histone acetyl 
transferase enzyme. Adding acetyl group on positively charged lysine residues results in 
less electrostatic interactions between histone and negatively charged DNA leading to an 
open chromatin which is accessible transcription factors.     
1.4. Histone deacetylation 
Dynamic acetylation and deacetylation of histones is one of the mechanisms of 
regulation of gene expression. Histone acetylation status is controlled by the activities of 
histone acetyl transferases (HAT) and histone deacetylase (HDAC) enzymes. HDACs are 
functionally opposing to HATs as they hydrolyze the acetyl groups of acetylated lysine 
residues on the tail of histones [20]. HDAC isoforms not only remove the acetyl group 
from the tail of histones, they also bind to and deacetylate other non-histone proteins that 
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are responsible for regulating cell growth, differentiation, transcription, apoptosis and 
tumorigenesis inhibition: such as p53, p21, p65, E2F, STAT3 and NF-ҝB [21]. Histone 
deacetylation has a vital role in cancer development by regulating expression of proteins 
that are involved in initiation and progression of cancer (Figure 1.2).    
 




The hydrolysis of the acetyl group increases the net positive charge on histones, 
resulting in enhanced electrostatic interactions with the negative charge of DNA 
backbone and ultimately compacting chromatin (Figure 1.3). 
Figure 1.3. HDAC enzymes are functionally opposite to the HAT enzymes. They 
hydrolyze the acetyl groups from the amine moiety of terminal lysine residues of 
histones. This leaves a positive charge on histone and induces electrostatic interactions 
with negatively charged DNA, resulting in condensed chromatin less accessible to 
transcription factors. HDACi impede HDAC isoforms functions and shift the equilibrium 
towards an open and accessible chromatin.  
 
           Apart from cancer, HDAC activities have also been implicated in survival of 
Plasmodium spp., the causative organisms of malaria, neurodegenerative diseases, 
embryogenesis, immunological responses and cell differentiation. Impeding the activity 
of HDAC enzymes by using HDACi shifts the equilibrium toward more open and 




1.4.1. Histone deacetylase isoforms  
There are 18 isoforms of HDAC. These isoforms are divided into four classes 
depending on their sequence homology to their yeast homologs as well as their cellular 
location. Classes I, II, IV are zinc atom (Zn2+) dependent while class III is nicotinamide 
adenine dinucleotide (NAD+) dependent, and is not the focus of this dissertation. Class I 
isoforms (HDAC1 - 483 AA, HDAC2 - 488 AA, HDAC3 - 423 AA, HDAC8 - 377 AA) 
are located in nucleus and are homologous to yeast Rpd3 protein. Class II isoforms are 
divided into two subclasses. Class IIa isoforms (HDAC4 - 1084 AA, HDAC5 - 1122 AA, 
HDAC7 - 855 AA, HDAC9 - 1011 AA) have both nucleus and cytoplasmic localizations 
while class IIb isoforms (HDAC6 - 1215 AA, HDAC10 - 699 AA) are mainly localized 
in cytoplasm. Class IIb isoforms are the only isoforms with two catalytic active sites [21]. 
The only isoform of class IV is HDAC11 (with 347 AA) can be found both in nucleus 
and cytoplasm (Table 1.1) [24].  
 
Table 1.1. HDAC isoforms with their size, function, localization, and selected examples 




























Table 1.2. HDAC isoforms with their size, function, localization, and selected 
examples of their target proteins (continued) 
 















Cardiovascular growth and 
function/ Gluconeogenesis/ 
Cardiac myocytes and 






































1.4.1.1. Class I isoforms 
Class I HDAC isoforms are located in the nucleus. They are found in many 
human tissues and cell lines [28].  Class I isoforms can be divided into three subclasses, 
class Ia (HDAC1 and HDAC2), class Ib (HDAC3) and class Ic (HDAC8) [26], [27]. 
HDAC1 and HDAC2 interact with each other, and form the catalytic core of multiprotein 
complexes, while HDAC3 is in complex with nuclear receptor corepressors [29]. 
HDAC8, with less tissue expression compared to other class I HDAC isoforms, is an 
unusual member of class I family. According to its sequence homology it should be 
classified as a class I member, but based on phylogenetic analysis it is on the border line 
of class I and class II. The main difference between HDAC8 and other class I isoforms is 
that HDAC8 lack the 50-111 amino acid terminal domain which is necessary for other 
class I isoforms to modulate their enzyme activity and localization [30]. Furthermore, 
unlike other class I members it is not phosphorylated by Casein kinase II (CKII) but by 
protein kinase A (PKA) which is involved in regulation of catalytic activity of HDAC8 
[31].  
Class I HDAC isoforms are activated by other mechanisms including inositol 
phosphate which are derived from membrane phospholipids. Class I HDAC isoforms 
regulation by inositol phosphate was first reported by the discovery of inositol 1,4,5,6-
tetrakisphosphate (Ins(1,4,5,6)P4) in the crystal structure of HDAC3:SMRT [32]. Inositol 
phosphates locate in a binding pocket between HDACs and co-repressor proteins and 
meditate their interactions [32].  
1.4.1.2. Class II isoforms        
Class II isoforms are homologues to Hda1 yeast protein. This class of HDAC 
isoforms shuttle between nucleus and cytoplasm and their expression level varies 
between different tissues. Class IIa HDAC isoforms are involved in differentiation 
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process, and is believed their deacetylation activity is due to their interaction with 
HDAC3 [33].  
The unique property of class IIb isoforms is the presence of two catalytic active 
sites [22]. HDAC6 has a C-terminal zinc finger domain with cysteine and histidine rich 
regions that binds to proteins. However, since HDAC6 is mainly located in cytosol it is 
not counted strictly as an epigenetic enzyme. HDAC6 does not deacetylase histones. The 
anti-cancer activity of HDAC6 inhibitors, such as tubacin and Tubastatin A, is not due to 
the perturbation of epigenomes which leads to re-expression of tumor suppressor genes, 
but most likely due to regulation of protein degradation through aggresome and 
controlling the Hsp90 chaperone activity [34].  
HDAC6 is the only class II isoform that is able to deacetylate α-tubulin [35]. 
Furthermore, inhibition of HDAC6 results in acetylation of HSP90 and disruption of its 
chaperone activity. HDAC6 has a key role in degradation of misfolded proteins by using 
its ubiquitin-binding domain [36]. Additionally, HDAC6 is involved in tumorigenesis 
especially in Ras-induced transformation [37].  
HDAC10 is the least characterized and the last isoform of class II that was 
discovered [38]. Even though it is in the same subclass as HDAC6 they are different in 
some aspects. For example, unlike HDAC6 that mostly resides in the cytoplasm and 
possesses two independent active sites, only one of the HDAC10 catalytic site is active 
and the other one is catalytically inactive. HDAC10 can be found both in cytoplasm and 
nucleus [38].     
1.4.1.3. Class IV isoforms 
The only isoform of class IV is HDAC11. HDAC11’s structure is related to both 
class I and class II HDAC isoforms. It is mostly found in the nucleus and in tissues such 
as brain, heart, kidney, testis and skeletal muscle. HDAC 11 is a promising target for 
autoimmune diseases [39].  
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1.5. Histone Deacetylase inhibition 
Since HDAC enzymes induce gene silencing and transcription factors repression, 
they are implicated in various diseases including cancer, malaria, and leishmanial [20]. 
Inhibition of HDAC activity can reverse epigenetic silencing associated with cancer. As a 
result, HDAC isoforms have become promising targets for drug discovery and 
development. HDACi induce cellular differentiation and migration, cell cycle arrest 
(mostly at the G1/S checkpoint) and apoptosis [40], leading to growth arrest, DNA 
damage and tumor cell death. HDACi boost host immune response and decrease 
angiogenesis in tumor [41], [42].  
1.6. Pharmacophoric model of HDACi 
Despite all the structurally differences among HDACi, they all follow a well-
established pharmacophoric model (Figure 1.4). They all are comprised of three distinct 
groups, a variable surface recognition cap group that interacts at the protein surface, a 
linker group which travels through the tunnel of the active site, and a zinc binding group 
(ZBG) that chelates the zinc ion at the active site of the HDAC enzyme (Figure 1.5) [43]. 
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Figure 1.4. Pharmacophoric model of HDACi with selected examples of each group. All 
HDACi have surface recognition group that interacts with amino acid at the protein 
surface, a linker group that traverses the active site and a zinc binding group that chelates 
zinc atom in the active site pocket of the enzyme.  
 
Recognition 
 cap group  
Linker group  Zinc binding 
group (ZBG) 
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Figure 1.5. Selected examples of HDACi. Most HDACi follow a common three-motif 
pharmacophoric model comprising of recognition cap group, linker moiety and ZBG. 
(Note the color coding, purple indicates the cap recognition group, green shows the linker 
groups and blue indicates the ZBG).  
1.6.1. Recognition cap group 
The recognition cap group is generally a hydrophobic group that interacts with 
amino acids at the entrance of the active site and has an important role in inhibitory 
potency and isoform selectivity of HDACi [23].  
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Cyclic-peptide and depsipeptide recognition cap groups have been shown to 
impact class I isoform selectivity to HDACi. Their selectivity towards class I isoforms is 
due to their similarity to and/or imitation of the natural substrates of this class of HDAC 
proteins [44].  Natural products such as trapoxin A (TPX) (Figure 1.6), chlamydocin and 
Cyl-2 show great selectivity for class I isoforms. Romidepsin (depsipeptide, FK-228) is a 
FDA approved HDACi that shows a high selectivity for HDAC1 and HDAC2 compared 
to class II isoforms [45]. In addition to the similarities to the natural substrates, existence 
of two loops in class II isoforms prevents binding of bulky cap groups and makes it 
sterically unfavorable for cyclic peptides to bind and interact with the amino acids at the 
surface. The trends show that compounds with smaller cap groups have less isoform 
selectivity towards class I HDACs compared to the bulky ones. In fact using a bulky 
recognition cap group has turned into a strategy for developing class I isoform selective 
HDACi [23].  
 
                        
Figure 1.6. Chemical structure of trapoxin A, a naturally occurring selective class I 
isoform HDACi [46]. 
1.6.2. Linker group 
The linker group traverses the tunnel leading to the active site and connects the 
surface recognition cap group to the zinc binding group. The linker domain typically 
consists of hydrophobic groups that interact with the lipophilic residues within the tunnel 
leading to the active site. The linker group can be a linear chain or a cyclic chain with 
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saturated or unsaturated bonds. Like two other compartment of the pharmacophoric 
model, this region can be modified to yield isoform selective HDACi as well. However, 
only a few class I selective HDACi have been reported up to date [23].    
1.6.3. Zinc binding group 
 The ZBG, which chelates the Zn2+ ion in the active site pocket, is a major 
determinant of HDACi isoform selectivity and potency. However, the sequence similarity 
near the catalytic metal makes it very difficult to design and synthesize HDACi that are 
selective toward certain isoforms. Figure 1.7 illustrates zinc ion at the base of the 
catalytic pocket of HDAC 1, a class I isoform of HDAC enzymes.  
 
Figure 1.7. Zinc atom in the catalytic pocket of HDAC1, a class I HDAC isoform. Green 
sphere represents zinc atom.  
The most common ZBG is hydroxamic acid. It owes its high potency to its strong 
bidentate chelation of zinc ion. The most well-known example of an HDACi with 
hydroxamic acid-based ZBG is suberoylanilide hydroxamic acid (SAHA) (also known as 
Vorinostat). The second common zinc binding group is alkyl thiol found in naturally 
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occurring depsipeptide prodrugs like largazole, FK228, or spiruchostatins. These 
prodrugs disulfide bridge is reduced to alkyl thiol ZBG upon their administration in vivo, 
resulting in isoform selective HDAC inhibition [45]. The third most common ZBG is the 
benzamide moiety which leads to class I isoform selectivity. Entinostat (MS-275) is a 
benzamide based HDACi which is currently in clinical trials for treating various types of 
cancers [22]. Additionally, there are other ZBGs that are not as common as the previously 
mentioned ones. These less common ZBGs include ketones, fluoroketones, carboxylic 
acids, carboxamide, thioamide, and epoxides (Table 1.2) [44]. 
 
Table 1.2. Selected examples of HDACi with various zinc binding groups [47].  
Zinc binding group Name Isoform selectivity 
Hydroxamic acid Vorinostat (SAHA) Pan inhibitor 
Belinostat (PXD101) Pan inhibitor 
Panobinostat (LBH589) Pan inhibitor 
Abexinostat (PCI 24781) Pan inhibitor 
Pracinostat (SB939) Pan inhibitor 
Givinostat (ITF2357) Pan inhibitor 
Resminostat (4SC-201) Pan inhibitor 





Table 1.2. Selected examples of HDACi with various zinc binding groups 
(continued). 
Alkyl thiol Romidepsin (FK228) Class I 




Fatty acid Valproic acid (VPA) Class I 
Phenylbutyrate Class I and II 
  
 
1.6.3.1. Zinc dependent mechanism of lysine deacetylation 
Finnin et al. [48] was the first to propose a mechanism for zinc dependent lysine 
deacetylation for HDLP which is almost similar for all zinc dependent HDAC enzymatic 
activity (Figure 1.8). In class I HDAC isoforms, the zinc ion in the active site is 
surrounded by two histidine-aspartic acid dyads (His131-Asp166 and His132-Asp173). 
Each histidine has a hydrogen bond with aspartic acid carboxylate oxygen, which is a 
characteristic of a charge-rely system found in the active site. The charge-rely system of 
His131-Asp166 is more buried in the active site than His132-Asp173. His131-Asp166 
makes a hydrogen bind to the zinc bound water molecule. In class II isoforms in one of 
the dyads, one aspartic acid is replaced by asparagine, resulting in His-Asn pair. There is 
also a tyrosine residue (Tyr297) in class I HDAC isoforms that provides a proton. The 
tyrosine residue interacts with two aspartic acids (Asp258 and Asp168) as well as one 
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histidine (His170).  In class II HDAC isoforms, the tyrosine residue is replaced with a 
histidine.  
Lysine deacetylation starts with the zinc ion chelation of the water molecule as 
well as the carbonyl group of the acetyl lysine. The chelated water molecule is activated 
through H-bonding interaction with His131, resulting in nucleophilic attack of the 
carbonyl group of acetylated lysine. The resulting acyl anion is stabilized by the H-
bonding with the hydroxyl group of Tyr297. The acyl anion then undergoes a 
rearrangement which results in formation of an acetate ion as well as a terminal 
ammonium on the terminal lysine residue of histone [49]. 
 
                 
Figure 1.8. Proposed mechanism for lysine residue deacetylation by zinc-dependent 
HDAC enzymes [49]. Zinc atom chelates a water molecule and the carbonyl group of 
acetylated lysine ultimately leading to the hydrolysis of the acetyl group from the 
terminal lysine residues.  
 20 
1.6.3.2. Hydroxamic acid derived HDACi 
Hydroxamic acid based antiproliferative therapeutic agents were the first group of 
HDACi that were introduced. Hydroxamic acid-based HDACi are the broadest group of 
agents used in establishment of HDACi pharmacophoric model. Like all other classes of 
HDACi, this group is comprised of a bulky cap recognition group that interacts with the 
amino acids at the surface of the active site and a linker which helps position the 
hydroxamic acid ZBG for chelation to the zinc ion at the base of HDAC catalytic pocket 
and blocks the access of the substrate to the zinc atom [50]. The most well-known 
hydroxamic acid based HDACi is the FDA approved SAHA, which is pan inhibitor of 
HDAC isoforms [51]. 
Trichostatin A (TSA) (Figure 1.9), one of the first naturally occurring hydroxamic 
acid-based HDACi discovered, is isolated from Streptomyces hygroscopicus strain. TSA 
is known as an antifungal agent due to its ability to inhibit HDAC isoforms. TSA inhibits 
cell proliferation and induces growth arrest, differentiation, and apoptosis in various 
transformed cell lines. However its toxicity, relative instability, and lack of HDAC 
isoform selectivity led to the search for other substances. Many HDACi drug designs 
have been inspired by the structure of TSA [52].  
 
                             
 
Figure 1.9. Chemical structure of tichostatin A (TSA), a naturally occurring non-




1.6.3.3. Depsipeptide-derived HDACi  
This class of HDACi has the most complex structure. They inhibit HDAC 
isoforms at nanomolar concentrations. They have also shown to be antiangiogenic by 
modulation of the expression of c-myc and regulatory genes [52]. Romidepsin (FK-228), 
a natural prodrug, is the most distinguished depsipeptide in this class. It is believed that 
its disulfide bond breaks and forms alkyl thiol once it is inside the cells. The 4-mer-
captobut-1-enyl fits into the HDAC enzyme catalytic pocket and chelates the zinc atom at 
the base of the active site [45].  
1.6.3.4. Benzamide-derived HDACi  
This group of HDACi is less potent compared to their corresponding hydroxamic 
acid derivatives.  However, several class I isoform-selective HDACi are derived from this 
group. Entinostat (MS-275) shows about 135 fold preference for HDAC1 and HDAC3 
compared to HDAC6 and HDAC8 [54]. MS-275 is in clinical trials for treating patients 
with advanced and refractory solid tumors and lymphoma [55].  
A crystallographic comparison between bacteria homologues of class I (HDLP) 
and class II (FB188HDAH) HDAC enzymes revealed the existence of a 14 Å 
hydrophobic internal cavity within the active site near the zinc ion. It is believed this 
internal cavity is an exit channel for releasing the acetate byproduct after deacetylation 
process [56]. The sequence difference in the internal cavity for HDLP and FB188HDAH 
can be used to design and synthesize isoform selective HDACi [57]. In fact, docking of 
MS-275 in the active site of an HDAC1 homology model revealed that more nonpolar 
substituents can be placed on the benzamide ring to favor the hydrophobic interactions 
with the lipophilic residues into the 14 Å internal cavity [58]. Furthermore, SAR study 
has shown the 2´-amino moiety of the benzanilide group is essential for HDAC inhibition 
[47]. The amino group is involved in zinc chelation in addition to interactions with 
histidines 140 and 141 through hydrogen binding [59].  
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1.6.3.5. Epoxide-derived HDACi 
The HDAC inhibitory potency of epoxide-derived HDACi comes from their 
chelation of the active site zinc ion or an interaction with an amino acid within the active 
pocket. However, these compounds do not show much activity in vivo due to liability 
issues. Previously mentioned natural product, cyclic tetrapeptide trapoxin A is a member 
of this family [50]. 
1.6.3.6. Carboxylic acid (short fatty acid) HDACi 
This group of HDACi has simple structures, and are less potent compared to the 
hydroxamic acid-derived HDACi. Two members of this group, valproic acid (VPA) and 
phenylbutyrate (Figure 1.10) are well-characterized and have already been approved for 
treating epilepsy. These two HDACi are in clinical trials for treating various types of 
cancer, including such as refractory solid tumors, lymphoma, prostate and breast cancers 
[60]. VPA promotes selective proteasomal degradation of HDAC2 [52] and shows 
growth suppression, proliferation inhibition and apoptosis induction [52]. VPA has been 
tested in many clinical trials both as a standalone and in combination therapies. It has 
been tested in a phase I study in patients with refractory solid or central nervous system 
tumors (CNS) [61]. VPA, in combination with 5-aza-2´-deoxycytidine (decitabine), was 
tested in patients with non-small cell lung cancer (NSCLC). Even though this 
combination therapy was found to be effective, it had to be terminated due to 
neurological toxicities at low doses [62].  
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Figure 1.10. Chemical structures of valproic acid and phenylbutyrate, two well-
established short fatty acid HDACi have been tested in clinical trials for treating various 
types of cancer [27]. 
1.7. FDA approved HDACi  
In the last few years more than 490 clinical trials have been performed on a wide 
variety of HDACi [63], with phenybutyrate being the first one enter clinical trials for 
treating various types of cancers such as prostate cancer, lymphoma and leukemia [64]. 
There are currently four FDA approved HDACi in the market. Vorinostat was the first to 
obtain FDA approval, followed by romidepsin and belinostat. Panobinostat is the latest 
HDACi which got approved in 2015 (Figure 1.11).  
 




1.7.1. Suberoylanilide hydroxamic acid (SAHA) 
SAHA, also known as vorinostat, is the first HDACi in the clinic. It was approved 
by the US FDA in 2006 for treating relapsed and refractory cutaneous T-cell lymphoma 
(CTCL). Vorinostat is an orally active drug, manufactured by Merck & Co., Inc. [65]. Its 
approval was based on a phase II clinical trials in 74 patients with stage IB or higher 
CTCL, who already had two failed systematic therapies. This clinical trial only had 30% 
objective response rate [65], and nine patients had to stop taking the drug because of 
adverse side effects while eleven needed dose modification [66]. 
Vorinostat has been investigated in several clinical trials for treating solid tumors 
including relapsed and refractory breast and non-small cell lung cancers. Unfortunately 
vorinostat showed either a low or no activity in all of these trials [67]. Vorinostat is 
currently being studied in clinical trials in combination with other therapeutic agents [68]. 
For example, it is in phase I study in combination with bortezomib in patients with 
advanced, relapsed and refractory multiple myeloma [69], [70]. Additionally, vorinostat 
in combination with decitabine is in a phase I clinical trials for treatment of relapsed or 
newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome [71].  
Despite its potent HDAC inhibition vorinostat is a pan HDACi which suffers from toxic 
side effects possibly due to its lack of isoform selectivity [62].    
1.7.2. Romidepsin (FK228) 
Romidepsin (FK228) is the second HDACi and only depsipeptide that has so far 
obtained FDA approval. It was approved in 2009 for treating patients with cutaneous T-
cell lymphoma as well as peripheral T-cell lymphoma (PTCL) who had received at least 
one failed systematic therapy. Romidepsin, is a potent, bicyclic class I isoform selective 
HDACi isolated from chromobacterium violaceum, a gram negative bacteria in a 
Japanese soil sample [72]. Romidepsin acts as a prodrug and its disulfide bond is reduced 
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by glutathione upon administration, leading to formation of a free thiol which is able to 










Figure 1.12. Reduction of romidepsin to its active form. Romidepsin is a prodrug, and its 
disulfide bond is reduced to alkyl thiol by glutathione in vivo [22].  
1.7.3. Belinostat (PXD101) 
Belinostat (PXD101) is a hydroxamic acid-based pan HDACi given FDA 
accelerated approval in 2014 for treating patients with relapsed or refractory peripheral T-
cell lymphoma. Its approval was based on efficacy and safety data acquired from a single 
arm phase II trial. Belinostat has the trade name Beleodaq and it is manufactured by 
Spectrum Pharmaceuticals, Inc [65].  
Belinostat inhibits tumor cell proliferation and like all other HDAC inhibitors, 
promotes expression of cycline dependent kinase inhibitor, p21, and apoptosis [74]. It 
inhibits growth of several human cell lines such as non-small cell lung, breast and 
prostate in vitro, and shows antitumor activity in vivo in human tumor xenografts [75]. 
Following the same trend for FDA approved HDACi, belinostat was tested in clinical 
trials for both solid and hematological cancers which resulted in no or poor activity. It is 
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suggested that HDACi lack of efficacy in treating solid tumors is due to their instability 
to reach the tumor site [27]. 
1.7.4. Panobinostat (LBH589)    
Panobinostat (LBH589) is another potent hydroxamic acid-based pan HDACi. It 
is developed by Novartis with the trade name Farydak and can be administered both 
orally and intravenously. Panobinostat was granted FDA approval in 2015 based on 
progression free survival in pre-specified analysis of a phase III PANORAMA 1 trial 
[76]. Panobinostat is the first HDACi approved in US for treating patients with multiple 
myeloma who had received at least two prior treatments including the 
immunomodulatory agent, bortezomib. Panobinostat is undergoing more clinical trials as 
a combination therapy with other therapeutic agents in the relapsed, refractory and newly 
diagnosed patients with myeloma [77]. Currently, there is a regulatory submission for use 
of panobinostat in combination therapy for treating multiple myeloma in Europe and 
Japan [78]. 
1.8. Mechanism of HDACi-induced cell death 
In general, HDACi induce tumor cell death through five mechanisms [26]. The 
first mechanism is through apoptosis which by itself has two aspects - extrinsic and 
intrinsic. Extrinsic or death receptor pathway occurs when a ligand like tumor necrosis 
factor-related apoptosis-induced ligand (TRAIL) binds to their death receptors and 
triggers activation of caspase-8 and recruitment of adaptor protein FADD. The promotion 
of TRAIL- induced apoptosis is due to blocking of the activity of HDAC1 and HDAC2 
enzymes. The intrinsic or mitochondrial pathway is stress-stimulated, resulting in damage 
to the mitochondria membrane. This damage causes the release of proteins like 
cytochrome C and SMAC and eventually leads to apoptosis [79]. 
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HDACi also trigger formation of reactive oxygen species (ROS) which has been 
suggested to induce cell death through intrinsic pathway [80].  
Another mechanism of HDACi-induced tumor cell death involves angiogenesis 
inhibition. Angiogenesis is an essential process for tumor development and metastasis.  
HDACi have been shown to decrease the levels of pro-angiogenic factors including 
vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 1α (HIF1α) 
[81].  
The last putative mechanism of HDACi-induced tumor cell death is promotion of 
autophagy. Autophagy is a protein degradation system whose activation induces a 
necrotic-type cell death. However, autophagy acts as a double edge sword [82]. It can 
both mediate cell death, associated with HDACi antitumor activity improvement, or 
promotes tumor cell survival during nutrient or hypoxic stress which contributes to 
HDACi undesired side effects [83]. 
1.9. FDA approved HDACi in combination therapy  
Despite the success of HDACi in treating hematological tumors such as CTCL, 
PTCL and multiple myeloma, they have been ineffective against solid tumors. It has been 
suggested that HDACi will be more effective if they are used in combination with other 
therapeutic agents. Specifically, HDACi are expected to reduce tumor cells threshold to 
undergo apoptosis induced by other agents, primarily due to their effect in lowering the 
levels of anti-apoptotic molecules such as XIAP, survivin and Bcl-2 and enhancing the 
levels pro-apoptotic molecules like bim, bid, and bmf [84], [85].     
HDACi have been tested in combination therapy with direct activators of the 
apoptotic process, lexatumumab and mapatumumab, to improve their efficacy in treating 
cancer. Lexatumumab and mapatumumab are DR5 and DR4 agonist antibodies 
respectively that bind to death receptors on the surface of tumor cells to initiate extrinsic 
apoptosis [86]. In addition to inducing apoptosis, HDACi promote formation of the 
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death-inducing signaling complex (DISC) [87]. Combination of compounds that are 
agonists of death receptor with HDACi promotes both intrinsic and extrinsic apoptosis 
pathways. This strategy sensitizes TRAIL-resistance tumors to apoptosis [26]. HDACi 
also induce expression of p21 that leads to cell cycle arrest in G1 phase [86]. Studies have 
shown that tumor cells are more sensitive to TRAIL-induced apoptosis when arrested in 
G1 phase of cell cycle. Additionally p21-mediated induction by HDACi helps to inhibit 
Cdc2 activity which blocks the phosphorylation of survivin and promotes its degradation 
[86].     
HDACi also have synergistic effects in combination with the proteasome 
inhibitor, bortezomib [26]. Both HDACi and bortezomib inhibit NF-ҝB activity, a key 
factor for angiogenesis and tumor metastasis [89]. Furthermore, both agents induce ROS 
generation and endoplasmic reticular (ER) stress which enhances apoptosis [90]. 
Chloroquine and 3-methyladenine have been used in combinational therapy with HDACi 
to suppress their autophagy mediated cell survival effect and induce apoptosis [91]. 
 
1.10. HDACi in clinical trials 
In addition to the four FDA approved HDACi, there are several more in various 
phases of clinical trials as a standalone or combination therapy for treating multiple 
cancer types (Figure 1.13). 
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Figure 1.13. HDACi in clinical trials. 
1.10.1. Abexinostat (PCI-24781) 
Abexinostat is an orally available hydroxamic acid-based pan HDACi that has 
shown antitumor activity for a wide range of cancers. It has been in clinical trials as 
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monotherapy as well as combinational therapy. Abexinostat promotes apoptosis by 
cleaving caspase-3 and PARP. Its combination with the tyrosine kinase inhibitor, 
pazopanib was tested in phase I study in patients with metastatic solid tumor. The result 
from this study revealed a partial response and disease stabilization (clinical trial 
informationNCT01543763). Currently, abexinostat is in combination therapy with 
cisplatin in phase I study in patients with advanced keratinizing nasopharyngeal 
carcinoma (NPC) (clinical trial information: ISRCTN96922360) [27].  
1.10.2. Givinostat (ITF2357) 
Givinostat is a hydroxamic acid-based pan HDACi with anti-inflammatory, anti-
angiogenic, and antineoplastic activities. Givinostat has shown activity towards 
Hodgkin’s lymphoma, multiple myeloma and chronic lymphocytic leukemia. It is 
currently undergoing a phase II clinical study for treatment of myeloproliferative 
neoplasms (MPN) [92]. 
1.10.3. Resminostat (4SC AG) 
Resminostat is another hydroxamic acid-based pan HDACi has been tested in 
phase I study for treating advanced solid tumors [93]. It has also shown cell growth and 
apoptosis induction in multiple myeloma cell lines [94]. In a phase II study it was tested 
in relapsed and refractory Hodgkin lymphoma and showed promising results with a good 
safety profile [95]. Resminostat is in phase II clinical trial for treating liver cancer [96]. 
1.10.4. Pracinostat (SB939) 
Pracinostat is a hydroxamic acid based-pan HDACi which is in phase II studies in 
patients with intermediate or high risk myelofibrosis (MF) [97] or advanced solid tumors 
[98]. Additionally, pracinostat is in a phase III study for acute myeloid leukemia 
treatment as well as a phase II study for treating myelodysplastic syndrome [96]. 
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1.10.5. CUDC-101 
CUDC-101 is a multi-target inhibitor of HDACs and epidermal growth factor 
(EGFR) and human epidermal growth factor receptor 2 (HER2). It shows anti-
proliferative and pro-apoptotic activities in vitro and in vivo [99]. It has a hydroxamic 
acid moiety as its ZBG. Its dual inhibition activity makes it a potential therapeutic 
compound for treatment of drug-resistant tumors that cannot be treated with single target 
agents. CUDC is in clinical trials for treating advanced solid tumors [100]. 
1.10.6. Mocetinostat (MGCD0103) 
Mocetinostat is a benzamide-based HDACi that is selective for class I isoforms. It 
showed anti-leukemia activity in a phase I trials in patients with leukemia or 
myelodysplastic syndromes (MDS) [101]. It shows synergetic growth arrest, cell death, 
and cell cycle arrest effects in treating pancreatic cancer when combined with tubastatin 
A (an HDAC 6 selective inhibitor) or MC1568 (a class IIa selective HDACi). 
Furthermore, it showed promising results in a phase II study for treating relapsed 
classical Hodgkin’s lymphoma. However, the study had to be terminated due to four 
patients sudden death, which two of whom were probably treatment related deaths 
(clinical trial identifier: NCT00358982) [27], [102].  
1.10.7. Entinostat (MS-275) 
Entinostat is a benzamide derived class I selective HDACi which has been tested 
in many clinical trials for treating various types of cancer such as breast, colon, renal cell, 
non-small cell lung cancers, and lymphoblastic leukemia either as a monotherapy or 
combinational therapy [103]. Entinostat showed promising results when it was tested in a 
phase II clinical trial in combination with exemestane in patients with estrogen receptor 
positive advanced breast cancer [104]. Moreover, testing entinostat in patients with 
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refractory solid tumors and lymphomas resulted in disease stabilization and antitumor 
activities [105]. 
1.10.8. Valproic acid (VPA) 
 Valproic acid is a short fatty acid HDACi that has been in clinical trials as a 
standalone agent and in combination therapy. In a phase I study, treatment of patients 
with refractory solid or central nervous system tumors with VPA resulted in HDAC 
inhibition in half of the patients [61]. Combination of VPA and bevacizumab has been 
tested in patients with colorectal, prostate and gastroesophageal cancers [106].  
1.11. HDACi deficiencies  
Despite the HDACi encouraging results in treating CTCL, PTCL, and multiple 
myeloma, they suffer from various common side effects. The prevalent and predominant 
toxicities of HDACi are diarrhea, nausea, fatigue, vomiting, neutropenia, peripheral 
neuropathy [70], dehydration, and thrombocytopenia [107]. In addition to all these side 
effects, their lack of accumulation in solid tumors, as well as their cardiotoxicities has 
hampered their use [22].       
1.11.1. Lack of accumulation in solid tumors 
Up to date, none of the HDACi has shown benefits in treating solid tumors. 
HDACi have been tested extensively in various clinical trials to treat different solid 
tumors, such as breast, colorectal, prostate, head and neck, ovarian, and non-small cell 
lung cancers, but lack of potency and activation was observed when they were used as a 
single therapy. However their antitumor activity improved when they were used in 





 HDACi are associated with serious cardiotoxicities, such as ST-segment 
depression, T-wave-flattering and QT interval prolongation with the last one being the 
most severe and predominant one [22], [110]. QT prolongation is associated with 
torsades de pointes (TdP) which is a life threatening arrhythmia leading to syncope, 
ventricular and sudden cardiac death [111]. 
 QT is considered prolonged when it is more than 430 msec for men and more 
than 450 msec for women. QT intervals can be influenced by ventricular conduction 
velocities as well as the velocity of repolarization. It is measured when the QRS complex 
starts and continues till T-wave ends. It demonstrates the time needed for ventricular 
depolarization. QT prolongation is mostly the result of factors that are able to prolong the 
action potential in most cases by delaying the repolarization phase 3, which can be 
caused either by blocking the ion channel cavity of hERG or triggering an abnormal 
trafficking that is essential for locating hERG subunit in the cell membrane [112].  
Targeted therapeutic agents can affect cardiac and vascular function. Targeted 
anticancer drugs are usually associated with QT prolongation because of their influence 
on ventricular repolarization mostly through restricting the activating rectifier K+ current 
(Ikr) carried by pore-forming α-subunit encoded by human ether-a-go-go-related gene 
potassium ion channels (hERG K+) [113], [114]. It has been hypothesized that HDACi, 
anti-hER2, anti-VEGF, and tyrosine kinase inhibitors are associated with the risk of 
delayed ventricular repolarization and various life-threatening arrhythmias [115]. These 
drugs all block the potassium channel, resulting in increase in the repolarization time and 
hence QT interval prolongations [116]. The blockage of the hERG K+ channel by various 
drugs is due to the interactions of lipophilic molecules with the hydrophobic aromatic 
residues in the channel’s large inner cavity [111]. 
There are other suggested mechanisms for QT prolongation induced by targeted therapies 
in addition to blocking the hERG K+ channel. The mechanism of QT prolongation in 
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some drugs lies in their ability to increase Na+ current. For instance, alfuzosin, an α1-
andrenergic receptor antagonist, which is designed to help men to urinate, increases QT 
prolongation by involving the Na+ channel. In fact alfuzosin is one of the few examples 
of agents that cause cardiac repolarization through enhancing the sodium current [117]. 
Additionally, mutations or lack of proteins, such as Mink and Mink-related 
peptide 1 (MiRP1) that forms assemblies with hERG and are needed for its proper 
functioning in vivo, are associated with arrhythmia and changes in channel function thus 
leading to QT prolongation [118].      
No major cardiotoxicity other than QT prolongation has been reported for 
vorinostat, belinostat and panobinostat; there was a report of death for romidepsin. 
Preclinical studies in dogs and rats have shown FK228 is able to induce myocardial 
inflammation and prolong QT intervals [119]. In a phase II study, a total of 15 patients 
with metastatic neuroendocrine tumors, received a 4-hour i.v. infusion of romidepsin at 
14 mg/m2 on days 1, 8, 15 every 28 days. This study had to be terminated because of a 
sudden death possibly related to ventricular arrhythmia, as well as a high number of 
cardiac side effects including 2 patients with asymptomatic grade 2 ventricular 
tachycardia (n=2), 3 patients with QT prolongation (n=3) [120]. Six patients out of the 
more than 500 patients who were treated with romidepsin died unexpectedly [119], [121]. 
Although observations from the use of HDACi in the clinic strongly suggest that 
they can induce cardiotoxicity, pre-existing cardiovascular diseases in cancer patients can 
contribute to cardiovascular adverse effects after treatments with anti-cancer agents. 
Sinus tachycardia, previous myocardial infection, atrial fibrillation as well as other 
cardiac abnormalities increases the chance of QT prolongation upon drug administration 
[122]. Furthermore, other factors such as obesity, gender, and age will elevate 




1.12. Mechanism of resistance to HDACi  
Cancer cells have the ability to develop resistance to growth inhibitory and 
damaging factors. Tumorigenesis is a selection of malignant cells that are able to adjust 
to environmental constraints and be more independent from external proliferative and 
survival inhibitors. Factors including drug efflux, target overexpression and 
desensitization, epigenetic changes, anti-apoptotic and pro-survival mechanisms, and 
stress response mechanisms are involved in development of resistance to HDACi by the 
tumor cells [124]. However, in addition to the aforementioned factors, the tissue of 
origin, as well as genetic context are critical features in resistance development [124].  
1.12.1. Efflux pump 
Tumor overexpression of the ATP-binding cassette transporter family of efflux 
pumps is a hallmark of multidrug resistance. Various HDACi, including vorniostat, 
romidepsin and belinostat, have been tested in multidrug-resistant human cancer cell lines 
and only romidepsin has shown to be a substrate for a multidrug resistance associated 
protein [125]. 
1.12.2. Epigenetic changes 
Inactivation and mutation of various isoforms of HDACs have been identified in 
different types of cancers. For instance, mutation in HDAC2 was observed in human 
colon and endometrial cancer cell lines with microsatellite instability [126]. Histone 
acetylation and DNA methylation activate or suppress gene transcription. However, DNA 
methylation is a predominant mechanism of tumor suppressor genes silencing, and has 
dominance over histone repressive markers in cancer cells [127]. Therefore, methylation 
of DNA impedes the ability of HDACi to restore expression of epigenetically silenced 
genes leading to resistance to HDACi. Studies have revealed that gene silencing induced 
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by DNA methylation cannot be overcome by the single action of HDACi and they need 
to be used with other hypomethylation-inducing agents [128]. 
1.12.3. Anti-apoptotic and pro-survival mechanisms 
HDACi induced cell death is through apoptotic pathways involving mitochondria 
damage, cytochrome c release and production of reactive oxygen species. These cell-
death mechanisms can be hindered by overexpression of anti-apoptotic proteins Bcl-2 
and Bcl-XL. It has been observed in various types of cancers that Bcl-2 was 
overexpressed while pro-apoptotic genes such as Bim and Bid were silenced. [129], 
[130]. It is suggested that changes in these proteins may be responsible for resistance to 
HDACi [126].  
Additionally, the anti-apoptotic nuclear factor ҝB (NF-ҝB) is another mediator that may 
be involved in resistance to HDACi. In some cases inhibiting HDACs results in 
activation of NF-ҝB via acetylation of the Rel/p65 subunit and stimulates expression of 
genes that interfere with triggered cell death [131]. In fact, it has been shown the 
activation of NF-ҝB by some HDACi hinders apoptosis in non-small cell lung cancer 
[132] as well as leukemia [133].  
  The HDACi-mediated cyclin-dependent kinase inhibitor p21 (CIP1/WAF1) 
upregulation is involved in induction of cell cycle arrest, differentiation, and programmed 
cell death through p53-dependent and p53-indepe pathway [134]. However, some studies 
have revealed that in U937 leukemia cell line, HDACi-mediated induction of p21 
(CIP1/WAF1) protected cells from apoptosis [135]. 
1.12.4. Autophagy  
Despite the role of autophagy in the death of some cancer cells, it has a protective 
role in some others which help them to adjust and manage the HDACi-induced cellular 
damage and apoptosis [136]. Combining HDACi with inhibitors of autophagy leads to 
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enhancement in efficacy of HDACi. For example, combination of chloroquine, an 
autophagy inhibitor, with vorinostat in treating imatinib-resistant chronic myeloid 
leukemia results in enhanced antineoplastic activity of vorinostat [91].    
Based on the preceding discussion, several mechanisms of tumor resistance to 
HDACi have been described and many more are expected to be unraveled. 
Understanding these tumor resistance mechanisms is of great significance not only in 
design and development of new HDACi with higher potency and tumor selectivity but 
also in combinational therapy of the current HDACi with other therapeutic anticancer 
agents to develop optimum combination cocktails able to overcome the resistance 
pathways.    
1.13. Improving HDACi efficacy in clinic 
Despite HDACi potent antitumor activity, their use in clinic is hampered by their 
poor bioavailability, lack of accumulation in solid tumors, and off-target toxicities. In 
many cases they have to be used in combination with other anticancer drugs to 
compensate for their deficiencies [26], [27]. In the efforts to overcome HDACi 
deficiencies, developing non-viral and tumor selective delivery methods to enhance their 
concentration at the tumor site and diminish their off-target toxicities is of a great 
importance. Design and synthesis of isoform-selective HDACi, their localized 
administration or targeted delivery to the desired tissue and tumor site, as well as 
reducing their hERG binding affinity are strategies being pursued to improve their 
potency and activity and lower their adverse effects. 
1.13.1. Localized administration  
  Localized administration is a target independent strategy for releasing the active 
ingredient near the area of the target site to avoid possible off-target toxicities. Local 
administration can be very beneficial in case of solid tumors which comprise about 85% 
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of human cancers [137]. It is used to overcome several drugs poor and variable oral 
bioavailability and adverse side effects. Additionally this strategy provides a sustainable 
and higher concentration of the drug in close proximity of target site [138].  
In recent years, injection of therapeutic drugs as a means of localized 
administration has received much interest. In a study done by Eyupoglu, et al. 
intratumoral injection of HDACi MS-275 in rats to treat malignant gliomas showed 
enhanced level of acetylate H3 in brain tissue as well as low neurotoxicity, indicating 
MS-275 as a promising drug candidate for treating malignant gliomas [139].  
Second strategy for localized administration is the topical application of the 
therapeutic agents. It has been shown that topically applying a drug which can easily and 
rapidly penetrate skin, enhances the pace of wound healing by accelerating the formation 
of granulation tissue even in severe tumor lesions [140]. HDACi are mainly used for 
treating CTCL. Despite their promising results for treating aforementioned cancer, they 
still suffer from cytotoxicity and lack of effectiveness when they are administered 
internally. This gets worse when it involves skin tumors, skin ulcer or repeated shedding 
of the skin. Indeed many CTCL patients die due to skin infections. To overcome the off-
target toxicity of HDACi and to boost their potency and selectivity, some HDACi have 
been studied as viable candidates for topical therapy [141]. In a phase I study conducted 
by national Cancer Institute (NCI), a formulation of romidepsin was applied on the skin 
of patients with CTCL (clinical identifier number: NCT01445340). This study had to be 
terminated due to the side effects. Chung et al. also tested a topical formulation of two 
HDACi - PB (phenylbutyrate) and TSA - in vivo study to achieve increased level of local 
concentrations and avoid potential systematic adverse effects in treating rheumatoid 
arthritis. The topical formulations of these HDACi possessed high stability and high skin 
penetration ability with a low skin irritation and a long shelf-life. Additionally, a selective 
induction of cell cycle inhibitors in the synovium as well as pervasive suppression of 
TNF-α in affected tissues were observed once the prepared cream or ointment was 
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applied [142].     Another example of HDACi being investigated in phase I clinical trial 
as a topical therapy in treating CTCL is SHP-141, a HDACi derived from SAHA. In a 
study done by Kim.Y.H. et al. SHP-141 showed excellent tolerability and efficacy with 
no systematic HDACi related toxicity [143]. 
The last method for localized administration is utilizing surgically placed natural 
and synthetic biodegradable polymers, which can benefit from high drug concentration at 
the target site, longer drug exposure duration, and lower systematic toxicity [137]. 
1.13.2. Reduction of hERG binding 
Cardiotoxicity of HDACi is one of the major and serious drawbacks that has 
hampered their use in clinics. As discussed earlier, the commonly accepted mechanism of 
cardiotoxicity of HDACi is their interactions with hERGK+ channel inner cavity residues 
which lead to blockage of human ether-a-go-go-related gene potassium ion channel. 
Understanding the link between HDACi cardiotoxicity and QT prolongation in relation to 
their hERG binding affinity is of great importance. This appreciation has been explored 
to design and synthesize novel potent HDACi that have lower affinity for hERG. 
Specifically, Novartis was able to design and synthesize non-cardiotoxic highly potent 
hydroxamic acid-based HDACi that show low or no hERG affinity [144].     
1.13.3. Isoform-selective HDACi  
Although, it is not completely clear if selective inhibition of one HDAC isoform 
yields less cardiotoxicity and more clinical benefit, it has nonetheless been hypothesized 
that the HDACi cytotoxicity and side effects are partially due to their lack of selectivity 
toward one HDAC isoform. It is believed HDAC5 and HDAC9 are modifiers of cardiac 
diseases phenotypes and their dysfunction results in susceptibility to cardiovascular 
diseases [145]. It has been shown that class I HDAC isoforms induce cardiomyocyte 
hypertrophy while class II HDAC enzymes suppress cardiomyocyte hypertrophy through 
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protein interactions in cardiomyocyte nucleus specifically with cardiomyocyte 
hypertrophy and not through their histone deacetylation mechanism [146]. Therefore 
inhibiting certain HDAC isoforms can have a great impact in diminishing some of 
HDACi-related cytotoxicity. Extensive efforts are currently on-going to design and 
synthesize isoform selective HDACi. In addition to class I selective, FDA approved 
romidepsin, there are several isoform selective HDACi in clinical or preclinical trials. 
Isoform selectivity can be achieved through utilizing certain groups as recognition cap 
group or ZBG [23].  
1.13.3.1. Isoform selectivity through cap group modification 
There has been substantial effort and research dedicated to modification of the cap 
group to achieve isoform selectivity. Surface recognition cap group interacts with the 
amino residues near the entrance of active site. The amino acid residues are specific to 
each HDAC enzyme class. Key examples of modification to the cap group which have 
resulted in isoform selective HDACi are the use of cyclic peptide which impacted class I 
isoform selectivity [21], and carboline in Tubastatin A which impacted exclusive HDAC6 
selectivity [147]. 
1.13.3.2. Isoform-selectivity through ZBG modification 
Although amino acids sequence similarity near the catalytic metal has made it 
problematic and challenging to design and develop isoform-selective HDACi, isoform 
selectivity has also been achieved through modification to HDACi ZBG. As a prime 
example, benzamide group is a ZBG that provides class I selectivity due to its 
interactions with the lipophilic residues in 14 Aº internal cavity. An example of 
benzamide based HDACi in clinical trial is MS-275 which is under investigation for 
treating NSCL, breast cancer, and advanced solid tumors, refractory solid tumors and 
lymphoma [27]. Epidaza (chidamide) is another benzamide-derived HDACi which was 
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recently approved by the Chinese regulatory authority to treat peripheral T cell 
lymphoma [148]. 
1.13.4. Targeted delivery 
Targeted drug delivery is a promising strategy to improve anticancer agents’ 
therapeutic window and their target to non-target ratio. Targeted delivery has several 
advantages including decreasing the drug off-target toxicity, increasing the drug 
concentration at the site of tumor and lowering the minimum effective dose of the drug 
which all lead to improvement in drug efficacy and potency [149].    
Several approaches are plausible to achieve targeted delivery of HDACi to tumor 
site. Approaches mentioned below are the ones that are the focus of this thesis study. The 
first approach is to employ FDA approved drugs that are known to accumulate in certain 
tissues as the surface recognition group.  
The second approach in targeted HDACis design is, equipping them with FDA 
approved targeting ligands such as anti-folate, anti-androgen, and anti-estrogen that have 
a preference for a certain receptor, which is overexpressed in particular cancers resulting 
in their selective accumulation in malignant cells [153], [154]. 
These targeting delivery strategies have the potential to result in selective delivery 
of HDACi to the site of tumor and lead to higher efficacy and therapeutic properties as 
well as and greater potency and lower off-target toxicity.  
1.13.4.1. Tissue selective FDA approved drugs as the ‘cap group’ 
One of the FDA approved class of drugs that selectively accumulate in lung tissue 
is macrolides [143]. Macrolides are a class of natural product with antibiotic and 
antifungal activity. They consist of a large macrocyclic lactone ring which is attached to 
deoxy sugars mostly cladinose and desosamine. Azithromycin is a macrolide which is 
approved for treating bacterial infection. It has been shown that azithromycin mostly 
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accumulates in lungs 1, which is due to its high accumulation in macrophage cells [144]. 
Although macrophages are in almost all tissues, it has been proved that they mainly 
reside in lung and liver [145], which in return results in azithromycin high accumulation 
in these tissues. Different macrolides such as azithromycin, clarithromycin, or 
telithromycin can be modified through their sugar rings to serve as surface recognition 
cap group in HDACi pharmacophoric model. In fact in an in vivo study done by my 
labmate Dr. Will Guerrant (unpublished data), it was shown that macrolide based HDACi 
maintain their lung accumulation even after modification.  
Herein, following our lab’s previous work, I designed, developed and synthesized 
various classes of azithromycin conjugated HDACi with two different zinc binding 
groups for treating lung cancer (chapter 2 and chapter 3). Based on our unpublished data, 
these conjugated HDACi are anticipated to accumulate selectively in lung tissue by 
taking advantage of azithromycin selective accumulation in macrophage cells which 
predominantly reside in lung tissue [155], [156]. Chapter 2 is focused on azithromycin 
conjugated hydroxamic acid based HDACi, while chapter 3 is devoted to azithromycin 
conjugated N-(2-amino-5-(thiophen-2-yl)phenyl)acylamide derived HDACi, as isoform 
selective HDACi. These classes of HDACi exhibited nanomolar range HDAC inhibition 
potency toward all or selected zince-dependent HDAC enzymes based on their zinc 
binding groups. Furthermore, evaluation of their antiproliferative activity against various 
transformed cell lines, showed a high nanomolar to low macromolar range cytotoxicity to 
cancer cells with less cytotoxicity against healthy cells compared to FDA approved 
HDACi SAHA. In fact, one of these azithromycin conjugated HDACi currently under 




1.13.4.2. Tumor receptor antagonist as the “cap group” 
Estrogen receptor (ER) is overexpressed on tumor cells. Tamoxifen, an antagonist 
of estrogen receptor alpha (ERα), competes with estrogen for binding to ERα in ERα 
positive breast cancers. Conjugating tamoxifen as the cap group to HDACi, results in 
tissue selective accumulation of the target compounds due to tamoxifen high affinity for 
ERα. Additionally, it improves tamoxifen efficacy in ERα negative or tamoxifen 
resistant-developed tumors because of HDACi-mediated induction of ER expression.   
It was previously shown in our lab that tamoxifen conjugated HDACi, have 
antiestrogen activity similar to tamoxifen with improved antiproliferative activity and 
nanomolar range HDAC inhibitory potency [157]. I synthesized various tamoxifen 
conjugated HDACis with different zinc binding groups and evaluated their 
antiproliferative activity as well as HDAC inhibitory potency. In addition to nanomolar 
range HDAC inhibitory activity, one class of these target compounds, tamoxifen 
conjugated hydroxamic acid HDACis, exhibited greater antiproliferative activity toward 
ERα positive breast cancer cells compared to tamoxifen, the most common and first line 
therapy for ERα positive breast cancer. Furthermore, many of these compounds were 
more selective toward ERα positive breast cancer cells relative to ERα negative breast 
cancer cells compared to tamoxifen that shows no selective antiproliferative activity 
between ERα positive and ERα negative breast cancer cells.  
The promising results of HDAC inhibition potency and antiproliferative activity 
of these class of compounds encouraged us to continue our studies further and test these 
compounds in animal models. Tamoxifen conjugated hydroxamic acid HDACis are 
currently under in vivo study. 
1.14. Thesis Overview 
I have designed and synthesized various HDACi with different cap recognition 
group and ZBG that have the potential to selectively accumulate in the macrophage and 
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lung tissues as well as have HDAC isoform selectivity. Additionally, in some cases, such 
as tamoxifen conjugated HDACi, synthesizing a dual functioning compounds, improved 
the therapeutic efficacy of the HDACi through dual effects which resulted in more anti-
cancer activity and potency. 
In all cases, cytotoxicity of designed conjugated HDACi were enhanced against 
transformed cell lines, while their cytotoxicity to healthy cells were reduced.  
Furthermore, in case of tamoxifen conjugated HDACi, in addition to an improved 
antiproliferative activity, I was able to achieve selectivity toward ERα positive breast 
cancer cells over ERα negative breast cancer cells, in comparison to tamoxifen which 
possesses the same antiproliferative activity toward ERα positive and ERα negative 
breast cancer cells.  
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STRUCTURE ACTIVITY RELATIONSHIP 
OFAZITHROMYCIN DERIVED HISTONE DEACETYLASE 
INHIBITORS WITH HYDROXAMIC ACID AS ZINC BINDING 
GROUP 
 
This work has been published in: 
S. Tapadar, S. Fathi, I. Raji, W. Omesiete,  J. Kornacki, S. Mwakwari, M. Miyata, K. 
Mitsutake, J. Li, M. Mrksich, M. Oyelereǀ.A structure–activity relationship of non-
peptide macrocyclic histone deacetylase inhibitors and their anti-proliferative and anti-
inflammatory activities. Bioorganic & Medicinal Chemistry, 2015, 23 (24), 7543-7564. 
2.1. Introduction 
Histone acetyltransferase (HAT) together with histone deacetylase (HDAC) 
control the acetylation state of histone proteins as well as non-histone proteins including 
p53, HSP90 and ERα [1]. Inhibition of the enzymatic activity of HDACs has become a 
potentially viable therapeutic approach for treating many human diseases such as malaria, 
leishmanial infection, and cancer [2], therefore various small molecule histone 
deacetylase inhibitors (HDACi) have been designed and synthesized.  
 HDACi cause growth arrest, differentiation and apoptosis with a high potency 
both in vitro and in vivo. To date four HDACi have been approved by FDA for 
cutaneous/peripheral T-cell lymphoma and multiple myeloma, and there are many more 
in different stages of clinical trials for treating solid tumors as well as hematological 
malignancies [3]. The approved HDACi are suberoylanilide hydroxamic acid (SAHA) 
approved in 2006 for cutaneous T-cell lymphoma [4], romidepsin (FK228) approved in 
2009 for cutaneous T-cell lymphoma and peripheral T-cell lymphoma [5], belinostat 
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(PXD101) approved in 2014 for peripheral T-cell lymphoma [6], and panobinostat 
(SB939) approved in 2015 for multiple myeloma [7]. Additionally, chidamide is a 
benzamide based HDACi which is only approved in China for refractory peripheral T-
cell lymphoma. Chidamide is in phase I and phase II clinical trials for treating non-small 
cell lung cancer and breast cancer in the U.S., respectively [8], [9].        
All HDACi follow a three-motif pharmacophoric model with a recognition cap 
group, linker group, and a zinc binding group (ZBG) (Figure 2.1) [10]. To date, several 
classes of small molecule HDACi have been designed and synthesized following this 
pharmacophoric model. Macrocylcic HDACi including cyclic tetrapeptides and 
depsipeptides possess the most complicated cap group that are able to maintain optimum 
interactions with the amino acid residues near the entrance of the HDAC enzyme active 
site. Despite the nanomolar range anticancer activity of this class of HDACi, their clinical 
development has been hampered by the drawbacks affiliated with peptide moieties and 
complex synthesis required to conduct structure activity relationship (SAR), [11]. To 
overcome these disadvantages, there has been an extensive research going on to replace 
the cap group with nonpeptide macrocyclic ones [12].    
We have previously shown that macrocycles derived from 15-membered azalide 
ring azithromycin mimic the peptide backbone of macrocyclic HDACi [13]. Our design 
is based on the hypothesis that replacing the cyclic peptide moiety of a cyclic peptide 
HDACi with macrolide skeleton will lead to a new class of potent HDACi [14]. 
Azithromycin belongs to a class of glycosylated polyketide antibiotics called 
macrolides which comprise of a large macrocyclic lactone ring with two deoxy sugars, 
mostly cladinose and desosamine [15]. Macrolides have been in the market for treating 
respiratory tract infections for more than half a century now. They are endowed with 
additional non-antibiotic effects such as anti-inflammatory and immunomodulatory 
effects [16].  
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Moreover, we envisioned that equipping HDACi with macrolides, as the 
recognition cap group, will result in developing therapeutic agents with selective lung 
tissue accumulation property, due to macrolides accumulation in macrophage cells. 
Although macrophage cells reside in almost all tissues, they are highly concentrated in 
the liver (Kupffer cells), the lung (alveolar macrophages) and linings of splenic and 
lymph node medullary sinusoids to filter foreign materials [17], where they are 
responsible for nonspecific host defense as well as in specific immune responses in each 
tissue [18]. Macrophage cell accumulation in lungs consequently leads to macrolide 
selective accumulation in lung tissue. Therefore, conjugating azithromycin as the 
recognition cap group to HDACi could result in HDACi with selective tissue 
accumulation property [19], [20].  
 
Figure 2.1. Naturally occurring HDACi trichostatin A and FDA approved HDACi 
SAHA. All following the three-motif pharmacophoric model of HDACi. 
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2.2. Azithromycin derived HDACi design 
Following the three motif pharmacophoric model of HDACi, and inspired by 
previous study done in our lab [14], [25], I designed and disclosed three different classes 
of macrolide conjugated HDACi with different point of aryl-triazole moiety attachment, 
where azithromycin served as the recognition cap group and hydroxamic acid as the ZBG  
 To further define the depth of the structure activity relationship (SAR) of these 
azithromycin-derived HDACi, they were synthesized with various linker length (Figure 
2.2).  The influence of linker length on their HDAC inhibitory, anti-proliferative and anti-
inflammatory activities was then investigated. 
 
Figure 2.2. Structure activity relationship of azithromycin conjugated HDACis by 
modifying desosamine and cladinose sugar rings. 
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2.3. Chemistry and synthesis 
To synthesize the first group of azithromycin derived HDACi, the ethynylbenzyl 
moiety was installed at desosamine sugar after removing one of the methyl groups and 
formation of the secondary amine 2 [21]. Subsequently, copper (I) catalyzed azide-
alkyne-cycloaddition (AAC) reaction [22] between TBS-protected azidohydroxamates 
5a-d and compound 4, followed by removal of TBS-group [23] afforded the final 
compounds 6a-d (Scheme 2.1). Compounds 6e-f (n=5-6) were previously synthesized by 





Scheme 2.1. (a) I2, NaOAc, MeOH, 50 °C, 2 h, 50% (b) Hünig’s base, DMSO, 85 °C, 3 
h, 97%; (c) CuI (15 mol%), Hünig’s base, THF-DMSO (1:1), 40 °C, 12 h; (d) CsF, 
MeOH, rt, 30 min (40-83%, c and d). 
 
For the synthesis of the second group of azithromycin derived HDACi, a dimethyl 
amine group was installed at  the C4״ position of cladinose sugar of 4, a substitution that 
may influence the acid stability of the cladinose sugar glycosidic bond [24] (Scheme 2.2).  
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Scheme 2.2. (a) I2, NaOAc, MeOH, 50 °C, 2 h, 50% (b) Hünig’s base, DMSO, 85 °C, 3 
h, 97%;  (c) acetic anhydride, CH2Cl2, 40 °C, 48 h, 100% conversion; (d) NCS, DMS, 
TEA, CH2Cl2, -15 °C, 6 h, 95%; (e) (CH3)3SOI, NaH, DMSO, THF, rt, 4 h, 89%; (f) 
KI, MeOH, 60 °C, 6 h; (g) MeOH, 90 C, 3 days, (84%, f and g); (h) CuI (15 mol%), 
Hünig’s base, THF, rt, 12 h; (i) CsF, MeOH, rt, 2 h (70-80%, h and i). 
 
Finally, the third group of azithromycin derived HDACi was synthesized through 
the introduction of the ethynylbenzyl to cladinose sugar of azithromycin in four steps 
[21]. Acetic anhydride treatment of azithromycin 1 in dichloromethane selectively gave 
2-O-acetylazithromycin 13. Corey-Kim oxidation on 13 followed by Corey-Chaykovsky 
epoxidation of intermediate 4-oxo-2-O-acetylazithromycin 14 yielded epoxy 
compounds 15. Regioselective opening of epoxide ring of 15 with 4-ethynylbenzyl-N-
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methyamine 16 in methanol, followed by a concomitant acetyl group deprotection, gave 
key intermediate 17. Then it was subjected to AAC reaction with various TBS-protected 
azido hydroxamates 5a-f followed by removal of TBS-group to give target molecules 
18a-f in moderate to good yields (Scheme 2. 3). 
 
Scheme 2.3. (a) CH2Cl2, Ac2O, rt, 3 h, 100% conversion; (b) NCS, DMS, TEA, CH2Cl2, 
-15 °C, 4.5 h, 93%; (c) (CH3)3SOI, NaH, DMSO, THF, rt, 4 h, 75%; (d) KI, MeOH, 60 
°C, 6 h, 92%; (e) CuI (15 mol%), Hünig’s base, THF, rt, 12 h; (f) CsF, MeOH, rt, 2 h, 
(70-85%, e and f) . 
2.4. Docking study 
Docking studies on different azithromycin conjugated HDACis were performed 
using AutoDock Vina. These compounds were docked against various isoforms of 
HDACs. Compounds with more than four methylene groups exhibited more potent 
HDAC inhibition potency which is in correlation with obtained HDAC inhibitory 













Figure 2.3. Docking studies of example cladinose modified azithromycin HDACi with 
six methylene linker group (18f) against HDAC1 and HDAC6. As illustrated, these 
compounds chelate zinc atom and show HDAC inhibition potency. The first two figures 
show zinc ion chelation in the active pocket of HDAC1 isoform. The grey spheres 
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illustrates the zinc atom. The last two figures show zinc ion chelation in the active site of 
HDAC6. The grey sphere represents zinc ion. 
2.5. HDAC inhibitory activity  
All the three groups of azithromycin derived HDACi and previously synthesized 
controls [14], [25] and compounds were tested against class I (HDAC1 and HDAC8) and 
class IIb (HDAC6) enzymes to evaluate their anti-HDAC activities. HDAC activity was 
determined using label-free mass spectrometry-based SAMDI assay [26]. As expected 
from previous observations, most of these new HDACis were less active against HDAC8 
(Table 2.1). 
 
     
Table 2.1. HDAC 1, HDAC6, and HDAC8 inhibition activities of azithromycin derived 
hydroxamic acid compounds.  
Compound n HDAC1 nM HDAC6 nM HDAC8 nM 
6a 1 >10 µM 5660 ± 320 >10 µM 
6b 2 >10 µM 2170 ± 200 >10 µM 
6c 3 >10 µM 106 ± 13 >10 µM 
6d 4 1650 ± 456 145 ± 42 5380 ± 650 
6e 5 316 ± 61 14.3 ± 0.6 644 ± 244 
6f 6 68.6 ± 3.3 7.29 ± 0.56 314 ± 90 
18a 1 >10 µM >10 µM 4510 ± 660 
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Table 2.1. HDAC 1, HDAC6, and HDAC8 inhibition activities of azithromycin 
derived hydroxamic acid compounds (continued). 
18b 2 >10 µM 2030 ± 300 2230 ± 560 
18c 3 >10 µM 181 ± 24 1180 ± 210 
18d 4 531 ± 79 95.3 ± 12.3 709 ± 141 
18e 5 203 ± 35 31.9 ± 1.2 786 ± 176 
18f 6 50.4 ± 8.4 31.3 ± 1.3 817 ± 308 
12a 5 160 ± 66 14.7 ± 1.8 1090 ± 240 
12b 6 79.5 ± 54 18.9 ± 3.4 749 ± 98 
SAHA - 42 34 2800 
 (HDAC inhibition assay was performed by Dr. James Kornaki at Northwestern University) 
Analysis of the HDAC1 and HDAC6 inhibitory effects of these macrolide derived 
HDACi revealed that their potency is largely dependent on the macrolide template as 
well as the length of the methylene spacer-group connecting the triazolyl group to the 
ZBG, hydroxamic acid. An increase in the length of the linker group (C1 to C6) led to an 
increase in HDAC1 and HDAC6 potencies. Introduction of the dimethylamino methyl 
group at cladinose sugar of azithromycin had moderate impact on HDAC inhibition 
(Table 1, compare 6e-f and 12a-b). Points of attachment of the aryl triazolyl hydroxamate 
group on the macrolide template also influenced HDAC inhibition potency. Attachment 
of the aryl-triazolyl cap group to cladinose sugar of azithromycin did not negatively 
impact HDAC1 inhibition while it only moderately attenuated HDAC6 inhibition potency 
(Table 1, compare 6e-f and 18e-f).  Overall, the optimum HDAC1 and HDAC6 inhibition 
was obtained for the five and six methylene spacers. .  
2.6. Anti-proliferative activity 
To determine if the HDAC inhibitory activities of these macrolide derived 
HDACi translate to anti-proliferative activity,  representative members from each class 
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were tested against three cell lines, two transformed cell lines, lung (A549) and breast 
(MCF-7) cancers as well as one normal cell line (VERO- monkey kidney epithelial cell). 
The selected compounds have diverse HDAC inhibitory activities ranging from weak to 
potent HDAC inhibition. 
Compound 6c is inactive against all transformed cell lines tested. The lack of 
cytotoxicity of 6c may be due to its poor HDAC inhibition activity. The other two 
compounds tested – 12b and 18f have broad HDAC inhibition activity. Surprisingly 
however, only 12b displayed the characteristic broad cytotoxicity activity of HDACi 
against all the cell lines investigated (Table 2.2). The reason for the lack of whole cell 
effect of 18f is not apparent from this study. Relative to the previously synthesized 6f 
and12b has slightly weaker anti-proliferative activity.    
     
Table 2.2. Anti-proliferative activity of selected azithromycin conjugated HDACi (IC50 
values in µM). 
Compound A549 MCF-7 Vero 
6c NI NI NT 
6f       2.32 ± 0.53        4.08 ± 1.03        5.90 ± 0.18 
18f NI NI NT 
12b       6.80 ± 0.50         5.92 ± 1.82       5.73 ± 0.49 
SAHA      5.00 ± 0.24       3.27 ± 0.05     1.03  0.09 
Each value is obtained from a duplicate of three simultaneous experiments. NI=No inhibition, NT=not tested. 
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2.7. Anti-inflammatory activity 
Cancer, especially lung cancer and many other lung diseases are associated with 
inflammation [27]. The transcriptional regulator nuclear factor-ҝB (NF-kB) is the main 
driver of inflammation [28], [28]. In 1863, Virchow discovered that cancer occurs at the 
site of chronic inflammation, and chronic inflammatory diseases are affiliated with higher 
risk of cancer [29]. It has been shown that HDACs play an important role in regulating 
inflammation [30], [31]. HDAC activity is essential for initiation of NF-ҝB mediated 
transcription of inflammatory genes. HDACis such as SAHA [32], entinostat [33], and 
trichostatin A [34] diminish inflammation by inhibiting NF-ҝB activation and signaling 
as well as promoting blockage of pro-inflammatory cytokine release [31]. 
To determine azithromycin conjugated HDACi anti-inflammatory activity, their 
effects on NF-ҝB activity in BEAS-2B cell infected with nontypeable Haemophilus 
influenza (NTHi) was evaluated using NF-B luciferase assay [35]. NTHi, a Gram-
negative bacterium, causes infection in the human respiratory tract [36]. This infection 
leads to activation of NF-B in human epithelial cell by translocating it from cytoplasm 
to nucleus and consequently up-regulating certain pro-inflammatory cytokines such as 
IL-1β, IL-6, and TNF-α. For prescreening, these azithromycin derived HDACi were first 
treated with NTHi infected BEAS-2B cells at 1 µM. It was observed that the compounds 
ability to inhibit NF-B had a direct correlation with their HDAC inhibitory potency. 
Analogs lacking or possessing weak anti-HDAC activities did not suppress NF-B 
activation while those with potent anti-HDAC activities suppressed NF-B activation to 
varying degrees with a close correlation with their HDAC inhibition potency. 
Subsequently, selected compounds were screened to determine the IC50 of their 
NF-B inhibitory activity. SAHA was used as the positive control. It was observed that 
these compounds suppressed the NTHi-induced NF-B activation with IC50 ranging from 
low to high nanomolar (Table 2.3). Azithromycin did not show any effect in this assay as 
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its relative percentage luciferase activity was indistinguishable from no drug treatment in 
presence of NTHi (100%), which indicates that the anti-inflammatory activity of these 
compounds is derived from their HDAC inhibition activities.  
  
Table 2.3. Anti-inflammatory activity (NF-B inhibition) of selected HDACis 
Compound IC50 (nM) Imax% 
6f 280 41.4 
18e 368 46.1 
12b 575 43.4 
SAHA 88 37.4 
 *Imax (%) at 1 M. Anti-inflammatory activity was performed at Dr. Li lab at Georgia State University 
2.8. Conclusion 
Toward delineating the SAR of macrolide derived HDACi, I synthesized three 
new classes of hydroxamic acid-based HDACis derived from azithromycin. A subset of 
these compounds showed nanomolar range HDAC inhibitory activity. Compounds with 
more potent HDAC inhibition activity, exhibited low micromolar cytotoxicity against 
lung (A549) and breast (MCF-7) cancer cell lines. They were less cytotoxic against 
healthy cells (VERO) compared to the FDA approved HDACi SAHA that is more 
cytotoxic against healthy cells rather than transformed cells. Additionally, selected 




2.9.1. Materials and methods 
Azithromycin was purchased from Greenfield chemical. 4-ethynylbenzyl alcohol 
was purchased from Sigma-Aldrich. All commercially available starting materials were 
used without purification. Reaction solvents were high performance liquid 
chromatography (HPLC) grade or American Chemical Society (ACS) grade and used 
without purification. Analtech silica gel plates (60 F254) were used for analytical TLC, 
and Analtech preparative TLC plates (UV 254, 2000 µm) were used for purification.  UV 
light and anisaldehyde/iodine stain were used to visualize the spots.  200-400 Mesh silica 
gel was used in column chromatography. Nuclear magnetic resonance (NMR) spectra 
were recorded on a Varian-Gemini 400 MHz or Bruker 500 MHz magnetic resonance 
spectrometer.  1H NMR Spectra were recorded in parts per million (ppm) relative to the 
residual peaks of CHCl3 (7.24 ppm) in CDCl3 or CHD2OD (4.78 ppm) in CD3OD or 
DMSO-d5 (2.49 ppm) in DMSO-d6. 
13C spectra were recorded relative to the central peak 
of the CDCl3 triplet (77.0 ppm) or CD3OD septet (49.3 ppm) or DMSO-d6 septet (39.7 
ppm) and were recorded with complete hetero-decoupling. Original ‘fid’ files were 
processed using MestReNova LITE (version 5.2.5-5780) program. High-resolution mass 
spectra were recorded at the Georgia Institute of Technology mass spectrometry facility 
in Atlanta.  
2.9.2. Cell viability assay 
All cell lines used in this study were maintained in Dulbecco’s Modified Eagle 
Medium (DMEM) (Lonza, GA), supplemented with 10% fetal bovine serum (FBS) 
(Atlanta Biologicals, Atlanta, GA) and 1% Penicillin-Streptomycin. Cells were incubated 
in 96 well plates for 24 h prior to treatment and then treated with various drugs’ 
concentration for 72 h. Drug anti-proliferative activity was measured using the MTS 
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assay (CellTiter 96 Aqueous One Solution and CellTiter 96 Non-Radioactive Cell 
Proliferation Assays, Promega, Madison, WI) as described by the manufacturer. All 
drugs solution were made in DMEM while DMSO concentration was maintained at 
0.1%. 
2.9.3. SAMDI assay (In vitro HDAC inhibition, performed by Dr. James Kornaki at 
Northwestern University) 
HDAC1, HDAC6 were purchased from BPS Biosciences. To obtain IC50 values, 
in 96-well microtiter plates (60 min, 37 °C), isoform- optimized substrates (50 μM) were 
incubated with enzyme (250nM) and inhibitor (at concentrations ranging from .1 nM to 
1.0 mM) in HDAC buffer (25.0 mM Tris-HCl, pH 8.0, 140 mM NaCl, 3.0 mM KCl, 1.0 
mM MgCl
2
, and 0.1 mg/mL BSA). Solution-phase deacetylation reactions were quenched 
with trichostatin A (TSA) and transferred to SAMDI plates to immobilize the substrate 
components. SAMDI plates consist of an array of self-assembled monolayers (SAMs) 
presenting maleimide in standard 384-well format for high-throughput handling 
capability. Following immobilization, plates were washed to remove buffer constituents, 
enzyme, inhibitor, and any unbound substrate and analyzed by MALDI mass 
spectrometry using automated protocols. Deacetylation yields in each triplicate sample 
were obtained from the integrated peak intensities of the molecular ions for the substrate 
and the deacetylated product ion by taking the ratio of the former over the sum of both. 
Yields were plotted with respect to inhibitor concentration and fitted to obtain IC50 
values for each isoform−inhibitor pair.  
Isoform-optimized substrates were prepared by traditional FMOC solid-phase 
peptide synthesis (Anaspec) and purified by semi-preparative HPLC on a reverse-phase 
C18 column (Waters). The peptide GRKacFGC was used for HDAC1 and HDAC8 
assays, whereas the peptide GRKacYGC was used for HDAC6 assays.  
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2.9.4. Anti-inflammatory assay (Performed at Dr. Li lab at Georgia State 
University) 
Luciferase assay was used for measuring NF-B activity. BEAS-2B cells were 
transfected with NF-B luciferase reporter construct in pGL3 basic vector [35]. 24 hours 
after transfection, the cells were treated with drugs for 1 hour followed by stimulation 
with NTHi for 5 hours. Then cells were lysed with cell lysis buffer (250 mM Tris HCl 
(pH 7.5), 0.1% Triton-X, 1 mM DTT) and luciferase activity was measured by luciferase 
assay system (promega). Relative luciferase activity (RLA) was evaluated using the 
equation: RLA = luciferase unit of the cells treated with NTHi and drug / luciferase unit 
of the cells treated with mock. IC50 was determined by treating the cells with a serial dose 
of the drug followed by luciferase assay. % Inhibition was calculated using the equation: 
% inhibition = RLA of the cells treated with indicated concentration of the drug / RLA of 
the cells treated with mock. 
2.9.5. Synthesis   
Desmethylazithromycin 2, 3′-N-(4-Ethynylbenzyl) azithromycin 4, 4-ethynylbenzyl 
methanesulfonate 30, and linker 5c were synthesized as previously described in [14], 
[25].  
2.9.5.1. 3′-Desmethylazithromycin (2) 
To a 50 mL solution of azithromycin (20 g, 0.02 mmol) and sodium acetate (29 g, 
0.21 mmol) in 80% aqueous methanol at 90°C. Iodine (7 g, 0.03 mmol) was added in 
three batches within 5 min. The mixture was maintained at pH 8-9 by addition of 1 M 
NaOH (once at 10 min of reaction time), and stirring continued for 3 h. The mixture was 
poured into cold water containing 5% sodium thiosulfate and extracted with CH2Cl2 
(2×40 mL). The aqueous layer was basified with concentrated NH4OH and extracted with 
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10% MeOH in CH2Cl2 (3×40 mL), and the organic layer was dried over Na2SO4. Solvent 
was evaporated off to give 17.7 g of compound 2 as an off-white solid (>90% purity, 
TLC, CH2Cl2/MeOH/NH4OH 12:1:0.1). The crude 2 was used without further 
purification. 
2.9.5.2. 4-Ethynylbenzyl methanesulfonate (3) 
4-Ethynyl benzyl alcohol (1.20 g, 9.08 mmol) was dissolved in anhydrous DCM 
(15 mL) at rt. Triethyl amine (2.52 mL, 18.16 mmol) was added and reaction mixture 
stirred for 10 minutes. Then cooled to -15 °C and methane sulfonyl chloride (1.25 g, 
13.62 mmol) was added. The reaction mixture stirred at -15 °C for 40 minutes. Then 
reaction mixture was quenched with NaHCO3 followed by Brine (work up). The organic 
layer was separated and dried over Na2SO4.  The crude product was purified by column 
chromatography (Silica gel, 2:3 Hex: DCM) to give the product (1.46 g, 88%) as a pale 
yellow solid. 
2.9.5.3. (3′-N-(4-Ethynylbenzyl)) azithromycin (4) 
Desmethyl azithromycin 2 (2.72 g, 3.70 mmol) was dissolved in anhydrous 
acetonitrile (20 mL), followed by addition of 4-Ethynylbenzyl methanesulfonate 3 (1.46 
g, 6.94 mmol) and K2CO3 (3.58 g, 25.91 mmol). The rraction stirred at 80 °C for 3 h. 
Then it was washed with EtOAC (3x30 mL), NaHCO3 and then brine solution and dried 
over Na2SO4 and concentrated in vacuo. The crude product was purified by column 
chromatography (Silica gel, 12:1:0.5 DCM: MeOH: NH4OH) to give the product (3.03 g, 
96%) as a white solid. 
2.9.5.4. 4-Azido-N-((tert-butyldimethylsilyl)oxy)butanamide (5c) 
2-Azidoacetic acid (540 mg, 5.34 mmol) was dissolved in anhydrous 
dichloromethane (20 mL). The solution was cooled to 0 C and then TBTU (2.06 g, 6.41 
mmol) was added and the solution was stirred for another 15 min at 0 C. After that O-
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(tert-butyldimethylsilyl) hydroxylamine  (1.28 g, 6.95 mmol) dissolved in 5 mL of 
anhydrous dichloromethane containing Hünig’s base (2 mL, 10.69 mmol) was added and 
the resulting reaction mixture was stirred at room temperature for 12 h. Reaction was 
quenched by adding water (5 mL) and the organic layer was separated. The aqueous layer 
was extracted twice with dichloromethane (10 mL) and the combined organic layer was 
washed with saturated aqueous NaHCO3 solution (5 mL), water (10 mL), brine (10 mL), 
dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude was purified 
by column chromatography (Silica gel, 15% ethyl acetate in hexane) to afford the target 
compound 5c (438 mg, 35%) as colorless oil 1H NMR (CDCl3, 400 MHz)   (ppm)7.79 
(bs, 1H), 3.33 (t, J = 6.9 Hz, 2H), 2.17 (t, J = 6.9 Hz, 2H), 1.89 (q, J = 6.9 Hz and 4.3 Hz, 
2H), 0.93 (s, 9H), 0.16 (s, 6H). 
2.9.5.5. (Azithromycin-3-(N-(4-triazolylbenzyl)))-N-hydroxyacetamide (6a)                                              
(3-N-(4-ethynylbenzyl))azithromycin 4 (0.10 g, 0.12 mmol) and 2-Azido-N-
((tert-butyldimethyl silyl)oxy) ethanamide 5a (0.05 g, 0.22 mmol) were dissolved in 
degassed anhydrous THF (5 mL) . CuI  (0.01 g, 0.06 mmol) and Hünig’s base (0.04 mL, 
0.24 mmol) were added to the reaction and the resulting reaction was stirred at room 
temperature for another 12h. Then, the reaction mixture was diluted with excess ethyl 
acetate (30 mL) and was transferred to a separatory funnel and then the ethyl acetate 
layer was washed with a solution (20 mL) of 4:1 mixture of saturated aqueous NH4Cl 
solution /NH4OH solution, water (10 mL), brine (10 mL), dried over anhydrous Na2SO4, 
filtered, and concentrated in vacuo. The crude was dissolved in 5 mL of anhydrous 
methanol and to that the solution caesium fluoride (0.03 g, 0.18 mmol) was added and the 
reaction was stirred at room temperature for 2 h. Afterward, water (10 mL) and ethyl 
acetate (30 mL) were added to the reaction and the organic layer was separated and then 
the organic layer was washed with brine (10 mL), dried over anhydrous Na2SO4, filtered 
and concentrated in vacuo. .The crude was purified by preparative chromatography 
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(Silica gel, 5:1:1 EtOAc/MeOH/NH4OH) to give the title compound 6a as light yellow 
solid (0.045 g, 40% yield). 1H NMR (400 MHz, CD3OD) δ (ppm) 8.47 (d, J = 2.4 Hz, 
1H), 7.96 (d, J = 7.0 Hz, 2H), 7.62 (d, J = 7.4 Hz, 2H), 5.13 (d, J = 4.6 Hz, 2H), 4.66 (d, 
J = 7.2 Hz, 1H), 4.31 – 4.20 (m, 2H), 4.15 (d, J = 12.9 Hz, 1H), 3.86 (d, J = 12.7 Hz, 
2H), 3.76 – 3.70 (m, 2H), 3.52 (d, J = 6.9 Hz, 2H), 3.43 (dd, J = 3.2, 1.6 Hz, 3H), 3.29 (s, 
3H), 3.20 – 3.12 (m, 2H), 3.07 (s, 1H), 3.01 – 2.97 (m, 1H), 2.88 (s, 3H), 2.55 (s, 3H), 
2.30 (d, J = 14.2 Hz, 2H), 2.09 – 2.01 (m, 28H), 1.69 (dd, J = 15.2, 5.1 Hz, 2H), 1.56 (s, 
3H), 1.44 (s, 3H), 1.32 (s, 3H), 1.17 (s, 3H), 1.03 (t, J = 7.4 Hz, 3H). 13C NMR (126 
MHz, CD3OD) δ (ppm) 180.7, 177.2, 149.5, 141.0, 140.9, 131.7, 127.5, 124.5, 104.7, 
102.3, 97.6, 85.1, 80.1, 78.9, 76.8, 76.7, 76.2, 75.5, 73.2, 70.2, 70.1, 67.5, 66.8, 65.4, 
59.3, 52.0, 51.0, 50.1, 49.3, 47.5, 44.1, 43.5, 38.4, 37.7, 36.7, 33.8, 32.7, 31.6, 29.1, 27.7, 
24.5, 22.8, 19.8, 18.2, 16.5, 12.3, 10.6, 8.9. HMRS (ESI) m+2/2z Calcd for C48H82N6O14 
[M+2H+]: 483.2939, found for 483.2935. 
2.9.5.6. Azithromycin-3-(N-(4-triazolylbenzyl)))-N-hydroxypropanamide (6b) 
Reaction of (3-N-(4-ethynylbenzyl))azithromycin   4 (0.18 g, 0.22 mmol) and 3-
Azido-N-((tert-butyldimethyl silyl)oxy) propanamide 5b (0.08 g, 0.33 mmol) followed by 
TBS deprotection with caesium fluoride as described for the synthesis of 6a, gave 6b as 
light yellow solid (170 mg, 79%). 1H NMR (400 MHz, CD3OD) δ (ppm) 8.39 (s, 1H), 
7.93 (d, J = 8.0 Hz, 2H), 7.61 (d, J = 8.3 Hz, 2H), 5.14 (d, J = 4.5 Hz, 1H), 4.88 (s, 3H), 
4.67 (d, J = 7.3 Hz, 1H), 4.23 (d, 2H), 4.15 (d, J = 13.2 Hz, 1H), 3.86 (d, J = 13.3 Hz, 
2H), 3.77 – 3.71 (m, 2H), 3.62 – 3.52 (m, 2H), 3.46 – 3.41 (m, 3H), 3.30 (s, 3H), 3.16 (d, 
J = 9.5 Hz, 2H), 2.91 (s, 3H), 2.55 (s, 3H), 2.32 (s, 1H), 2.15 – 2.01 (m, 24H), 1.70 (d, J 
= 10.6 Hz, 2H), 1.57 (s, 3H), 1.48 (d, J = 6.9 Hz, 2H), 1.43 (s, 3H), 1.38 – 1.33 (m, 2H), 
1.29 (s, 3H), 1.20 (s, 3H), 1.16 (s, 3H), 1.03 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, 
CD3OD) δ (ppm) 178.3, 175.0, 147.1, 138.1, 129.6, 125.4, 102.5, 95.4, 83.0, 78.4, 77.8, 
76.5, 73.9, 73.2, 72.3, 70.7, 70.0, 69.8, 65.4, 64.7, 60.8, 57.1, 5.54, 51.2, 48.2, 48.0, 47.9, 
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47.2, 46.1, 45.7, 45.3, 45.2, 41.9, 41.1, 36.1, 35.6, 31.7, 29.4, 29.1, 25.5, 22.7, 22.4, 20.6, 
16.1, 13.2, 12.9, 10.1, 8.5, 6.9. HRMS (ESI) m/z Calcd. for C49H83N6O14 [M+H
+]: 
979.5962, found for 979.5958. 
2.9.5.7. Azithromycin-3-(N-(4-triazolylbenzyl)))-N-hydroxybutanamide (6c) 
Reaction of (3-N-(4-ethynylbenzyl))azithromycin 4 (0.15 g, 0.17 mmol) and 4-
Azido-N-((tert-butyldimethyl silyl)oxy) butanamide 5c (0.08 g, 0.32 mmol) followed by 
TBS deprotection with caesium fluoride as described for the synthesis of 6a, gave 6c as 
light yellow solid (110 mg, 62%). 1H NMR (400 MHz, CD3OD) δ (ppm) 8.21 (s, 1H), 
7.66 (d, J = 7.5 Hz, 2H), 7.33 (d, J = 6.2 Hz, 2H), 4.35 (d, J = 7.1 Hz, 2H), 3.97 – 3.88 
(m, 1H), 3.66 – 3.55 (m, 1H), 3.42 (s, 3H), 3.26 (d, J = 10.4, 7.0 Hz, 3H), 3.13 – 3.11 (m, 
2H), 2.96 (s, 3H), 2.92 – 2.78 (m, 1H), 2.66 (dd, J = 12.4, 7.4 Hz, 3H), 2.59 (s, 3H), 2.29 
(s, 3H), 2.18 (d, J = 15.0 Hz, 2H), 2.00 (dd, J = 20.2, 12.5 Hz, 2H), 1.81 (d, J = 7.6 Hz, 
2H), 1.75 (s, 24H), 1.39 (dd, J = 15.2, 9.7 Hz, 2H), 1.26 (s, 3H), 1.16 (d, J = 6.8 Hz, 3H), 
1.11 (d, J = 3.8 Hz, 3H), 1.06 – 1.00 (m, 1H), 0.96 (s, 3H), 0.88 (d, J = 7.4 Hz, 3H), 0.84 
(d, J = 6.8 Hz, 3H), 0.71 (t, J = 7.3 Hz, 3H). 13C NMR (126 MHz, CD3OD) δ (ppm) 
180.5, 177.2, 172.2, 149.5, 131.7, 131.6, 127.5, 123.1, 104.7, 97.6, 85.2, 80.6, 80.1, 78.8, 
76.7, 76.1, 75.6, 75.1, 73.1, 70.1, 65.4, 59.4, 51.5, 50.8, 50.5, 50.2, 50.1, 49.5, 47.6, 44.1, 
38.2, 37.7, 36.7, 32.8, 31.6, 31.5, 31.3, 31.2 28.1, 27.8, 22.9, 22.9, 22.8, 22.4, 19.8, 18.2, 
16.5, 12.3, 10.6, 9.0. HRMS (ESI) m/z Calcd for C50H85N6O14 [M+H
+]: 993.6118, found 
993.6113 
2.9.5.8. Azithromycin-3-(N-(4-triazolylbenzyl)))-N-hydroxypentanamide (6d) 
Reaction of (3-N-(4-ethynylbenzyl))azithromycin 4 (0.14 g, 0.16 mmol) and 5-
Azido-N-((tert-butyldimethyl silyl)oxy) pentanamide 5d (0.07 g, 0.24 mmol) followed by 
TBS deprotection with caesium fluoride as described for the synthesis of 6a, gave 6d as 
light yellow solid (110 mg, 66%). 1H NMR (400 MHz, CD3OD) δ (ppm) 8.28 (s, 1H), 
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7.73 (d, J = 7.7 Hz, 2H), 7.40 (d, J = 7.9 Hz, 2H), 4.47 (d, J = 7.2 Hz, 1H), 4.41 (s, 2H), 
4.12 (d, J = 17.0 Hz, 2H), 3.80 (d, J = 13.0 Hz, 1H), 3.68 (s, 1H), 3.64 – 3.50 (m, 4H), 
3.35 – 3.24 (m, 2H), 3.13 (s, 3H), 3.00 – 2.91 (m, 2H), 2.76 (dd, J = 7.5, 4.4 Hz, 2H), 
2.65 (d, J = 11.8 Hz, 1H), 2.39 (s, 3H), 2.32 (d, J = 15.0 Hz, 2H), 2.24 (s, 3H), 2.15 – 
2.09 (m, 3H), 1.98 – 1.86 (m, 22H), 1.31 (s, 3H), 1.23 (d, J = 5.9 Hz, 5H), 1.18 – 1.09 
(m, 7H), 1.06 (s, 3H), 1.01 (d, J = 7.5 Hz, 4H), 0.91 (s, 2H), 0.84 (t, J = 7.3 Hz, 3H). 13C 
NMR (126 MHz, CD3OD) δ (ppm) 180.5, 177.2, 149.5, 141.7, 131.6, 131.4, 127.4, 
122.9, 104.8, 97.3, 85.3, 80.5, 80.2, 78.9, 76.3, 76.2, 76.1, 75.1, 73.3, 70.0, 67.3, 65.3, 
59.6, 51.8, 50.8, 50.3, 50.1, 50.0, 49.8, 49.5, 49.3, 47.5, 44.3, 43.9, 38.2, 37.6, 36.8, 32.8, 
31.5, 28.5, 28.3, 24.4, 23.1, 22.9, 22.5, 19.8, 18.2, 16.5,12.4, 10.7, 8.6. HRMS (ESI) m/z 
Calcd. for C51H87N6O14 [M+H
+]: 1007.6275, found 1007.6272. 
2.9.5.9. ((3-O-Acetyl)-4-N-(4-ethynylbenzyl))azithromycin (7) 
To the solution of (4-ethynylbenzyl)azithromycin 4 (1.00 g, 1.18 mmol) in DCM 
(10 mL) was added acetic anhydride (0.13 mL, 1.41 mmol). Then the mixture was heated 
to 40 °C in a pressure tube and stirring continued for 48 h. The reaction mixture was 
cooled and diluted with DCM (100 mL) and washed with saturated NaHCO3 (50 mL), 
water (50 mL), and brine (50 mL). The organic layer was dried over anhydrous Na2SO4, 
filtered and concentrated in vacuo. The solid crude product 7 (1.1 g, 95%) was 
sufficiently pure to be used for the next reaction without any further purification. . 1H 
NMR (400 MHz, CDCl3) δ (ppm) 7.38 (d, J = 8.1 Hz, 2H), 7.17 (d, J = 8.1 Hz, 2H), 5.06 
– 5.00 (m, 1H), 4.94 (dd, J = 10.6, 2.3 Hz, 1H), 4.86 (dd, J = 10.5, 7.6 Hz, 1H), 4.79 (d, J 
= 4.4 Hz, 1H), 4.45 (d, J = 7.6 Hz, 1H), 4.13 (t, J = 5.6 Hz, 1H), 3.97 (dq, J = 12.5, 6.2 
Hz, 1H), 3.64 (d, J = 13.8 Hz, 1H), 3.57 – 3.44 (m, 2H), 3.40 (d, J = 4.3 Hz, 1H), 3.29 
(dd, J = 12.3, 4.8 Hz, 1H), 3.20 (s, 3H), 3.02 – 2.94 (m, 2H), 2.74 (td, J = 12.2, 4.2 Hz, 
1H), 2.67 – 2.58 (m, 1H), 2.53 (q, J = 7.2 Hz, 2H), 2.28 (d, J = 14.9 Hz, 2H), 2.19 (s, 
3H), 2.14 (d, J = 6.8 Hz, 3H), 2.10 (d, J = 7.4 Hz, 3H), 2.04 (d, J = 5.4 Hz, 3H), 1.99 – 
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1.89 (m, 1H), 1.82 – 1.70 (m, 3H), 1.68 – 1.34 (m, 3H), 1.28 – 1.17 (m, 13H), 1.13 (d, J 
= 7.1 Hz, 6H), 1.04 – 0.91 (m, 10H), 0.89 – 0.80 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 
(ppm) 176.5, 175.5, 171.0, 170.0, 140.8, 132.0, 128.4, 128.1, 128.0, 120.7, 101.4, 96.5, 
84.3, 83.7, 80.6, 79.8, 77.9, 76.4, 75.3, 74.1, 72.9, 71.2, 69.0, 65.6, 61.9, 61.1, 58.2, 49.4, 
48.9, 45.5, 42.9, 41.4, 36.9, 35.1, 34.4, 31.0, 29.6, 27.1, 25.2, 23.6, 21.9, 21.6, 20.6, 17.9, 
14.1, 11.7, 11.1, 8.3. HRMS (ESI) m+2/2z Calcd. for C48H80N2O13 [M + 2H
+]: 446.2825, 
found 446.2810. 
2.9.5.10. ((4-Oxo)-3-O-acetyl)-4-N-(4-ethynylbenzyl))azithromycin (8) 
A solution of N-chlorosucciniamide (0.46 g, 3.47 mmol) in DCM (5 mL) was 
stirred at -15 °C for 10 min. Then DMS (0.30 mL, 3.90 mmol) was added drop wise to 
form a white solution. After stirring for 20 min a DCM (5 mL) solution of compound 7 
(1.93 g, 2.17 mmol) was added over 30 min and the resulting suspension was stirred at -
15 °C for 30 min. Subsequently, TEA (0.5 mL, 3.47 mmol) was added and the reaction 
cleared up within a minute. Stirring continued at -10 °C for 2 h and the reaction was 
quenched with saturated aqueous NaHCO3 solution (20 mL), extra DCM (20 mL) was 
added and the organic layer was separated. The aqueous layer was again extracted with 
DCM (2 x 10 mL) and the combined organic layer was dried over anhydrous Na2SO4, 
filtered, and concentrated in vacuo. The crude was purified by column chromatography 
(Silica gel, 12:1:0.5 DCM: MeOH: NH4OH) to give the title compound 8 (1.79 g, 93% 
yield) aswhitle solid. 1H NMR (400 MHz, CDCl3) δ (ppm) 7.37 (d, J = 8.1 Hz, 2H), 7.17 
(d, J = 7.3 Hz, 2H), 5.18 – 5.04 (m, 1H), 5.05 – 4.73 (m, 2H), 4.65 (d, J = 9.7 Hz, 1H), 
4.48 – 4.34 (m, 1H), 4.20 (d, J = 4.3 Hz, 1H), 4.16 – 4.06 (m, 1H), 3.95 (dd, J = 15.2, 8.5 
Hz, 1H), 3.72 – 3.57 (m, 2H), 3.56 – 3.37 (m, 3H), 3.31 (dd, J = 16.4, 9.8 Hz, 1H), 3.23 
(t, J = 5.2 Hz, 1H), 3.19 (s, 1H), 3.07 (d, J = 6.2 Hz, 1H), 3.05 – 2.91 (m, 2H), 2.86 – 
2.55 (m, 2H), 2.49 (d, J = 10.1 Hz, 1H), 2.27 (dd, J = 11.5, 6.2 Hz, 3H), 2.20 (d, J = 5.6 
Hz, 3H), 2.17 – 2.13 (m, 2H), 2.11 (d, J = 5.3 Hz, 2H), 2.08 – 1.95 (m, 5H), 1.83 – 1.70 
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(m, 2H), 1.66 – 1.46 (m, 2H), 1.44 – 1.34 (m, 3H), 1.34 – 1.16 (m, 14H), 1.13 (dd, J = 
6.8, 4.2 Hz, 4H), 1.10 – 1.01 (m, 4H), 1.00 – 0.91 (m, 3H), 0.90 – 0.73 (m, 3H). 13C 
NMR (126 MHz, CDCl3) δ (ppm) 211.6, 177.2, 176.5, 170.0, 169.7, 140.6, 132.0, 128.3, 
120.6, 100.5, 94.6, 83.6, 75.8, 75.3, 74.3, 73.9, 73.0, 72.4, 72.2, 71.2, 69.8, 69.0, 68.0, 
65.6, 63.1, 61.8, 58.3, 51.2, 49.5, 48.9, 45.1, 37.1, 36.9, 35.2, 34.4, 29.5, 23.0, 22.1, 21.5, 
21.1, 20.6, 18.1, 15.5, 14.3, 12.3, 11.3, 9.0, 7.7. HRMS (ESI) m/z Calcd. for C48H77N2O13 
[M+H+]: 889.5420, found 889.5412. 
2.9.5.11. ((4-Epoxy)-3-O-acetyl)-4-N-(4-ethynylbenzyl))azithromycin (9) 
NaH (0.2 g, 4.67 mmol, 60%w/w) was added to an oven dried three necked flask 
and was washed with petroleum ether (×3). The flask was immediately flushed with Ar 
and dry DMSO (6 mL) was introduced through a septum. The mixture was stirred at 
room temperature under Ar. Then trimethyloxosulfonium iodide (1.05 g, 4.67 mmol) was 
added over a period of 5 min. After hydrogen gas ceased to evolve, the resulting yellow 
clear solution was treated with a solution of  compound 8 (1.88 g, 2.12 mmol) in 
anhydrous THF (5 mL) over 10 min and stirring continued for 2 h after which TLC 
(4:1:0.5 Hex, EtOAc: EtOH) showed a near quantitative conversion to a new product. 
THF was evaporated off, EtOAc (20 mL) was added to the remaining residue and the 
mixture was washed  with water several times to remove DMSO. The organic layer was 
dried over Na2SO4 and concentrated to give light yellow solid product 9 (1.63 g, 85% 
yield). 1H NMR (400 MHz, CDCl3) δ (ppm) 7.37 (d, J = 8.0 Hz, 2H), 7.18 (d, J = 6.7 Hz, 
2H), 5.26 (s, 1H), 5.06 (d, J = 10.0 Hz, 1H), 4.98 (d, J = 8.5 Hz, 1H), 4.95 – 4.76 (m, 
2H), 4.72 (dd, J = 12.6, 6.2 Hz, 1H), 4.62 (t, J = 7.4 Hz, 1H), 4.50 (s, 1H), 4.44 (d, J = 
7.6 Hz, 1H), 4.09 (t, J = 7.3 Hz, 1H), 4.03 (dd, J = 12.6, 5.9 Hz, 1H), 3.70 – 3.60 (m, 
1H), 3.60 – 3.52 (m, 1H), 3.51 – 3.42 (m, 1H), 3.34 (d, J = 19.2 Hz, 1H), 3.28 – 3.14 (m, 
2H), 3.09 (d, J = 7.6 Hz, 1H), 3.01 (d, J = 4.1 Hz, 1H), 2.91 (d, J = 4.3 Hz, 1H), 2.82 – 
2.61 (m, 3H), 2.61 – 2.52 (m, 1H), 2.35 – 2.25 (m, 1H), 2.24 – 2.11 (m, 6H), 2.10 – 2.00 
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(m, 4H), 1.95 – 1.84 (m, 2H), 1.83 – 1.64 (m, 4H), 1.56 (ddd, J = 20.9, 13.1, 6.4 Hz, 2H), 
1.49 – 1.32 (m, 3H), 1.30 – 1.14 (m, 10H), 1.12 (d, J = 8.3 Hz, 2H), 1.06 (s, 3H), 1.03 (d, 
J = 4.9 Hz, 3H), 1.03 – 0.97 (m, 4H), 0.94 (dd, J = 15.2, 8.7 Hz, 3H), 0.91 – 0.75 (m, 
3H). 13C NMR (126 MHz, CDCl3) δ (ppm) 182.2, 175.8, 173.7, 169.7, 145.2, 142.9, 
140.2, 132.2, 131.9, 128.6, 128.1, 120.9, 106.6, 105.0, 103.7, 97.4, 83.7, 78.3, 75.5, 74.3, 
73.7, 72.5, 71.0, 70.6, 69.9, 69.3, 65.5, 65.3, 61.7, 60.9, 59.3, 49.9, 49.4, 42.7, 40.4, 39.7, 
37.0, 31.9, 29.2, 22.9, 21.5, 19.3, 17.9, 15.2, 14.1, 11.7, 11.0, 10.3, 8.8. HRMS (ESI) m/z 
Calcd. for C49H79N2O13 [M+H+]: 903.5577, found 903.5568. 
2.9.5.12. ((4-(N,N-Dimethylaminomethyl)-4-N-(4-ethynylbenzyl))azithromycin (11) 
Reaction of compound 9 (2.00 g, 2.2 mmol) and N,N-dimethylmethyl amine 10 
(8.92 mL, 168.3, 2M in THF) mmol) in anhydrous methanol (20 mL). The solution was 
heated at 60 C for 6 h. MeOH and residual methylamine was evaporated off to give light 
yellow solid which was again dissolved in MeOH (10 mL) and heated at 90 C for three 
days after which TLC showed complete conversion. Excess MeOH was evaporated off to 
give compound give 11 as white solid (2.0 g, 90%) after purification by column 
chromatography (Silica gel, 20:1:0.1 DCM, MeOH, and NH4OH). 
1H NMR (400 MHz, 
CDCl3) δ (ppm) 7.38 (t, J = 5.6 Hz, 2H), 7.19 (d, J = 8.0 Hz, 2H), 4.98 (d, J = 4.7 Hz, 
1H), 4.80 (dd, J = 10.7, 7.5 Hz, 1H), 4.61 (dd, J = 16.8, 8.0 Hz, 1H), 4.53 – 4.47 (m, 1H), 
4.32 (dd, J = 11.6, 6.2 Hz, 1H), 4.08 (t, J = 7.2 Hz, 1H), 4.02 (q, J = 6.4 Hz, 1H), 3.70 
(dt, J = 9.6, 5.5 Hz, 1H), 3.67 – 3.59 (m, 2H), 3.54 (d, J = 6.2 Hz, 1H), 3.49 (s, 1H), 3.41 
(ddd, J = 22.7, 11.0, 6.6 Hz, 2H), 3.31 (d, J = 7.3 Hz, 1H), 3.20 – 3.12 (m, 1H), 3.11 – 
2.98 (m, 3H), 2.92 (d, J = 3.3 Hz, 1H), 2.85 (d, J = 2.4 Hz, 1H), 2.78 (dd, J = 17.2, 10.1 
Hz, 1H), 2.73 (s, 1H), 2.65 (dd, J = 14.3, 7.6 Hz, 2H), 2.57 (d, J = 9.5 Hz, 1H), 2.45 (dt, J 
= 23.1, 10.2 Hz, 1H), 2.31 (d, J = 11.6 Hz, 7H), 2.24 – 2.16 (m, 3H), 2.13 (dd, J = 11.4, 
4.5 Hz, 1H), 2.10 – 2.01 (m, 4H), 2.00 – 1.78 (m, 6H), 1.68 (dd, J = 23.3, 12.9 Hz, 2H), 
1.23 (qd, J = 15.5, 7.1 Hz, 17H), 1.13 (dd, J = 9.7, 4.5 Hz, 3H), 1.09 – 0.98 (m, 8H), 0.86 
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(ddd, J = 11.8, 10.2, 6.2 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ (ppm) 178.0, 169.7, 
140.7, 131.8, 128.3, 120.5, 100.4, 95.6, 84.2, 83.5, 78.8, 76.8, 76.0, 74.9, 74.2, 73.3, 71.4, 
70.2, 70.1, 67.5, 67.4, 61.9, 61.3, 58.4, 57.9, 53.6, 49.0, 47.3, 47.2, 45.1, 44.7, 41.9, 41.4, 
40.1, 36.8, 36.5, 31.5, 30.6, 30.0, 27.0, 26.5, 21.7, 21.3, 20.9, 18.5, 16.1, 15.7, 14.7, 11.1, 




Compound 11 (0.17 g, 0.18 mmol) and 6-Azido-N-((tert-butyldimethyl silyl)oxy) 
hexanamide 5e (0.08 g, 0.30 mmol) were dissolved in anhydrous THF (5 mL) and stirred 
under Ar at room temperature. Copper (I) iodide (0.02 g, 0.09 mmol) and Hunig’s base 
(0.07 mL, 0.37 mmol) were added to the mixture and stirring continued for 12 h. 
Caesium fluoride (0.04 g, 0.28 mmol) and MeOH (4 mL) were added to the mixture to 
remove TBS protecting group and stirring continued for an additional 2h.  A solution of 
4:1 saturated NH4Cl/NH4OH (30 mL) was added to the reaction mixture and extracted 
with 20% MeOH/ CH2Cl2 (3×30 mL). The organic layer was dried over Na2SO4 and 
concentrated in vacuo. The crude product was purified by preparative chromatography  
(Silica gel, 5:1:1 EtOAc: MeOH: NH4OH) to give the product (0.16 g, 80%) as light 
yellow solid. 1H NMR (400 MHz, CD3OD) δ (ppm) 7.74 (s, 1H), 7.20 (d, J = 7.8 Hz, 
2H), 6.83 (d, J = 7.9 Hz, 2H), 3.83 (s, 2H), 3.74 (d, J = 7.3 Hz, 1H), 3.60 – 3.46 (m, 2H), 
3.26 (d, J = 13.0 Hz, 1H), 2.99 – 2.89 (m, 3H), 2.78 (s, 1H), 2.75 – 2.67 (m, 3H), 2.37 (d, 
J = 3.6 Hz, 3H), 2.23 – 2.10 (m, 2H), 1.96 (t, J = 14.2 Hz, 3H), 1.80 – 1.64 (m, 11H), 
1.60 – 1.45 (m, 3H), 1.43 – 1.30 (m, 11H), 1.28 (s, 1H), 1.22 (d, J = 6.6 Hz, 1H), 1.13 
(dd, J = 24.4, 9.4 Hz, 3H), 1.02 (d, J = 15.3 Hz, 2H), 0.93 – 0.81 (m, 1H), 0.74 (dd, J = 
14.2, 7.2 Hz, 3H), 0.68 (dd, J = 10.0, 4.1 Hz, 5H), 0.67 – 0.58 (m, 3H), 0.55 (d, J = 6.7 
Hz, 6H), 0.48 (d, J = 4.3 Hz, 6H), 0.38 (d, J = 7.5 Hz, 3H), 0.33 – 0.21 (m, 10H). 13C 
NMR (126 MHz, CD3OD) δ (ppm) 180.5, 178.8, 177.3, 173.7, 172.8, 149.4, 141.7, 
 85 
131.8, 127.5, 122.8, 105.1, 102.9, 97.3, 86.5, 80.7, 78.8, 77.9, 76.3, 75.9, 73.7, 72.8, 71.4, 
70.0, 69.2, 64.7, 63.2, 61.6, 60.1, 55.7, 53.1, 52.1, 50.9, 48.5, 47.3, 44.5, 44.1, 43.9, 38.3, 
37.6, 32.9, 32.4, 32.3, 32.2, 31.9, 31.7, 30.2, 28.4, 27.9, 23.1, 22.7, 19.7, 18.1, 16.4, 12.4, 
10.7, 8.4. HRMS (ESI) m+2/2z Calcd. for C55H97N7O14 [M + 2H+]: 539.8541, found 
539.8549.                                 
2.9.5.13. (Azithromycin-(4-N-(4-benzyltriazolyl))-4-(N,N-dimethylaminomethyl))-N-
hydroxyheptanamide (12b) 
Reaction of compound 11 (0.08 g, 0.09 mmol)  with 7-Azido-N-((tert-
butyldimethylsilyl)oxy)heptanamide 5f (0.04 g, 0.14 mmol) followed by TBS removal 
with caesium fluoride as described for the synthesis of compound 12a, gave 12b as light 
yellow solid (0.069 g, 70%). 1H NMR (400 MHz, CD3OD) δ (ppm) 7.46 (s, 1H), 6.92 (d, 
J = 8.0 Hz, 2H), 6.56 (d, J = 8.0 Hz, 2H), 3.55 (d, J = 6.2 Hz, 2H), 3.47 (d, J = 7.2 Hz, 
1H), 3.33 – 3.17 (m, 2H), 2.99 (d, J = 12.9 Hz, 1H), 2.76 (d, J = 13.2 Hz, 1H), 2.67 (dd, J 
= 14.5, 9.8 Hz, 3H), 2.51 (s, 1H), 2.43 (ddd, J = 6.2, 4.9, 2.3 Hz, 2H), 2.26 (t, J = 15.8 
Hz, 1H), 2.09 (d, J = 5.7 Hz, 3H), 1.98 – 1.83 (m, 2H), 1.69 (dd, J = 14.5, 9.6 Hz, 2H), 
1.55 – 1.37 (m, 13H), 1.35 – 1.23 (m, 2H), 1.22 (d, J = 13.4 Hz, 3H), 1.16 – 1.01 (m, 
11H), 0.87 (t, J = 11.8 Hz, 3H), 0.75 (d, J = 15.1 Hz, 3H), 0.46 (d, J = 19.0 Hz, 6H), 0.44 
– 0.40 (m, 3H), 0.35 (dt, J = 15.7, 9.2 Hz, 6H), 0.32 – 0.25 (m, 6H), 0.20 (t, J = 5.5 Hz, 
6H), 0.11 (d, J = 7.5 Hz, 3H), 0.07 – 0.06 (m, 6H). 13C NMR (126 MHz, CD3OD) δ 
(ppm) 180.4, 180.1, 177.3, 173.5, 172.7, 149.5, 141.7, 141.2, 131.8, 131.4, 127.4, 122.8, 
105.1, 102.8, 97.3, 86.1, 80.3, 78.9, 76.5, 75.7, 73.7, 72.8, 71.5, 70.1, 69.2, 64.6, 63.5, 
61.7, 60.1, 55.7, 53.2, 52.1, 51.0, 48.5, 47.6, 47.4, 44.1, 43.8, 38.5, 38.0, 37.6, 32.1, 31.5, 
29.0, 28.8, 27.7, 26.8, 23.1, 22.4, 20.0, 18.2, 16.4, 16.0, 12.6, 10.8, 8.5. HRMS (ESI) 
m+2/2z Calcd. for C56H99N7O14 [M + 2H
+]: 546.8620, found 546.8611.  
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2.9.5.14. 3-O-Acetylazithromycin (13)   
Acetic anhydride (0.8 mL, 8.34 mmol) was added to a solution of azithromycin 1 
(2.50 g, 3.34 mmol) in DCM (10 mL) at room temperature. The resulting solution was 
stirred under Ar for 3 h. The reaction was quenched by adding saturated NaHCO3 and the 
organic layer was separated. The aqueous layer was extracted twice with DCM (20 mL) 
and the combined organic layer was washed with water, brine, dried over anhydrous 
Na2SO4, filtered and concentrated in vacuo to give the target compound as a white solid 
(2.50 g, 95%). 1H NMR (400 MHz, CDCl3) δ (ppm) 5.25 (dd, J = 1.6, 0.9 Hz, 1H), 4.93 
(s, 3H), 4.74 – 4.67 (m, 2H), 4.59 (d, J = 10.2 Hz, 2H), 4.51 (d, J = 7.5 Hz, 2H), 4.18 – 
4.13 (m, 2H), 4.01 – 3.93 (m, 2H), 3.59 (s, 2H), 3.54 (d, J = 6.3 Hz, 2H), 3.30 (s, 3H), 
3.23 (s, 2H), 2.96 (d, J = 9.0 Hz, 2H), 2.79 – 2.71 (m, 2H), 2.68 – 2.52 (m, 4H), 2.40 (d, J 
= 11.8 Hz, 2H), 2.28 (d, J = 13.8 Hz, 4H), 2.04 – 2.01 (m, 1H), 1.98 (d, J = 2.3 Hz, 3H), 
1.94 – 1.85 (m, 3H), 1.64 (d, J = 13.7 Hz, 3H), 1.53 (dd, J = 15.3, 4.9 Hz, 2H), 1.28 – 
1.23 (m, 7H), 1.20 (d, J = 6.4 Hz, 3H), 1.16 (d, J = 6.0 Hz, 3H), 1.11 (d, J = 8.3 Hz, 3H), 
1.09 (s, 3H), 1.03 (d, J = 6.7 Hz, 3H), 0.99 (s, 3H). 13C NMR (101 MHz, CDCl3) δ (ppm) 
178.2, 176.2, 169.8, 166.3, 100.6, 95.4, 83.8, 78.7, 78.1, 75.8, 74.9, 74.4, 73.5, 72.6, 71.8, 
70.1, 68.2, 65.6, 63.7, 61.9, 49.3, 45.1, 42.0, 40.7, 36.5, 35.1, 30.4, 27.2, 26.3, 22.5, 22.0, 
21.6, 21.2, 21.1, 18.5, 16.3, 15.4, 11.3, 9.2, 7.8. HRMS (ESI) m+2/2z Calcd. for 
C40H76N2O13 [M+2H
+]/2: 396.2668, found 396.2656. 
2.9.5.15. 4-Oxo-3-O-acetylazithromycin (14) 
N-Iodosuccinimide (0.75 g, 5.61 mmol) was dissolved in anhydrous DCM (20 
mL) and the solution was cooled to -15 °C. After 10 min, dimethyl sulfide (0.5 ml, 6.32 
mmol) was added drop wise. The white suspension was stirred at -15 C for 20 min, then 
a DCM solution (5 mL) of compound 13 (2.78 g, 3.51 mmol) was added over 30 min. 
The resulting suspension was stirred at -15 °C for 30 min, and triethylamine (0.8 ml, 5.6 
mmol) was added. The solution became clear in a minute and stirring was continued at -
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10 °C for 2 h. The reaction was quenched by adding saturated aqueous NaHCO3 solution 
and the organic layer was separated. The aqueous layer was extracted twice with DCM 
(2x 50 mL). The combined organic layer was washed with water 50 mL), brine (50 mL), 
dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude was purified 
by column chromatography (Silica gel, 12:1:0.5 DCM: MeOH: NH4OH) to yield the 
product (2.49 g 90%) as white solid. 1H NMR (400 MHz, CDCl3) δ 1H NMR (400 MHz, 
CDCl3), 6.21 (d, J = 41.6 Hz, 2H), 5.27 (t, J = 6.6 Hz, 1H), 5.19 (s, 1H), 5.05 (t, J = 7.0 
Hz, 1H), 5.00 – 4.93 (m, 1H), 4.93 – 4.87 (m, 1H), 4.72 – 4.54 (m, 1H), 4.39 (q, J = 6.6 
Hz, 1H), 4.36 – 4.27 (m, 1H), 4.11 – 4.06 (m, 1H), 4.05 – 3.99 (m, 5H), 3.50 – 3.41 (m, 
1H), 3.36 (d, J = 6.1 Hz, 1H), 3.29 (s, 1H), 3.26 (s, 3H), 3.24 – 3.20 (m, 5H), 3.18 – 3.12 
(m, 1H), 2.70 – 2.51 (m, 4H), 2.41 (d, J = 12.0 Hz, 1H), 2.20 (dt, J = 16.6, 9.6 Hz, 4H), 
2.15 – 2.08 (m, 2H), 2.01 (d, J = 4.6 Hz, 1H), 1.97 (s, 3H), 1.93 (s, 1H), 1.86 (s, 3H), 
1.72 – 1.65 (m, 1H), 1.65 – 1.57 (m, 1H), 1.53 (d, J = 14.9 Hz, 1H), 1.47 – 1.38 (m, 1H), 
1.34 – 1.28 (m, 7H), 1.22 (t, J = 6.2 Hz, 1H), 1.18 (d, J = 7.3 Hz, 1H), 1.09 (ddd, J = 
23.5, 15.0, 8.7 Hz, 3H), 0.97 (d, J = 8.6 Hz, 3H), 0.84 (dd, J = 6.6, 3.3 Hz, 3H), 0.82 – 
0.72 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 211.4, 210.7, 177.7, 176.6, 173.3, 170.0, 
169.9, 101.8, 100.4, 97.7, 95.4, 85.1, 82.8, 81.2, 73.8, 72.6, 70.7, 69.2, 68.4, 63.2, 62.3, 
60.7, 50.9, 49.8, 45.4, 44.5, 41.4, 40.2, 36.2, 29.3, 26.9, 24.0, 22.6, 20.7, 16.2, 14.5, 11.6, 
10.8, 8.5, 7.8. HRMS (ESI) m/2z Calcd. for C40H73N2O13 [M + 2H
+]/2: 395.2590, found 
395.2587. 
2.9.5.16. 4-Epoxy-3-O-acetylazithromycin (15) 
NaH (0.3 g, 7.18 mmol, 60% w/w) was added to an oven dried three necked 
round bottom flask and was washed with petroleum ether (×3). The flask was 
immediately flushed with argon and dry DMSO (6 mL) was introduced through a septum. 
The mixture was stirred at room temperature under Ar. Over a priod of 5 min, 
trimethyloxosulfonium iodide (1.58 g, 7.18 mmol) was added to the reaction mixture. 
 88 
When hydrogen gas ceased to evolve, the resulting yellow clear solution was treated with 
a solution of oxidized azithromycin 14 (2.57 g, 3.26 mmol) in anhydrous THF (5 mL) 
over 10 min, and left to stir for 2 h. TLC (4:3:1:0.1 Hexane: EtOAc: MeOH: NH4OH) 
after 2 h showed 100% conversion to the product. THF was removed under vacuum and 
EtOAc (50 mL) was added to the remaining solution. The solution was washed severely 
with water to remove DMSO. Organic layer was dried over Na2SO4 and concentrated to 
give the product (2.48 g, 95% yield) as white solid. 1H NMR (400 MHz, CDCl3) δ 5.04 
(d, J = 17.3 Hz, 2H), 4.83 (s, 1H), 4.68 (d, J = 11.2 Hz, 2H), 4.06 (s, 1H), 3.68 (s, 2H), 
3.63 – 3.52 (m, 2H), 3.29 (p, J = 16.5 Hz, 7H), 2.86 (s, 2H), 2.72 – 2.39 (m, 9H), 2.11 
(dd, J = 21.0, 9.5 Hz, 4H), 1.98 (d, J = 14.8 Hz, 2H), 1.83 (s, 3H), 1.66 – 1.47 (m, 5H), 
1.41 (s, 3H), 1.27 (dt, J = 58.5, 7.3 Hz, 14H), 1.06 – 0.98 (m, 9H), 0.96 (s, 3H), 0.90 – 
0.73 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 180.6, 167.0, 158.0, 127.9, 121.1, 104.1, 
102.5, 95.8, 92.1, 74.2, 73.6, 64.7, 63.5, 60.3, 56.2, 50.0, 49.6, 46.4, 45.4, 43.3, 42.3, 
41.2, 40.4, 37.1, 36.7, 31.9, 29.8, 28.4, 26.9, 25.5, 23.6, 22.6, 20.9, 18.3, 16.8, 15.4, 14.1, 
13.9, 11.4, 8.9, 7.9. HRMS (ESI) m/z Calcd. for C41H74N2O13 [M + H
+]: 803.5264, found 
803.5262. 
2.9.5.17. 1-(4-Ethynylphenyl)-N-methylmethanamine (16) 
Methylamine (9.32 mL, 18.63 mmol, 2M in THF) was added to a solution of 4-
ethynylbenzyl methanesulfonate (3) (0.39 g, 1.86 mmol) in THF (20 mL) and left to stir 
at 50 C for 12 h. Methylamine was evaporated off and the residue dissolved in 1M HCl. 
This was then extracted multiple times with DCM. The aqueous layer was basified with 
1M NaOH and extracted with DCM. Organic layer was dried over anhydrous Na2SO4 and 
concentrated in vacuo. The residue obtained was purified by column chromatography to 
give compound 16 as a yellow liquid (0.15g, 55%). 1H NMR (400 MHz, CDCl3) δ (ppm) 
7.41 – 7.36 (d, 2H), 7.20 (d, J = 8.4 Hz, 2H), 3.65 (d, J = 9.0 Hz, 2H), 3.03 (d, J = 3.2 
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Hz, 1H), 2.65 (s, 1H), 2.34 (s, 3H). 13C NMR (101 MHz, CDCl3) δ (ppm) 140.5, 132.1, 
128.1, 120.6, 83.7, 55.3, 35.6. 
2.9.5.18. (4-(Methylamino)-N(methyl)(4-ethynylbenzyl))azithromycin (17) 
Compound 35 (1.057 g, 7.3 mmol) was added to a solution of compound 34 (1.95 
g, 2.4 mmol) in MeOH (10 mL). The mixture was stirred under argon at 60 C for 6 h , 
after that the solution was cooled to room temperature and diluted with excess ethyl 
acetate (100 mL). The organic layer was washed with saturated aqueous NaHCO3 
solution (30 mL), water (20 mL), brine (20 mL), dried over anhydrous Na2SO4, filtered 
and concentrated in vacuo. The crude was purified by column chromatography column 
(Silica gel, 4:3:2:0.1 Hexane: EtOAc: MeOH: NH4OH) to give compound 37 as light 
yellow solid ( 2.0 g, 92% yield) .1H NMR (400 MHz, CDCl3) δ (ppm) 7.43 (d, J = 8.2 
Hz, 2H), 7.21(d, 2H), 5.04 (d, J = 4.6 Hz, 1H), 4.62 (d, J = 8.6 Hz, 1H), 4.44 (d, J = 6.0 
Hz, 1H), 4.24 – 4.15 (m, 3H), 3.67 (d, J = 6.4 Hz, 2H), 3.63 (s, 3H), 3.46 (s, 3H), 3.26 (d, 
J = 21.0 Hz, 6H), 3.05 (s, 1H), 2.95 (d, J = 14.7 Hz, 3H), 2.81 (d, J = 7.1 Hz, 3H), 2.66 
(s, 3H), 2.44 (d, J = 10.1 Hz, 2H), 2.31 (d, J = 10.5 Hz, 9H), 2.18 (s, 3H), 2.15 (d, J = 0.5 
Hz, 1H), 2.02 (t, J = 11.7 Hz, 3H), 1.92 (dd, J = 15.0, 5.0 Hz, 2H), 1.29 (s, 3H), 1.21 (t, J 
= 6.9 Hz, 10H), 1.14 (s, 3H), 1.12 – 1.02 (m, 10H), 0.88 (t, J = 7.6 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) δ (ppm) 178.6, 139.4, 132.2, 128.8, 121.2, 102.8, 95.0, 94.8, 83.8, 
83.3, 76.8, 74.2, 73.5, 70.9, 70.1, 68.1, 67.2, 67.2, 65.7, 63.2, 62.6, 62.5, 56.9, 49.6, 49.5, 
45.4, 45.2, 43.2, 42.3, 42.2, 41.1, 40.9, 40.5, 40.4, 36.2, 31.3, 29.0, 27.5, 26.7, 22.7, 21.9, 
21.3, 18.8, 16.2, 15.0, 14.6, 11.2, 9.2, 7.2. HRMS (ESI) m+2/2z Calcd. for C49H85N3O12 
[M + 2H+]: 453.8061, found 453.8055. 
2.9.5.19. (Azithromycin-4-(methylamino)-N(methyl)(4-benzyltriazolyl))-N-
hydroxyacetamide (18a)  
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(4-(Methylamino)-N(methyl)(4-ethynylbenzyl))azithromycin  17 (0.14 g, 0.16 
mmol) and 2-Azido-N-((tert-butyldimethyl silyl)oxy) ethaneamide 5a (0 .06 g, 0.23 
mmol) were dissolved in anhydrous THF (5 mL) and purged with Ar for 15 min. Copper 
(I) iodide (0.01 g, 0.08 mmol) and Hunig’s base (0.06 mL, 0.31 mmol) were then added 
to the reaction mixture. The reaction mixture was purged with Ar for additional 15 
minand stirring continued for 12 h. Caesium fluoride (0.04 g, 0.24 mmol) and MeOH 
(5mL) were added to the mixture to remove TBS protecting group and the reaction 
continued for an additional 2 h. The reaction was quenched by adding a solution of 4:1 
saturated NH4Cl/NH4OH (30 mL) and extracted with 20% MeOH/ CH2Cl2 (3×30 mL). 
The organic layer was dried over Na2SO4 and concentrated in vacuo. The crude product 
was purified by preparative TLC (Silica gel, 5:1:1 EtOAc: MeOH: NH4OH) to give the 
product (0.131 g, 80% yield) as light yellow solid.  1H NMR (400 MHz, CD3OD) δ 
(ppm) 8.33 (s, 1H), 7.79 (d, J = 6.5 Hz, 2H), 7.37 (d, J = 7.1 Hz, 2H), 5.46 (s, 1H), 5.07 
(d, J = 4.6 Hz, 3H), 4.44 (d, J = 6.9 Hz, 1H), 4.32 – 4.18 (m, 3H), 3.69 (s, 2H), 3.64 – 
3.56 (m, 3H), 3.48 (d, J = 25.5 Hz, 2H), 3.34 (s, 3H), 3.32 – 3.21 (m, 3H), 3.09 – 2.93 
(m, 3H), 2.85 – 2.64 (m, 3H), 2.41 (t, J = 20.9 Hz, 12H), 2.33 – 2.20 (m, 3H), 2.19 – 2.09 
(m, 3H), 2.00 (dd, J = 25.3, 18.4 Hz, 3H), 1.95 – 1.83 (m, 3H), 1.82 – 1.70 (m, 3H), 1.52 
– 1.39 (m, 3H), 1.32 (s, 3H), 1.24 (d, J = 6.3 Hz, 3H), 1.22 – 1.12 (m, 13H), 1.08 (s, 3H), 
1.03 (d, J = 7.2 Hz, 3H), 0.96 – 0.82 (m, 3H). 13C NMR (126 MHz, CD3OD) δ (ppm) 
180.5, 177.3, 149.4, 140.9, 131.9, 131.6, 127.7, 124.6, 105.0, 102.0, 97.7, 85.6, 80.3, 
78.9, 78.3, 76.3, 76.0, 73.6, 73.2, 73.0, 71.0, 69.8, 69.5, 67.0, 65.5, 65.0, 59.0, 51.0, 47.6, 
45.0, 44.5, 44.1, 41.4, 37.7, 33.9, 33.2, 32.6, 31.6, 31.4, 28.6, 28.2, 24.6, 23.2, 23.0, 20.2, 
18.2, 16.5, 15.3, 12.3, 10.7, 8.8. HRMS (ESI) m+2/2z Calcd. for C51H89N7O14 [M + 2H
+]: 





Reaction of (4-(methylamino)-N(methyl)(4-ethynylbenzyl))azithromycin  17 
(0.20 g, 0.218 mmol) and 3-azido-N-((tert-butyldimethylsilyl)oxy)propanamide 5b (0.08 
g, 0.32 mmol) followed by TBS deprotection with cesium fluoride as described for the 
synthesis of 18a, gave 18b as light yellow solid (0.178 g, 79%). 1H NMR (500 MHz, 
CD3OD) δ (ppm) 8.26 (d, J = 10.7 Hz, 1H), 7.78 (d, J = 7.6 Hz, 2H), 7.39 (d, J = 7.8 Hz, 
2H), 5.48 (s, 1H), 5.13 – 5.07 (m, 2H), 4.74 (s, 3H), 4.46 (d, J = 7.2 Hz, 2H), 4.32 – 4.22 
(m, 1H), 3.69 (d, J = 18.3 Hz, 3H), 3.67 – 3.57 (m, 1H), 3.57 – 3.48 (m, 2H), 3.38 (d, J = 
13.2 Hz, 3H), 3.33 – 3.25 (m, 1H), 3.02 (dd, J = 23.0, 16.2 Hz, 3H), 2.86 – 2.75 (m, 3H), 
2.74 – 2.65 (m, 3H), 2.44 (s, 3H), 2.31 – 2.19 (m, 3H), 2.19 – 2.10 (m, 2H), 2.09 – 1.97 
(m, 3H), 1.94 – 1.87 (m, 9H), 1.87 – 1.82 (m, 2H), 1.81 – 1.72 (m, 3H), 1.53 – 1.40 (m, 
3H), 1.35 (d, J = 11.2 Hz, 3H), 1.27 (t, J = 11.9 Hz, 13H), 1.24 – 1.19 (m, 3H), 1.16 (d, J 
= 6.7 Hz, 3H), 1.10 (s, 3H), 1.05 (d, J = 7.5 Hz, 3H), 0.96 – 0.86 (s, 3H). 13C NMR (126 
MHz, CD3OD) δ (ppm) 180.4, 177.1, 169.8, 149.2, 140.8, 131.8, 131.3, 127.5, 123.5, 
104.8, 97.3, 85.4, 80.3, 78.9, 78.3, 76.2, 76.0, 74.5, 73.4, 72.9, 70.9, 69.9, 69.2, 66.8, 
65.6, 65.0, 63.0, 58.8, 57.0, 55.8, 50.9, 48.1, 47.5, 44.8, 43.9, 41.3, 37.7, 33.9, 32.7, 31.6, 
28.3, 24.5, 23.3, 22.8, 21.2, 20.1, 18.2, 16.8, 15.2, 12.3, 10.8, 8.8. HRMS (ESI) m/z 
Calcd. for C52H90N7O14 [M+H
+]: 1036.6540, found 1036.6550. 
2.9.5.21. (Azithromycin-4-(methylamino)-N(methyl)(4-benzyltriazolyl))-N-
hydroxybutanamide (18c) 
Reaction of (4-(methylamino)-N(methyl)(4-ethynylbenzyl))azithromycin  17 
(0.20 g, 0.18 mmol) and 4-azido-N-((tert-butyldimethylsilyl)oxy) butanamide 5c (0 .08 g, 
0.31 mmol) followed by TBS deprotection with caesium fluoride as described for the 
synthesis of 18a, gave 18c as light yellow solid (0.173 g, 80%). 1H NMR (400 MHz, 
 92 
CD3OD) δ (ppm) 8.30 (s, 1H), 7.76 (d, J = 7.2 Hz, 2H), 7.34 (d, J = 7.7 Hz, 2H), 5.44 (s, 
1H), 5.06 (d, J = 4.7 Hz, 1H), 4.51 – 4.35 (m, 3H), 4.30 – 4.19 (m, 2H), 3.60 (dd, J = 
23.4, 16.5 Hz, 3H), 3.45 (d, J = 25.7 Hz, 1H), 3.32 (s, 3H), 3.27 – 3.16 (m, 3H), 2.99 (d, 
J = 14.7 Hz, 1H), 2.84 – 2.69 (m, 2H), 2.63 – 2.43 (m, 2H), 2.30 (d, J = 14.5 Hz, 10H), 
2.24 – 2.04 (m, 15H), 1.95 (dd, J = 13.7, 6.5 Hz, 3H), 1.91 – 1.77 (m,3H), 1.77 – 1.64 
(m, 3H), 1.49 – 1.30 (m, 3H), 1.27 (s, 3H), 1.21 (d, J = 6.0 Hz, 6H), 1.16 (d, J = 6.1 Hz, 
11H), 1.03 (dd, J = 19.7, 6.7 Hz, 7H), 0.85 (dd, J = 14.1, 7.0 Hz, 3H). 13C NMR (126 
MHz, CD3OD) δ (ppm) 180.7, 177.2, 149.4, 141.0, 131.9, 131.6, 127.7, 123.7, 104.9, 
97.6, 85.5, 80.4, 78.8, 78.4, 76.4, 76.2, 74.5, 73.6, 73.1, 70.9, 69.9, 69.4, 66.9, 65.7, 64.9, 
57.2, 55.6, 51.1, 48.2, 47.5, 44.9, 44.3, 43.9, 41.5, 37.7, 34.0, 33.6, 33.4, 32.8, 31.7, 31.4, 
28.5, 28.2, 24.6, 23.2, 22.7, 20.3, 18.2, 16.7, 15.3, 12.5, 10.8, 8.7. HRMS (ESI) m+2/2z 
Calcd. for C53H93N7O14 [M+2H
+]: 525.8385, found 525.8385. 
2.9.5.22. (Azithromycin-4-(methylamino)-N(methyl)(4-benzyltriazolyl))-N-
hydroxypentanamide (18d) 
Reaction of (4-(methylamino)-N(methyl)(4-ethynylbenzyl))azithromycin  17 
(0.14 g, 0.15 mmol) and 5-azido-N-((tert-butyldimethylsilyl)oxy) pentanamide 5d (0.06 
g, 0.23 mmol) followed by TBS deprotection with caesium fluoride as described for the 
synthesis of 18a, gave 18d as light yellow solid (0.125 g, 75%). 1H NMR (400 MHz, 
CD3OD) δ (ppm) 7.72 (s, 1H), 7.19 (d, J = 7.9 Hz, 2H), 6.77 (d, J = 8.0 Hz, 2H), 4.47 (d, 
J = 5.0 Hz, 1H), 3.85 (d, J = 6.7 Hz, 3H), 3.63 (dd, J = 17.6, 4.5 Hz, 2H), 3.09 (s, 2H), 
3.04 – 2.97 (m, 3H), 2.75 (s, 3H), 2.68 (dt, J = 3.3, 1.6 Hz, 2H), 2.43 (d, J = 14.3 Hz, 
2H), 2.19 (dd, J = 7.4, 4.6 Hz, 2H), 2.12 (d, J = 11.6 Hz, 1H), 1.89 (d, J = 18.4 Hz, 15H), 
1.64 (d, J = 7.1 Hz, 5H), 1.59 – 1.46 (m, 6H), 1.37 (dd, J = 16.4, 7.9 Hz, 7H), 1.15 (t, J = 
7.3 Hz, 1H), 1.03 (s, 3H), 0.85 (td, J = 14.5, 7.5 Hz, 3H), 0.73 (s, 3H), 0.60 (ddd, J = 
18.8, 13.2, 6.4 Hz, 15H), 0.49 (s, 3H), 0.43 (d, J = 7.3 Hz, 3H), 0.32 (d, J = 6.8 Hz, 3H), 
0.27 (t, J = 7.4 Hz, 3H) .13C NMR (126 MHz, CD3OD) δ (ppm) 180.2, 176.9, 172.9, 
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149.1, 140.6, 131.6, 127.3, 122.8, 104.7, 97.1, 85.3, 80.1, 78.6, 78.0, 76.1, 75.8, 74.3, 
73.1, 71.1, 69.7, 66.6, 64.6, 64.5, 62.8, 58.7, 56.9, 55.5, 52.7, 51.6, 50.8, 47.3, 44.5, 44.1, 
43.9, 41.4, 37.3, 33.6, 33.0, 32.7, 31.3, 30.0, 28.6, 26.7, 24.2, 23.1, 22.7, 20.0, 17.9, 16.4, 





Reaction of (4-(methylamino)-N(methyl)(4-ethynylbenzyl))azithromycin  17 
(0.09 g, 0.10 mmol) and 6-azido-N-((tert-butyldimethylsilyl)oxy)hexanamide 5e (0.04 g, 
0.16 mmol) followed by TBS deprotection with caesium fluoride as described for the 
synthesis of 18a, gave 18e as light yellow solid (0.090 g, 80%). 1H NMR (400 MHz, 
CD3OD) δ (ppm) 8.27 (s, 1H), 7.74 (d, J = 8.1 Hz, 2H), 7.32 (d, J = 8.1 Hz, 2H), 5.05 (d, 
J = 5.0 Hz, 1H), 4.78 (dd, J = 10.0, 2.3 Hz, 3H), 4.37 (dd, J = 15.3, 7.2 Hz, 3H), 4.23 (dd, 
J = 12.4, 5.5 Hz, 2H), 4.00 (dq, J = 13.6, 6.9 Hz, 1H), 3.66 (d, J = 17.8 Hz, 1H), 3.60 – 
3.52 (m, 2H), 3.46 (dd, J = 9.9, 5.4 Hz, 1H), 3.29 (d, J = 12.7 Hz, 3H), 3.26 – 3.16 (m, 
3H), 3.02 – 2.93 (m, 1H), 2.78 – 2.68 (m, 2H), 2.59 – 2.46 (m, 1H), 2.27 (d, J = 16.0 Hz, 
3H), 2.22 – 2.15 (m, 3H), 2.10 (t, J = 8.1 Hz, 2H), 2.03 (d, J = 16.0 Hz, 3H), 1.97 – 1.91 
(m, 5H), 1.91 – 1.86 (m, 3H), 1.83 (d, J = 3.9 Hz, 2H), 1.73 – 1.63 (m, 2H), 1.60 – 1.47 
(m, 3H), 1.32 (dd, J = 21.9, 6.6 Hz, 6H), 1.26 (d, J = 5.2 Hz, 3H), 1.23 – 1.17 (m, 6H), 
1.17 – 1.08 (m, 11H), 1.01 (dd, J = 17.4, 6.0 Hz, 11H), 0.89 – 0.79 (m, 3H). 13C NMR 
(126 MHz, CD3OD) δ (ppm) 180.2, 177.0, 173.3, 149.2, 140.7, 131.8, 131.3, 127.4, 
122.9, 104.8, 97.2, 85.4, 80.1, 78.8, 78.3, 76.4, 75.9, 73.3, 73.2, 71.3, 69.9, 69.1, 66.6, 
64.9, 58.7, 55.6, 53.0, 52.0, 50.9, 47.5, 44.7, 44.2, 43.9, 41.4, 37.4, 34.2, 33.7, 33.1, 32.6, 
31.6, 30.3, 28.5, 28.2, 27.5, 26.6, 24.4, 22.9, 22.7, 20.0, 18.0, 16.4, 16.1, 12.4, 10.6, 8.4. 
HRMS (ESI) m+2/2z Calcd. for C55H97N7O14 [M+2H




Reaction of (4-(methylamino)-N(methyl)(4-ethynylbenzyl))azithromycin  17 
(0.16 g, 0.18 mmol) and 7-azido-N-((tert-butyldimethylsilyl)oxy)heptanamide 5f (0.08 g, 
0.27 mmol) followed by TBS deprotection with caesium fluoride as described for the 
synthesis of 18a, gave 18f as light yellow solid (0.154 g, 80%). 1H NMR (400 MHz, 
CD3OD) δ (ppm) 7.71 (s, 1H), 7.18 (d, J = 8.1 Hz, 2H), 6.77 (d, J = 8.1 Hz, 2H), 4.49 (d, 
J = 5.0 Hz, 1H), 3.83 (dd, J = 10.2, 7.1 Hz, 3H), 3.72 – 3.63 (m, 2H), 3.50 – 3.40 (m, 
1H), 3.11 (d, J = 16.2 Hz, 1H), 3.02 (d, J = 7.0 Hz, 1H), 2.99 – 2.95 (m, 1H), 2.90 (dd, J 
= 17.7, 14.2 Hz, 1H), 2.75 (s, 3H), 2.71 – 2.62 (m, 3H), 2.43 (d, J = 14.7 Hz, 1H), 2.24 
(d, J = 7.0 Hz, 1H), 2.18 (dd, J = 7.5, 4.6 Hz, 1H), 2.00 (t, J = 14.8 Hz, 1H), 1.75 (d, J = 
10.6 Hz, 9H), 1.70 – 1.58 (m, 6H), 1.55 – 1.44 (m, 3H), 1.44 – 1.34 (m, 3H), 1.33 – 1.30 
(m, 3H), 1.31 – 1.25 (m, 3H), 1.19 – 1.10 (m, 2H), 1.04 (d, J = 7.4 Hz, 3H), 0.76 (dd, J = 
20.3, 12.8 Hz, 3H), 0.70 (s, 3H), 0.68 – 0.61 (m, 6H), 0.60 (dt, J = 12.7, 4.4 Hz, 12H), 
0.53 – 0.46 (m, 10H), 0.43 (d, J = 7.5 Hz, 5H), 0.34 – 0.24 (m, 3H). 13C NMR (126 MHz, 
CD3OD) δ (ppm) 180.5, 177.4, 173.6, 149.4, 149.0, 140.7, 132.3, 131.9, 131.5, 127.6, 
123.2, 122.9, 105.1, 97.3, 85.6, 80.2, 78.9, 78.2, 76.5, 75.8, 73.5, 71.6, 70.1, 69.3, 66.7, 
65.1, 64.7, 58.7, 55.8, 53.3, 52.2, 50.9, 47.7, 44.9, 44.5, 44.3, 41.8, 37.7, 34.4, 33.4, 32.9, 
32.0, 31.6, 30.7, 30.3, 28.9, 28.0, 27.4, 23.3, 20.2, 18.4, 16.7, 16.5, 12.6, 10.9, 8.6. 
HRMS (ESI) m+2/2z Calcd. for C56H99N7O14 [M+2H
+]: 546.8620, found 546.8621. 
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ISOFORM SELECTIVE AZITHROMYCIN HDAC INHIBITOR 
CONJUGATES 
3.1. Introduction 
Epigenetic irregularities are key factors in many human diseases including cancer 
[1]. One class of epigenetic regulators is histone deacetylase (HDAC) that, together with 
histone acetyl transferase (HAT), regulate the chromatin structure by determining the 
histone acetylation state [2].  
HDACs repress gene expression by removing the acetyl group from the terminal 
lysine of histone tail. There are 18 HDAC isoforms divided into two groups of zinc and 
NAD+ dependent. Class I (HDAC1, 2, 3, 8), class IIa (HDAC4, 5, 7, 9), class IIb 
(HDAC6, 10), and class IV (HDAC11) are zinc dependent and have a zinc cation in their 
active site pockets [3] while class III (SIRT 1-7) is NAD+ dependent. HDACs 
dysfunction including overexpression has been observed in many cancerous pathologies. 
Various HDAC isoforms are expressed in different tumor tissues, therefore, they have 
emerged as encouraging therapeutic targets over the past few decades [4]. 
It has been shown that small molecules can modulate HDAC enzymes biological 
activities [5]. There has been extensive research on the design and synthesis of HDAC 
inhibitors (HDACi) and this has so far led to FDA approval of suberoylanilide 
hydroxamic acid (SAHA) for cutaneous T-cell lymphoma [6], romidepsin (FK228) for 
cutaneous T-cell lymphoma and refractory peripheral T-cell lymphoma [7], belinostat 
(PXD101) for relapsed and refractory peripheral T-cell lymphoma [8], and recent 
accelerated approval of panobinostat (SB939) for multiple myeloma [9]. Chidamide 
(epidaza), is another HDACi that was developed and approved in China for relapsed and 
refractory peripheral T cell lymphoma [10]. Chidamide is currently in clinical trials in US 
[11].  
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However, despite the promising results of HDACi, they are associated with 
several side effects possibly due to the role of HDAC enzymes in regulation of various 
proteins involved in different normal biological processes [12]. Clinical studies revealed 
that non-selective inhibition of HDAC enzymes (Figure 3.1) lead to adverse effects 
including bone marrow depression, fatigue, diarrhea, weight lost, and cardiac toxicities 
and arrhythmias [13]. Thus, there is an unmet need to design and synthesize isoform-
selective HDACis to impede only cancerous pathologies rather than affecting the normal 
cells in order to avoid side effects.  
Figure 3.1. US FDA approved pan-HDACis. These HDACi are affiliated with numerous 
side effects mostly due to their non-selective HDAC inhibition. 
3.2. Isoform selective HDACi  
Hydroxamate zinc binding group (ZBG) is associated with poor bioavailability as 
well as short half-life due to its enzymatic hydrolysis [14]. FDA approved HDACi 
bearing hydroxamate moiety are pan-inhibitors and lack isoform selectivity. They show 
poor pharmacokinetics and rapid clearance as well as various off-target interactions 
including inhibition of the hERG cardiac channel leading to cardiotoxicity [15]. 
However, in contrast, there is a hope that more selective HDACi will have wider 
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therapeutic index [16], [17]. There has been extensive effort aimed at developing isoform 
selective HDACi. Much of these studies have focused on replacing the common HDACi 
hydroxamate ZBG with alternatives that, in addition to being more stable and have longer 
half-lives, possess isoform selective HDAC inhibitory activity.    
Previous study has shown that substitution of hydroxamate with benzamide 
resulted in HDACi with class I isoform selectivity [18]. Crystallographic comparison of 
bacterial homologues of class I and class II revealed the existence of a 14 Å internal 
cavity within the HDAC active site near the catalytic metal cation (Figure 3.2) [19], [20], 
which is postulated to act as a channel for the release of the acetate byproduct after 
deacetylation of histone tail [21], [22]. The hydrophobic nature of the inner cavity 
suggested that hydrophobic substituents can be placed on the benzamide to enhance 
binding affinity to HDACs 1, 2 and 3[23].          
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Figure 3.2. Docking study of our proposed design of N-(2-amino-5-(thiophen-2-
yl)phenyl)acylamide derived azithromycin against HDAC2. The grey sphere represents 
zinc ion in the active pocket of HDAC2.  
 
To date, several class I isoform selective HDACi containing benzamide ZBG 
have been synthesized. Chidamide (CS055), is a benzamide derived HDACi that has been 
used for relapsed and refractory peripheral T-cell lymphoma in China, and is in clinical 
trials in US [10]. Etinostat (MS-275) is a benzamide derived class I HDACi that is in 
clinical trials both as a monotherapy and in combination with other therapeutic agents for 
treating advanced and refractory solid tumors, non-small cell lung cancer (NSCLC) and 
breast cancer [24]. Mocetinostat (MGCD0103) is another HDACi with benzamide zinc 
binding group that is selective toward class I and class IV HDAC isoforms. Mocetinostat 
is in clinical trials as a standalone therapy for treating leukemia, myelodysplastic 
syndrome (MDS), chronic lymphocytic leukemia (CLL), advanced solid tumors, and 
relapsed Hodgkin’s lymphoma (Figure 3.3) [25], [26]. 
    
Figure 3.3. Mocetinostat entinostat, and chidamide three benzamide derived HDACi in 
clinical trials for treating various types of cancers [11], [27].   
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3.3. Isoform selective HDACi design 
To design and develop more selective HDACi, various benzamide-derived 
HDACi have been evaluated [23], [28]. MS-275 was the first reported benzamide derived 
HDACi with strong HDAC inhibitory potency, suggesting that the 2‘-substituent of 
benzanilide has hydrogen bonding and electrostatic interactions with the enzyme amino 
acid residues  [29], [30]. In 2007, Moradei O. M. et al. reported isoform selective 
benzamide derived HDACi with enhanced potency and selectivity bearing an 
aminophenyl group attached to the benzamide zinc bonding group. Their most potent 
synthesized HDACi with a thienyl substitution on the benzamide exhibited a nanomolar 
range HDAC inhibitory potency toward HDAC1 and HDAC2 as well as nanomolar range 
cytotoxicity toward HCT116, human colon cancer cell line [23].   
In chapter 1, I had synthesized non-peptide macrocyclic pan HDACi with 
hydroxamic acid as the ZBG, derived from azithromycin that mimic the peptide 
backbone of macrocyclic HDACi [2], [31]. I hypothesized that replacement of the 
hydroxamic acid ZBG of azithromycin conjugated HDACi with benzamide ZBG will 
result in class I isoform selective HDACi [27]. Therefore, following the three motif 
pharmacophoric model of HDACi, I designed and synthesized a new class of 
azithromycin conjugated HDACi by changing the ZBG from hydroxamic acid to the 
thienyl benzamide in order to achieve isoform selective HDACi [23], [32]. Aryl triazole 
group was attached to the cap recognition group to enhance HDAC inhibition potency 




                 
Figure 3.4. Three-motif pharmacophoric model of SAHA as well as selected examples of 
designed and published class I selective N-(2-amino-5-(thiophen-2-yl)phenyl)acylamide  
derived HDACi, which led to the design of azithromycin conjugated N-(2-amino-5-
 128 
(thiophen-2-yl)phenyl)acylamide derived HDACi. The thienyl group fits favorably in the 
14 Å internal cavity of HDAC enzyme and improve the HDAC inhibitory potency 
through hydrophobic interactions with lipophilic amino acids residues of the cavity [22].   
Additionally, a structure activity relationship (SAR) was performed on the linker 
length to attain the optimal length for maximum HDAC inhibitory potency. Our previous 
study in designing macrolide conjugated HDACi revealed that the methylene spacers of 
the linker moiety ranging from one to four methylene groups exhibits no or low HDAC 
inhibition potency. While five and six methylene spacers had the maximum HDAC 
inhibitory activity [2]. Thus, in this design the linker length is varied from five to seven 
methylene spacers.      
3.4. Chemistry 
The azido N-(2-amino-5-(thiophen-2-yl)phenyl)acylamide intermediates 9a-c 
were synthesized as described in the literature [32], [28]. Starting from 4-bromo-2-
nitroaniline 1. Boc protection of 1, followed by Suzuki coupling [34], [35] with 2-
thiophenyl boronic acid 4 and reduction of the nitro group to amine using zinc powder 
[36] gave the Boc protected 2-amino-4-(thiophen-2-yl)phenyl 6. Coupling of compound 6 
with the azido carboxylic acid derivatives 8a-c [37], [38] followed by acid-promoted 
removal of the Boc protecting group yielded 9a-c (Scheme 3.1).   
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Scheme 3.1. (a) Et3N, DCM, reflux, overnight, 82%; (b) Pd(PPh3)4, K2CO3, THF, 70 °C, 
77%; (c) Zn, H2O: Dioxane (1:4), 70 °C, 3 days, 76%; (d) EDCI, HOBT, DMF, 70 °C, 6 
h, 62-92%; (e) TFA (1%), DCM, rt, 2h, 45-73%.  
The surface recognition cap group, 3′-N-(4-ethynylbenzyl) azithromycin 13 was 
synthesized by removing the methyl group and formation of desmethyl azithromycin 11, 
followed by introduction of ethynylbenzyl on the desosamine sugar ring (Scheme 3.2) 
[2], [31], [39].  
 
Scheme 3.2. (f) I2, NaOAc, MeOH, 50 °C, 2 h, 90%; (b) Hünig’s base, DMSO, 85 °C, 3 
h, 96%.   
Azithromycin conjugated N-(2-amino-5-(thiophen-2-yl)phenyl)acylamide derived 
HDACi 14a-c were synthesized through copper (I) catalyzed azide-alkyne-cycloaddition 
(AAC) reaction [40] of 2-thienyl benzamide zinc binding group 9a-c with 3′-N-(4-
ethynylbenzyl) azithromycin 13 (Scheme 3.3).  
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Scheme 3.3. (h) CuI, Hunig’s base, THF, rt, overnight, 47-71%.  
3.5. HDAC inhibitory activity (Performed by Dr. James Kornaki at 
Northwestern University and BPS BioScience)  
 To investigate the HDAC inhibition activities of azithromycin conjugated N-(2-
amino-5-(thiophen-2-yl)phenyl)acylamide derived HDACi 14a-c, they were tested 
against class I (HDAC1, 2, 3 and 8) and class IIb (HDAC6) enzymes. We used the 
previously synthesized hydroxamate derivative of azithromycin 15 (synthesized by Dr. 
Subhasish Tapadar) and SAHA as positive controls. HDAC inhibition activity was 
determined using the label-free mass spectrometry-based SAMDI assay. As expected 
azithromycin conjugated N-(2-amino-5-(thiophen-2-yl)phenyl)acylamide derived HDACi 
showed class I isoform selectivity with no HDAC inhibition activity against HDAC6, 
while azithromycin derived hydroxamate HDACi hit HDAC6 as well and exhibited no 
selectivity for HDAC isoforms (Table 3.1).  We then screened lead 15 and compound 
14b against all Zn-dependent HDAC isoforms using the Fluor de Lys assay available 
through BPS Bioscience (San Diego, USA). Fluorescent intensity was measured at 
certain wavelengths. The IC50 values were obtained employing fluorescent intensity in 
related equations to determine the concentration leading to half maximal percent activity 
(Table 3.2). 
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Table 3.1. HDAC 1, 2, 3, 6, and 8 inhibition activities of azithromycin conjugated N-(2-
amino-5-(thiophen-2-yl)phenyl)acylamide derived HDACi compounds (IC50 in nM) 
obtained using label-free mass spectrometry-based SAMDI assay, and their comparison 
with azithromycin derived hydroxamate and FDA approved pan- HDACi SAHA.   
Compound HDAC1 HDAC2 HDAC3 HDAC6 HDAC8 
14a 125±28 NI 123 NI NI 
14b 232±28 159±17 NI NI NI 
14c 217±23 65.1±23 29.4±7.8 NI NI 
15 50.4±8.4 NT NT 31.3±1.3 817±308 
SAHA 42 190 20 34 2800 
     NI= No Inhibition. NT= Not Tested 
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Table 3.2. HDAC inhibition potency against all Zn-dependent HDAC isoforms using the 
Fluor de Lys assay available through BPS Bioscience. 
HDAC inhibition  15 14b 
HDAC1 2.7 509 
HDAC2 8.1 3454 
HDAC3/NCOR2 1.7 NI 
HDAC4 1904 NI 
HDAC5 1773 NI 
HDAC6 1.7 NI 
HDAC7 2621 NI 
HDAC8 839 NI 
HDAC9 6910 NI 
HDAC10 4.5 2285 
HDAC11 7361 NI 
 
SAMDI assay was analyzed by SAMDI-MS and compounds were characterized 
by their m/z shifts after their acetyl loss. Fluor de Lys assay was analyzed by measuring 
the fluorescent signal generated after adding the developer to the substrate combination, 
by fluorescent plate scanner. The fluorescent signal was compared to positive and 
negative controls.   
3.6. Docking study  
Docking studies on azithromycin conjugated HDACi against HDAC isoforms 
were performed using AutoDock Vina. This study revealed a strong chelation of the zinc 
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ion at the bottom of the active pocket of class I isoforms to the benzamide ZBG (Figure 
3.5). This docking study confirmed the observed class I HDAC selectivity.  
 
Figure 3.5. Docked structure of azithromycin-HDACi conjugate with six methylene  
linker group (14b) against HDAC2.  
3.7. Anti-proliferative activity 
The azithromycin conjugated N-(2-amino-5-(thiophen-2- yl)phenyl)acylamide 
derived HDACi 14a-c were tested against three transformed cell lines, lung (A549), 
Estrogen receptor (ER) positive (MCF-7) and ER negative (MDA-MB231) breast cancers 
as well as one normal cell line (VERO) monkey kidney epithelial cell. We used 
hydroxamate derivative of azithromycin 15 and SAHA as positive controls. Despite their 
considerably weaker HDAC inhibition activities, compounds 14a-c possessed potent anti-
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proliferative activities against the tested tumor cell lines with 14b inherently more 
cytotoxic and tumor cell selective relative to 15 and SAHA (Table 3.2).  
 
 
Table 3.3. Anti-proliferative activity of azithromycin conjugated HDACi (IC50 values in 
µM). 
Compound A549 MCF-7 MDA-MB231 VERO 
14a 2.24±0.35 0.85±0.19 2.10±0.67 2.54±0.27 
14b 1.72±0.09 0.83±0.07 1.20±0.058 6.46±1.15 
14c 1.70±0.25 1.50±0.53 0.84±0.48 3.48±0.60 
15 2.32±0.53 4.08±0.30 NT 5.90±0.18 
SAHA 5.00±0.24 3.27±0.05 3.40±0.20 1.03±0.97 
Each value is obtained from a duplicate of three simultaneous experiments. NT=not tested 
   
Compound 14b was synthesized in a larger scale (1.5 g) sent to Augusta 
University (Professor Muthusamy Thangaraju’s Lab) for animal study.  
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3.8. In vivo study (Performed by Professor Muthusamy Thangaraju’s Lab at 
Augusta University)  
For in vivo studies, MMTV-PyMT-Tg mice were chosen since their mammary 
tumors mimic formation and progression of human breast cancer and they eventually 
metastasize to lung tissues. At the beginning tumors possess ER expression but ultimately 
they turn into ER negative breast tumors [41]. Mice with metastatic breast cancer were 
treated with 40 mg/kg body of compounds 14b (azithromycin conjugated N-(2-amino-5-
(thiophen-2- yl)phenyl)acylamide derived HDACi) and 15 (azithromycin conjugated 
hydroxamic acid derived HDACi) 3 times a week. After 6 weeks mice were sacrificed 






Figure 3.6. (A) Tumor regression and (B) number of nodules in MMTV-PyMT-Tg mice 
with metastatic lung cancer that were treated with compounds 14b and 15. Compound 
14b an isoform selective HDACi resulted in a better tumor regression compared to 
compound 15 a pan HDACi (Performed by Professor Muthusamy Thangaraju’s Lab 
at Augusta University). 
 
Compound 14b, a class I isoform selective HDACi, resulted in a greater tumor 
size regression compared to compound 15 a pan HDACi (Figure 3.7). HDAC1 strongly 
influences breast cancer progression. It promotes tumorigenesis and colony formation by 
suppressing the induction of ERα expression and its transcription activity [42]. ERα plays 
an important role in modulating tumor growth in breast cancer and loss of its expression 
and activity results in significant increase in tumor cell proliferation [43], [44], [45]. 
Therefore, selective inhibition of HDAC1 leads to a better breast cancer progression 
repression through re-expression of ER α-mRNA and its proteins [43].  
3.9. Conclusion 
I synthesized a new class of non-peptide macrocyclic N-(2-amino-5-(thiophen-2- 
yl)phenyl)acylamide derived HDACi that exhibited isoform selectivity toward class I 
HDAC isoforms, unlike their hydroxamate analogue and FDA approved pan-HDACin 
SAHA which show no selectivity for any classes of HDAC isoform. These azithromycin 
conjugated HDACi had a better therapeutic window and showed a low macromolar, and 
in some cases, high nanomolar cytotoxicity against transformed cell lines, lung (A549), 
ER positive (MCF-7) and ER negative (MDA-MB231) breast cancer, and less 





3.10.1. Materials and methods 
Azithromycin was purchased from Greenfield chemical. 4-ethynylbenzyl alcohol, 
thiophen-2-ylboronic acid, and 4-bromo-2-nitroaniline were purchased from Sigma-
Aldrich. All commercially available starting materials were used without purification. 
Reaction solvents were high performance liquid chromatography (HPLC) grade or 
American Chemical Society (ACS) grade and used without purification. Analtech silica 
gel plates (60 F254) were used for analytical TLC, and Analtech preparative TLC plates 
(UV 254, 2000 µm) were used for purification.  UV light and anisaldehyde/iodine stain 
were used to visualize the spots.  200-400 Mesh silica gel was used in column 
chromatography. Nuclear magnetic resonance (NMR) spectra were recorded on a Varian-
Gemini 400 MHz or Bruker 500 MHz magnetic resonance spectrometer.  1H NMR 
Spectra were recorded in parts per million (ppm) relative to the residual peaks of CHCl3 
(7.24 ppm) in CDCl3 or CHD2OD (4.78 ppm) in CD3OD or DMSO-d5 (2.49 ppm) in 
DMSO-d6. 
13C spectra were recorded relative to the central peak of the CDCl3 triplet 
(77.0 ppm) or CD3OD septet (49.3 ppm) or DMSO-d6 septet (39.7 ppm) and were 
recorded with complete hetero-decoupling. Original ‘fid’ files were processed using 
MestReNova LITE (version 5.2.5-5780) program. High-resolution mass spectra were 
recorded at the Georgia Institute of Technology mass spectrometry facility in Atlanta. 
Compounds 3, 5, 6, 8a-c, 9a-c, 11 and 13 were synthesized as described before [2], [32]. 
3.10.1.1. tert-butyl (4-bromo-2-nitrophenyl) carbamate (3) 
4-Bromo-2-nitroaniline 1 (10 g, 0.046 mol) was dissolved in anhydrous 
dichloromethane (15 mL). Boc anhydride 2 (22.12 g, 0.1 mol) followed by triethyl amine 
(14 mL, 0.1 mol) were added to the reaction mixture. Reaction stirred at reflux overnight. 
Reaction mixture was washed with NaHCO3 (10 mL) and brine solution (10 mL) and 
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dried over Na2SO4 and concentrated in vacuo. The crude product was purified by column 
chromatography (Silica gel, 10:1 Hex: EtOAc) to give the product (12.02 g, 82%) as a 
pale yellow solid. 1H NMR (400 MHz, CDCl3) δ 8.51 (d, J = 9.2 Hz, 1H), 8.33 (dd, J = 
2.4, 0.8 Hz, 1H), 7.69 (dd, J = 9.2, 2.4 Hz, 1H), 1.60 – 1.47 (m, 9H).      
3.10.1.2. tert-butyl (2-nitro-4-(thiophen-2-yl)phenyl)carbamate (5) 
Compound 3 (12.02 g, .038 mol) was dissolved in anhydrous THF (30 mL) 
followed by K2CO3 (15.71 g, 0.11 mol). After purging with argon for 20 minutes, 
thiophen-2-ylboronic acid 4 (6.30 g, 0.05 mol) was added followed by Pd(PPh3)4 (4.38 g, 
0.003 mol). The reaction mixture stirred at reflux overnight. Then it was washed with 
NaHCO3 (15 mL) and brine solution (20 mL) and dried over Na2SO4 and concentrated in 
vacuo. The crude product was purified by column chromatography (Silica gel, 10:1 Hex: 
EtOAc) to give the product (9.25 g, 77%) as a pale yellow solid. 1H NMR (400 MHz, 
CDCl3) δ 9.66 (s, 1H), 8.57 (dd, J = 13.2, 8.7 Hz, 1H), 8.40 (d, J = 2.3 Hz, 1H), 7.82 (dd, 
J = 8.9, 2.3 Hz, 1H), 7.38 – 7.27 (m, 1H), 7.10 (ddd, J = 13.6, 6.8, 4.9 Hz, 1H), 1.63 – 
1.47 (m, 9H).  
3.10.1.3. tert-butyl (2-amino-4-(thiophen-2-yl)phenyl)carbamate (6) 
Compound 5 (8.86 g, 0.027 mmol) was dissolved in 1,4-dioxane and water (20 
mL, 4:1). The mixture stirred at room temperature till all the starting material dissolved 
completely. Then zinc powder was added and the mixture stirred for three days at 70 °C. 
The reaction mixture stirred at reflux overnight. Then it was washed with NaHCO3 (15 
mL) and brine solution (15 mL) and dried over Na2SO4 and concentrated in vacuo. The 
crude product was purified by column chromatography (Silica gel, 3:1 Hex: EtOAc) to 
give the product (6.1 g, 76%) a brown solid. 1H NMR (400 MHz, CDCl3) δ 7.36 – 7.16 
(m, 3H), 7.08 – 6.91 (m, 3H), 1.64 – 1.42 (m, 9H).  
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3.10.1.4. tert-butyl (2-(4-azidohexanamido)-4-(thiophen-2-yl)phenyl)carbamate (8a) 
4-Azidohexanoic acid 7a (60 mg, 0.38 mmol) was dissolved in anhydrous DMF 
(5 mL) followed by adding EDCI (73 mg, 0.38 mmol) and HOBT (52 mg, 0.38 mmol). 
After 30 minutes of stirring at room temperature, compound 6 (80 mg, 0.27 mmol) was 
added and then the reaction mixture was heated to 70 °C for 6 h. The reaction mixture 
stirred at reflux overnight. Then it was washed with water (3×5 mL) NaHCO3 (5 mL) and 
brine solution (5 mL) and dried over Na2SO4 and concentrated in vacuo. The crude 
product was purified by preparative TLC (Silica gel, 30:1 DCM: Acetone) to give the 
product (109 mg, 92%) as a pale yellow solid. 1H NMR (400 MHz, CDCl3) δ 8.12 (s, 
1H), 7.73 (s, 1H), 7.38 (p, J = 8.5 Hz, 2H), 7.11 – 6.95 (m, 1H), 6.85 (s, 1H), 3.25 (dt, J = 
14.6, 6.6 Hz, 2H), 2.39 (t, J = 7.4 Hz, 2H), 1.82 – 1.68 (m, 2H), 1.63 (dd, J = 14.8, 7.3 
Hz, 2H), 1.56 – 1.47 (m, 9H), 1.50 – 1.34 (m, 2H).  
3.10.1.5. tert-butyl (2-(4-azidoheptanamido)-4-(thiophen-2-yl)phenyl)carbamate (8b) 
4-Azidoheptanoic acid 7b (687 mg, 4.01 mmol) was dissolved in anhydrous DMF 
(10 mL) followed by adding EDCI (767 mg, 4.01 mmol) and HOBT (542 mg, 4.01 
mmol). After 30 minutes of stirring at room temperature, compound 6 (832 mg, 2.87 
mmol) was added and then the reaction mixture was heated to 70 °C for 6 h. The reaction 
mixture stirred at reflux overnight. Then it was washed with water (3×10 mL), NaHCO3 
(5 mL) and brine solution (5 mL) and dried over Na2SO4 and concentrated in vacuo. The 
crude product was purified by column chromatography (Silica gel, 40:1 DCM: Acetone) 
to give the product (953 mg, 75%) as a pale yellow solid. 1H NMR (400 MHz, CDCl3) δ 
8.02 (s, 1H), 7.75 (s, 1H), 7.48 – 7.28 (m, 2H), 7.05 (dd, J = 5.0, 3.7 Hz, 1H), 6.83 (s, 
1H), 3.26 (dd, J = 16.5, 9.5 Hz, 2H), 2.40 (t, J = 7.4 Hz, 2H), 1.72 (d, J = 31.7 Hz, 2H), 




3.10.1.6. tert-butyl (2-(4-azidooctanamido)-4-(thiophen-2-yl)phenyl)carbamate (8c) 
4-Azidooctanoic acid 7c (808 mg, 4.36 mmol) was dissolved in anhydrous DMF 
(10 mL) followed by adding EDCI (833 mg, 4.36 mmol) and HOBT (589 mg, 4.36 
mmol). After 30 minutes of stirring at room temperature, compound 6 (908 mg, 3.11 
mmol) was added and then the reaction mixture was heated to 70 °C for 6 h. The reaction 
mixture stirred at reflux overnight. Then it was washed with water (3×10 mL), NaHCO3 
(10 mL) and brine solution (10 mL) and dried over Na2SO4 and concentrated in vacuo. 
The crude product was purified by column chromatography (Silica gel, 40:1 DCM: 
Acetone) to give the product (882 mg, 62%) as a pale yellow solid. 1H NMR (400 MHz, 
CDCl3) δ 7.98 (s, 1H), 7.75 (s, 1H), 7.40 (s, 2H), 7.13 – 6.95 (m, 1H), 6.83 (s, 1H), 3.25 
(dd, J = 14.3, 7.5 Hz, 2H), 2.40 (t, J = 7.4 Hz, 2H), 1.70 (d, J = 44.0 Hz, 2H), 1.61 – 1.55 
(m, 2H), 1.60 – 1.42 (m, 9H), 1.39 (s, 2H). 
3.10.1.7. N-(2-amino-5-(thiophen-2-yl)phenyl)-4-azidohexanamide (9a) 
Compound 8a (224 mg, 0.52 mmol) was dissolved in 1% TFA (1 mL) in DCM (5 
mL). The reaction mixture stirred for 1h at rt. The reaction mixture was quenched with 
NaHCO3 (5 mL) and then brine solution (5 mL) and dried over Na2SO4 and concentrated 
in vacuo. The crude product was purified by column chromatography (Silica gel, 40:1 
DCM: Acetone) to give the product (180 mg, 73%) a pale yellow solid. 1H NMR (400 
MHz, CDCl3) δ 7.42 (d, J = 2.0 Hz, 1H), 7.31 (dt, J = 10.1, 5.1 Hz, 1H), 7.15 (dd, J = 
3.6, 1.2 Hz, 1H), 7.02 (dd, J = 5.0, 3.6 Hz, 1H), 6.79 (d, J = 8.3 Hz, 1H), 3.35 – 3.21 (m, 
2H), 2.42 (t, J = 7.5 Hz, 2H), 1.78 (dt, J = 15.1, 7.4 Hz, 2H), 1.64 (dd, J = 14.6, 7.1 Hz, 
2H), 1.53 – 1.41 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 171.6, 144.1, 140.5, 127.7, 
126.8, 126.4, 125.0, 124.4, 123.5, 123.0, 121.8, 118.6, 51.1, 36.5, 28.5, 26.6, 25.2. 
HRMS (ESI) m/z Calcd. for C16H20N5S [M+H
+]: 330.1383, found for 330.1382. 
 141 
3.10.1.8. N-(2-amino-5-(thiophen-2-yl)phenyl)-4-azidoheptanamide (9b) 
Compound 8b (953 mg, 2.15 mmol) was dissolved in 1% TFA (1 mL) in DCM (5 
mL). The reaction mixture stirred for 1h at rt. The reaction mixture was quenched with 
NaHCO3 (5 mL) and then brine solution (5 mL) and dried over Na2SO4 and concentrated 
in vacuo. The crude product was purified by column chromatography (Silica gel, 7:1 
DCM: Acetone) to give the product (496 mg, 67%) a pale yellow solid. 1H NMR (400 
MHz, CDCl3) δ 7.39 (t, J = 16.6 Hz, 1H), 7.31 (dt, J = 10.0, 5.0 Hz, 1H), 7.21 – 7.13 (m, 
2H), 7.02 (dd, J = 5.0, 3.6 Hz, 1H), 6.79 (d, J = 8.2 Hz, 1H), 3.93 (s, 2H), 3.37 – 3.19 (m, 
2H), 2.54 – 2.23 (m, 2H), 1.77 (d, J = 6.9 Hz, 2H), 1.63 – 1.55 (m, 2H), 1.41 (dd, J = 
10.2, 6.3 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 171.6, 144.1, 140.5, 128.0, 126.1, 
125.2, 124.5, 123.5, 122.8, 121.8, 118.6, 51.4, 36.8, 29.0, 28.7, 26.4, 25.4. HRMS (ESI) 
m/z Calcd. for C17H22ON5S [M+H
+]: 344.1540, found for 344.1537. 
3.10.1.9. N-(2-amino-5-(thiophen-2-yl)phenyl)-4-azidooctanamide (9c) 
Compound 8c (882 mg, 1.93 mmol) was dissolved in 1% TFA (1 mL) in DCM (5 
mL). The reaction mixture stirred for 1 h at rt. The reaction mixture was quenched with 
NaHCO3 (5 mL) and then brine solution (5 mL) and dried over Na2SO4 and concentrated 
in vacuo. The crude product was purified by column chromatography (Silica gel, 70:1 
DCM: Acetone) to give the product (163 mg, 45%) a pale yellow solid. 1H NMR (400 
MHz, CDCl3) δ 10.62 (s, 1H), 7.79 (d, J = 1.4 Hz, 1H), 7.53 (dt, J = 8.4, 5.0 Hz, 2H), 
7.25 – 7.16 (m, 1H), 7.05 (dd, J = 5.1, 3.6 Hz, 1H), 3.09 (dt, J = 14.7, 7.1 Hz, 2H), 2.97 
(t, J = 7.7 Hz, 2H), 1.95 – 1.75 (m, 2H), 1.42 (ddd, J = 17.0, 12.1, 11.1 Hz, 2H), 1.31 – 




3.10.1.10. 3′-Desmethylazithromycin (11) 
To a solution of azithromycin 10 (20 g, 0.02 mmol) and sodium acetate (29 g, 
0.21 mmol) in 80% aqueous methanol (50 mL) at 90 °C. Iodine (7 g, 0.03 mmol) was 
added in three batches within 5 min. The mixture was maintained at pH 8-9 by addition 
of 1 M NaOH (once at 10 min of reaction time), and stirring continued for 3 h. The 
mixture was poured into cold water containing 5% sodium thiosulfate and extracted with 
CH2Cl2 (2×40 mL). The aqueous layer was basified with concentrated NH4OH and 
extracted with 10% MeOH in CH2Cl2 (3×40 mL), and the organic layer was dried over 
Na2SO4. Solvent was evaporated off to give 17.7 g of compound 13 as an off-white solid 
(>90% purity, TLC, CH2Cl2/MeOH/NH4OH 12:1:0.1). The crude 13 was used without 
further purification. 
3.10.1.11. (3′-N-(4-ethynylbenzyl)) azithromycin (13) 
Desmethyl azithromycin 11 (2.72 g, 3.70 mmol) was dissolved in anhydrous 
acetonitrile (15 mL), followed by addition of 4-thynylbenzyl methanesulfonate 12 (1.46 
g, 6.94 mmol) and K2CO3 (3.58 g, 25.91 mmol). The rraction stirred at 80 °C for 3 h. 
Then it was washed with EtOAC (3×30 mL), NaHCO3 (10 mL) and brine solution (10 
mL) and dried over Na2SO4 and concentrated in vacuo. The crude product was purified 
by column chromatography (Silica gel, 12:1:0.5 DCM: MeOH: NH4OH) to give the 
product (3.03 g, 96%) as a white solid. 
3.10.1.12. Azithromycin-3-(N-(4-triazolylbenzyl)))- N-(2-amino-5-(thiophen-2-
yl)phenyl) hexanamide (14a) 
(3-N-(4-Ethynylbenzyl))azithromycin 13 (127 mg, 0.15 mmol) and N-(2-amino-
5-(thiophen-2-yl)phenyl)-4-azidohexanamide 9a (49 mg, 0.15 mmol) were dissolved in 
degassed anhydrous THF (5 mL). CuI (8 mg, 0.075 mmol) and Hünig’s base (0.05 mL, 
0.30 mmol) were added to the reaction and the resulting reaction was stirred at room 
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temperature overnight. Then, the reaction mixture was diluted with excess ethyl acetate 
(30 mL) and was transferred to a separatory funnel and then the ethyl acetate layer was 
washed with a solution (20 mL) of 4:1 mixture of saturated aqueous NH4Cl solution 
/NH4OH solution, water (10 mL), brine (10 mL), dried over anhydrous Na2SO4, filtered, 
and concentrated in vacuo. The crude was purified by preparative chromatography (Silica 
gel, 30:1:0.5 EtOAc/MeOH/NH4OH) to give the title compound 14a (111 mg, 63%) as a 
light yellow solid. 1H NMR (400 MHz, CD3OD) δ 8.33 (s, 1H), 7.76 (d, J = 8.3 Hz, 2H), 
7.43 (d, J = 8.1 Hz, 2H), 7.30 (dd, J = 8.3, 2.1 Hz, 1H), 7.22 (d, J = 5.1 Hz, 1H), 7.20 – 
7.13 (m, 1H), 7.00 (dd, J = 5.1, 3.6 Hz, 1H), 6.84 (d, J = 8.3 Hz, 1H), 4.98 (d, J = 18.1 
Hz, 2H), 4.48 (dd, J = 17.6, 7.1 Hz, 2H), 4.25 – 3.98 (m, 3H), 3.61 (d, J = 16.0 Hz, 3H), 
3.16 (s, 2H), 2.99 (d, J = 9.4 Hz, 1H), 2.79 (s, 2H), 2.42 (dd, J = 19.9, 12.7 Hz, 3H), 2.31 
(d, J = 21.5 Hz, 4H), 2.06 – 1.93 (m, 6H), 1.95 – 1.84 (m, 14H), 1.76 (d, J = 8.7 Hz, 3H), 
1.39 (dd, J = 57.2, 29.4 Hz, 10H), 1.32 – 1.18 (m, 8H), 1.19 (dd, J = 16.9, 11.3 Hz, 8H), 
1.13 (d, J = 14.6 Hz, 3H), 1.08 (d, J = 17.2 Hz, 4H), 1.08 – 0.98 (m, 3H), 0.98 – 0.85 (m, 
6H). 13C NMR (126 MHz, CD3OD) δ 178.4, 175.1, 173.7, 155.3, 147.3, 144.2, 141.7, 
129.4, 127.5, 125.6, 125.0, 124.4, 123.8, 122.8, 122.3, 121.1, 120.7, 117.1, 102.5, 83.2, 
77.7, 76.3, 74.0, 72.6, 71.2, 67.9, 65.0, 63.9, 62.7, 60.3, 60.1, 57.0, 56.0, 55.8, 49.9, 45.2, 
42.0, 35.3, 34.6, 30.4, 29.2, 28.0, 25.6, 24.9, 21.1, 20.6, 20.2, 20.0, 19.5, 18.8, 17.6, 16.2, 
15.8, 13.8, 13.2, 12.6, 12.2, 10.3, 8.4. HRMS (ESI) m/z Calcd. for C62H97O13N7S 
[M+2H+/2]: 589.8424, found for 589.8421. 
3.10.1.13. Azithromycin-3-(N-(4-triazolylbenzyl)))- N-(2-amino-5-(thiophen-2-
yl)phenyl) heptanamide (14b) 
(3-N-(4-Ethynylbenzyl))azithromycin 13 (257 mg, 0.30 mmol) and N-(2-amino-
5-(thiophen-2-yl)phenyl)-4-azidoheptanamide 9b (104 mg, 0.30 mmol) were dissolved in 
degassed anhydrous THF (5 mL). CuI (29 mg, 0.15 mmol) and Hünig’s base (0.10 mL, 
0.60 mmol) were added to the reaction and the resulting reaction was stirred at room 
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temperature overnight. Then, the reaction mixture was diluted with excess ethyl acetate 
(30 mL) and was transferred to a separatory funnel and then the ethyl acetate layer was 
washed with a solution (20 mL) of 4:1 mixture of saturated aqueous NH4Cl solution 
/NH4OH solution, water (10 mL), brine (10 mL), dried over anhydrous Na2SO4, filtered, 
and concentrated in vacuo. The crude was purified by preparative chromatography (Silica 
gel, 30:1:0.5 EtOAc/MeOH/NH4OH) to give the title compound 14b (256 mg, 71%) as a 
light yellow solid. 1H NMR (400 MHz, CD3OD) δ 8.16 (s, 1H), 7.61 (d, J = 8.2 Hz, 2H), 
7.27 (dd, J = 9.4, 5.1 Hz, 3H), 7.16 (dd, J = 8.3, 2.2 Hz, 1H), 7.10 – 7.03 (m, 2H), 7.03 
(dd, J = 3.6, 1.0 Hz, 1H), 6.86 (dd, J = 5.1, 3.6 Hz, 1H), 6.71 (d, J = 8.3 Hz, 1H), 4.85 (t, 
J = 12.7 Hz, 1H), 4.71 (dd, J = 10.1, 2.5 Hz, 2H), 4.34 (dd, J = 22.9, 7.1 Hz, 2H), 4.31 (t, 
J = 6.9 Hz, 2H), 4.12 – 3.95 (m, 2H), 3.68 (d, J = 13.1 Hz, 1H), 3.50 (ddd, J = 45.5, 18.6, 
8.4 Hz, 4H), 3.21 – 3.11 (m, 4H), 3.03 (s, 3H), 2.85 (d, J = 9.5 Hz, 1H), 2.64 (dt, J = 
18.8, 9.2 Hz, 3H), 2.29 (t, J = 7.4 Hz, 2H), 2.21 (d, J = 15.5 Hz, 4H), 2.13 (s, 4H), 1.85 
(dd, J = 14.2, 7.0 Hz, 4H), 1.76 – 1.54 (m, 5H), 1.44 – 1.21 (m, 8H), 1.17 (d, J = 24.4 Hz, 
6H), 1.12 (t, J = 7.9 Hz, 4H), 1.09 – 0.98 (m, 7H), 0.96 (dd, J = 20.5, 14.4 Hz, 8H), 0.91 
(d, J = 7.5 Hz, 4H), 0.76 (dd, J = 15.3, 7.6 Hz, 6H). 13C NMR (101 MHz, CD3OD) δ 
209.7, 178.1, 173.6, 163.1, 157.6, 148.5, 145.8, 144.2, 129.3, 128.6, 127.4, 126.0, 125.2, 
124.5, 123.1, 122.6, 121.1, 120.5, 117.4, 115.9, 114.7, 114.0, 105.9, 102.5, 94.9, 82.9, 
78.1, 77.6, 76.7, 74.3, 72.9, 71.2, 67.8, 65.9, 65.2, 62.8, 57.3, 52.3, 49.9, 38.9, 35.8, 35.3, 
35.0, 34.6, 30.7, 29.5, 28.1, 26.4, 26.0, 25.2, 21.2, 20.7, 20.2, 17.8, 15.9, 14.2, 10.4, 8.5, 
5.4, 5.1, 1.3. HRMS (ESI) m/z Calcd. for C63H99O13N7S [M+2H
+/2]: 596.8505, found for 
598.8502. 
3.10.1.14. Azithromycin-3-(N-(4-triazolylbenzyl)))- N-(2-amino-5-(thiophen-2-
yl)phenyl) octanamide (14c) 
(3-N-(4-Ethynylbenzyl))azithromycin 13 (118 mg, 0.14 mmol) and N-(2-amino-
5-(thiophen-2-yl)phenyl)-4-azidooctanamide 9c (50 mg, 0.14 mmol) were dissolved in 
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degassed anhydrous THF (5 mL). CuI (13 mg, 0.07 mmol) and Hünig’s base (0.05 mL, 
0.27 mmol) were added to the reaction and the resulting reaction was stirred at room 
temperature overnight. Then, the reaction mixture was diluted with excess ethyl acetate 
(30 mL) and was transferred to a separatory funnel and then the ethyl acetate layer was 
washed with a solution (20 mL) of 4:1 mixture of saturated aqueous NH4Cl solution 
/NH4OH solution, water (10 mL), brine (10 mL), dried over anhydrous Na2SO4, filtered, 
and concentrated in vacuo. The crude was purified by preparative chromatography (Silica 
gel, 30:1:0.5 EtOAc/MeOH/NH4OH) to give the title compound 14c (78 mg, 47%) as a 
light yellow solid. 1H NMR (400 MHz, CDCl3) δ 7.74 (dd, J = 15.3, 12.0 Hz, 3H), 7.50 
(t, J = 5.8 Hz, 1H), 7.40 – 7.29 (m, 3H), 7.15 (dd, J = 8.0, 4.3 Hz, 2H), 7.01 (dd, J = 5.0, 
3.7 Hz, 1H), 6.78 (d, J = 8.4 Hz, 1H), 5.05 (d, J = 4.4 Hz, 1H), 4.70 (s, 1H), 4.39 (dt, J = 
16.8, 8.5 Hz, 3H), 4.23 (d, J = 2.8 Hz, 1H), 4.07 – 3.90 (m, 2H), 3.83 – 3.71 (m, 1H), 
3.66 (d, J = 22.0 Hz, 1H), 3.60 (d, J = 7.2 Hz, 1H), 3.53 – 3.38 (m, 3H), 3.36 (d, J = 10.6 
Hz, 1H), 2.98 (t, J = 9.8 Hz, 1H), 2.87 (s, 1H), 2.75 (s, 2H), 2.54 (s, 2H), 2.40 (dd, J = 
18.5, 10.7 Hz, 5H), 2.26 (d, J = 19.7 Hz, 5H), 2.17 (s, 1H), 2.12 – 2.01 (m, 2H), 2.02 – 
1.81 (m, 5H), 1.82 – 1.65 (m, 4H), 1.57 – 1.45 (m, 2H), 1.45 – 1.28 (m, 13H), 1.24 (dt, J 
= 20.9, 9.4 Hz, 11H), 1.19 – 1.13 (m, 4H), 1.07 (t, J = 12.9 Hz, 8H), 1.03 (d, J = 7.5 Hz, 
3H), 0.99 – 0.79 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 178.9, 172.2, 147.5, 144.4, 
140.5, 129.8, 129.5, 128.0, 127.4, 126.1, 125.9, 124.8, 123.6, 123.0, 121.8, 119.6, 118.4, 
102.9, 94.6, 83.5, 74.2, 73.8, 73.3, 72.8, 70.6, 69.9, 68.7, 65.5, 64.2, 61.7, 57.7, 56.0, 
50.3, 49.3, 45.4, 42.6, 42.1, 36.9, 36.6, 36.3, 34.6, 32.0, 30.1, 29.6, 29.3, 28.8, 28.3, 27.5, 
26.8, 26.0, 25.4, 22.7, 22.1, 21.5, 21.3, 18.0, 16.4, 14.6, 14.2, 11.3, 8.9, 7.5. HRMS (ESI) 
m/z Calcd. for C63H101O13N7S [M+2H




3.10.2. Cell viability assay 
All cell lines used in this study were maintained in phenol red free Dulbecco's Modified 
Eagle Medium (DMEM) (Corning, VA), supplemented with 10% fetal bovine serum 
(FBS) (Atlanta Biologicals, Atlanta, GA) and 1% Penicillin-Streptomycin. Cells were 
incubated in 96 well plate for 24 h prior to treatment and then treated with various drugs’ 
concentration for 72 h. Their anti-proliferative activity was measured using the MTS 
assay (CellTiter 96 Aqueous One Solution and CellTiter 96 Non-Radioactive Cell 
Proliferation Assays, Promega, Madison, WI) as described by the manufacturer. All 
drugs solution were made in DMEM while DMSO concentration was maintained at 
0.1%.  
 
3.10.3. SAMDI assay (In vitro HDAC inhibition, performed by Dr.  James Kornaki 
at Northwestern University) 
HDAC1, 2, 3, and 6 were purchased from BPS Biosciences. To obtain IC50 
values, in a 96-well microtiter plates (60 min, 37 °C), isoform- optimized substrates (50 
μM) were incubated with enzyme (250nM) and inhibitor (at concentrations ranging from 
0.1 nM to 1.0 mM) in HDAC buffer (25.0 mM Tris-HCl, pH 8.0, 140 mM NaCl, 3.0 mM 
KCl, 1.0 mM MgCl
2
, and 0.1 mg/mL BSA). Solution-phase deacetylation reactions were 
quenched with trichostatin A (TSA) and transferred to SAMDI plates to immobilize the 
substrate components. SAMDI plates were consist of an array of self-assembled 
monolayers (SAMs) presenting maleimide in standard 384-well format for high-
throughput handling capability. Following immobilization, plates were washed to remove 
buffer constituents, enzyme, inhibitor, and any unbound substrate and analyzed by 
MALDI mass spectrometry using automated protocols. Deacetylation yields in each 
triplicate sample were obtained from the integrated peak intensities of the molecular ions 
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for the substrate and the deacetylated product ion by taking the ratio of the former over 
the sum of both. Yields were plotted with respect to inhibitor concentration and fitted to 
obtain IC50 values for each isoform−inhibitor pair.  
Isoform-optimized substrates were prepared by traditional FMOC solid-phase 
peptide synthesis (Anaspec) and purified by semi-preparative HPLC on a reverse-phase 
C18 column (Waters). The peptide GRKacFGC was prepared for HDAC1 and HDAC8 
experiments, whereas the peptide GRKacYGC was prepared for HDAC6 experiments.  
3.10.4. In vitro HDAC inhibition (Performed through contractual agreement with 
BPS Bioscience) 
HDAC inhibition was performed via Fluor de Lys assay. This assay is based on 
Fluorimetric Histone deAcetylaseLysyl substrate and developer combination. First the 
substrate with the acetylated lysine chain is incubated with HDAC enszymes. Then the 
developer is added which results in generating a fluorophore.  
To perform the in vitro HDAC inhibition assay, different concentration of HDACi 
with 10% DMSO in HDAC assay buffer were prepared and added to the enzymatic 
reaction containing HDAC assay buffer, BSA, substrate and enzyme (all the HDAC 
isoforms) in 96 well plate. Developer was then added to each well and the plate was 
incubated at room tempretaure for 15 minutes. Fluorescent intensity at the certain 
wavelengths was measured using Bioteck Synergy microplate reader. Fluorescent 
intensities were measured in the absence and presence of the compounds as well as in the 
absence of HDAC , and the data was analyzed using Graphpad Prism. IC50 value for each 
compound was determined by the concentration leading to a half-maximal percent 
inhibition.   
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HISTONE DEACETYLASE INHIBITORS EQUIPPED WITH      
ESTROGEN RECEPTOR MODULATORS FOR SELECTIVELY 
TARGETING BREAST CANCER 
4.1. Introduction 
Histone deacetylase enzymes (HDAC) are among the most promising targets in 
cancer therapy due to their critical role in chromatin remodeling and gene expression 
regulation. Through their deacetylase activities, HDACs are not only involved in 
regulating DNA-histone interaction, they regulate non-histone protein functions as well 
[1]. Removal of the acetyl group by HDAC enzymes from lysine residue of the histone 
proteins leads to a condensed chromatin and transcriptional repression [2], while addition 
of the acetyl group by HAT results in an open and accessible chromatin and favors the 
expression of tumor suppresser genes [3].  
Epigenetic changes leading to gene expression modulations are responsible for 
cancer progression, therefore, inhibiting HDACs activity has emerged as a potential 
strategy to invert changes that are affiliated with cancer, and an ongoing research has 
been dedicated to develop potent and selective HDACi. Currently, there are four US FDA 
approved HDACi, with many others in various stages of clinical trials [4]. SAHA was the 
first FDA approved HDACi in the clinic. SAHA obtained approval in 2006 for treating 
cutaneous T-cell lymphoma [5], followed by approval of FK228 in 2009 for cutaneous T-
cell lymphoma and peripheral T-cell lymphoma [6], and belinostat in 2014 for peripheral 
T-cell lymphoma [7]. Panobinostat is the last HDACi that received accelerated FDA 
approval in 2015 for treating multiple myeloma [8]. Chidamide (CS055) is a HDACi only 
approved in China for treating relapsed/refractory peripheral T-cell lymphoma. 
Chidamide is currently being investigated in phase II clinical trials in US [9].  Despite 
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promising results in treating certain types of cancer, HDACi share common drawbacks 
including lack of isoform selectivity and poor solid tumor accumulation as well as poor 
bioavailability and cardiotoxicity [10].  
Studies have shown HDACi are more potent and have a greater efficiency when 
they are used in combination with other therapeutic agents [11], [12]. One promising 
example of HDACi combinational therapy is their use in hormone resistant breast cancer 
together with selective estrogen receptor modulators (SERM) such as tamoxifen (Tam). 
Tamoxifen is a potent estrogen receptor (ER) antagonist [13]. It is considered one of the 
essential drugs by world health organization (WHO) and is a first line therapy and the 
most commonly used treatment for endocrine dependent breast cancer. However its use is 
limited since almost all patients with metastatic breast cancer, 40% of whom received 
tamoxifen as an adjuvant therapy, relapse and acquire resistance to it and eventually die 
[14], [15]. Although the mechanism of tamoxifen resistance development is not fully 
defined to date, it is however clear that tamoxifen resistant tumors still exhibit ER 
expression 70% of the time in form of ERα or upregulation of ERβ expression, a closely 
related ERα isoform [16]. In some cases, however, tumors are ER negative due to 
epigenetic silencing of ERα subtypes [17]. Tamoxifen sensitivity in ER negative breast 
cancers can be restored by inducing ERα expression, using DNA demethylating agents 
such as [5-aza-2′-deoxycytidine (5-aza-dC)] and HDACi like SAHA or trichostatin A 
[17], [18], [19]. 
One potential strategy to extend the therapeutic utility of antiestrogens to ER 
expressing, antiestrogen resistant breast tumors is to use design-multiple ligand approach 
[20] wherein a prototypical antiestrogen such as tamoxifen is covalently linked to a 
moiety having independent anticancer activity [21], [22] Recent studies have shown that 
covalent linkage of ER antagonist ligands to HDACi resulted in bifunctional agents with 
improved in vitro therapeutic indices and anti-proliferative activity [23], [24]. 
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In our effort to achieve more potent HDACi with targeted delivery to the site of 
tumor we designed three classes of SERM-HDACi. We hypothesized that dual-acting 
SERM-HDACi not only could result in targeted delivery of compounds to the breast 
tissue due to tamoxifen affinity for ER but also could explore cell ER expression status to 
achieve higher concentrations in ER antagonist resistant, ER expressing breast tumors 
and subsequent HDAC inhibition by the HDACi moiety of these agents will result in 
selective tumor growth inhibition.   
ERs reside in cytoplasm while they are bound to heat shock proteins. Upon 
binding to estrogen they get activated and are translocated to nucleus. However, small 
populations of ERs that are involved in modulating cell survival and proliferation exist on 
the plasma membrane [25] of target tumor cells. These ERs can facilitate tumor selective 
uptake of SERM conjugated HDACi [26].     
A previous study by Gryder et al revealed that incorporation of tamoxifen into 
HDACi surface recognition group furnished dual-acting SERM-HDACi with antagonist 
activity similar to tamoxifen and exhibiting nanomolar range HDAC6 inhibition activity. 
These dual-acting SERM-HDACi also demonstrated more potent anti-proliferative 
activity against MCF-7 (ERα positive breast cancer cell line) compared to tamoxifen.     
In order to complete the SAR from the previous project, I synthesized various 
tamoxifen conjugated HDACi having different zinc binding groups and compared 
activities for compounds with various linker lengths to determine the optimal length.  
4.2. Synthesis of Tamoxifen-derived Dual-acting SERM-HDACi 
Following the previously disclosed dual-acting SERM-HDACi template [24], 
[27], I designed three classes of tamoxifen conjugated HDACi having different zinc 
binding groups and methylene linker lengths to evaluate the impact of these modification 
on HDAC inhibitory potency.  
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Based on our previous work, the optimal linkers were predicted to be five or six 
methylene groups [28].  Therefore, I limited my SAR study on the linkers having 
between five and eight methylene groups. Additionally, Gryder et al [24] disclosed that 
having the triazolyl moiety attached to benzyl-tamoxifen moiety results in a better HDAC 
inhibitory potency and anti-proliferative activity. 
 
 
Figure 4.1. Three classes of tamoxifen conjugated HDACi with different ZBG and linker 




4.3. Chemistry and synthesis 
N-Desmetyl tamoxifen 3 was obtained through demethylation of tamoxifen 1 by 
reacting it with 1-chloroethyl chloroformate 2 [29]. Compound 3 was then reacted with 4-
ethynylbenzyl methanesulfonate 4 to yield N-alkynated tamoxifen 5 (Scheme 4.1) [30].  
 
                      
Scheme 4.1. (a) DCM, 30 min; (b) MeOH, reflux, overnight 98% (a and b); (c) Hunig’s 
base, DMSO, 85 °C, 4 h, 62%.   
 
The reaction of bromo alkanoic acids 6a-b with sodium azide resulted in azide 
alkanoic acids 7a-b which was then coupled with O-trityl hydroxylamine  [31] to yield 
9a-b. Additionally, the azido thiophene-benzamide 20a-c were synthesized as described 





Scheme 4.2. (a) NaN3, DMF, 80 °C, overnight, 90%; (b) N-Methyl morpholine, O-
tritylhydroxyl amine, isobutyl chloroformate, THF, 3h, 97%; (c) Et3N, DCM, reflux, 
overnight, 82%; (d) Pd(PPh3)4, K2CO3, THF, 70 °C, 77%; (e) Zn, H2O: Dioxane (1:4), 70 
°C, 3 days, 76%; (f) EDCI, HOBT, DMF, 70 °C, 6 h, 62-92%; (g) TFA (1%), DCM, rt, 
2h, 45-73%. 
 
All the three classes of tamoxifen conjugated HDACi were synthesized through 
Cu (I) catalyzed azide-alkyne cycloaddition reaction between benzyl-alkynyl tamoxifen 5 
and azides 9a-b and 20a-c to furnish the requisite compounds 10a-b and 12a-c [24], 
[33], [34]. Control carboxylic compound 8 was similarly synthesized from 5 and azido 
acid 7b (Scheme 4.3) [35]. 
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Scheme 4.3. (a) THF, CuI, Hunig’s base, rt, overnight, 25%; (b) THF, CuI, Hunig’s base, 
rt, overnight; (c) TFA, TIPS, DCM, rt, 1 h, 61-70% (b and c); (d) THF, CuI, Hunig’s 
base, rt, overnight, 14-93%.  
4.4. HDAC inhibitory potency (Performed by Lindsey Szymczak at 
Northwestern University) 
All three classes of synthesized tamoxifen conjugated HDACi were tested against 
class I HDAC isoforms and HDAC6 to evaluate their HDAC inhibitory potency as it has 
been established that these HDAC isoforms are involved in breast cancer [36], [37]. 
HDAC activity was determined by the label-free mass spectrometry-based SAMDI assay 
[38].  
As expected, the thiophene-benzamide-based compounds 12a-c were selective 
toward HDAC1 and HDAC2 and did not inhibit other HDAC isoforms [39], while the 
hydroxamate-based compounds 10a-b showed low to mid nanomolar range HDAC 
inhibitory potency toward all tested isoforms. Compound 8 did not exhibit any HDAC 
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inhibitory potency. Based on this finding, the tamoxifen-derived hydroxamic acid 
compounds 10a-b were the most potent HDACi among these three groups (Table 4.1).  
 
Table 4.1. HDAC 1, 2, 3, 6, and HDAC8 inhibition activities of three different classes of 
tamoxifen conjugated HDACi (IC50 in nM). 
Compound n HDAC1 HDAC2 HDAC3 HDAC6 HDAC8 
8 4 NI NI NI 1880±540 NI 
10a* 3 524 ND ND 567 ND 
10b 4 317±29 785±66 96±12 33±7.6 3050±250 
12a 3 635±110 281±25 NI NI NI 
12b 4 543±82 281±39 NI NI NI 
12c 5 NI 1130±120 NI NI NI 
SAHA - 42 190 20 34 2800 
ND: Not determind, NI: No inhibition.  * HDAC inhibitory potency of compound 10a was previously reported by Gryder et al and performed byy BPS BioScience 
[24].  
4.5. Anti-proliferative activity and therapeutic index 
After obtaining the HDAC inhibitory activity of tamoxifen conjugated HDACi, 
they were tested against three cell lines, two transformed cell lines, ER positive (MCF-7) 
and ER negative (MDA-MB231) breast cancers as well as one non-cancerous mamalian 
cell line (VERO- monkey kidney epithelial cell). These compounds were compared to 
tamoxifen, the first line therapy for treating ER positive breast cancer, and SAHA, an 
FDA approved HDACi. As anticipated, the control carboxylic acid compound 8 was 
inactive against all tested cell lines. Surprisingly, the benzamide compounds 12a-c did 
not show cytotoxicity against these cancer cell lines despite their class I HDAC 
selectivity. The reason for the lack of antiproliferative activity of compounds 12a-c is not 
apparent from this study. Gratifyingly, we observed that the hydroxamic acid compounds 
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10a-b displayed ER dependent antiproliferative activity. Relative to tamoxifen, 10a-b 
were about 8 fold more potent toward ER positive breast cancer cells and about 2 fold 
more potent toward ER negative breast cancer cells (Table 4.2).  
Furthermore, compounds 10a-b displayed tumor-selective cytotoxicity with in 
vitro therapeutic index (IVTI) of 4.3 and 1.4 while tamoxifen and SAHA showed no 
tumor-selective cytotoxicity (Table 4.2).    
 
Table 4.2. Anti-proliferative activity of selected azithromycin conjugated HDACi (IC50 
values in µM). 
Compound n MCF-7 MDA-MB231 VERO 
In vitro therapeutic index  
IC50 in VERO 
IC50 in MCF-7 
8 4 NI NI NI - 
10a 3 2.1±0.1 10±0.5* 9.1±2.8 4.3 
10b 4 2.4±0.4 6.4±0.5 3.4±0.1 1.4 
12a 3 NI NI NI - 
12b 4 NI NI NI - 
12c 5 NI NI NI - 
Tamoxifen - 15.6±1.3 17±1.2 16±0.1 1.1 
SAHA - 3.3± 0.1 3.4±0.2 1±0.1 0.2 
          Each value is obtained from a duplicate of three simultaneous experiments. NI=No inhibition. * Value reported previously by           
Gryder. et al [24]. 
 
IVTI is safety window for comparing the therapeutic efficacy of drug candidates [40]. It 
is a comparison between drug cytotoxicity to transformed cells and healthy cells. The 
higher the therapeutic index, the safer the drug is expected to be. 
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Overall, these tamoxifen-derived dual-acting SERM-HDACi are more selective 
toward breast cancer cells compared to SAHA.   The promising anti-proliferative activity 
and HDAC inhibitory potency results of compounds 10a and 10b encouraged us to 
synthesize these two compounds in a larger scale to study their activity in animal models. 
Compounds 10a and 10b are currently under in vivo investigation.  
4.6. Conclusion 
Tamoxifen is the most common therapy for treating ER positive breast cancer 
[41], however, many patients relapse and acquire resistance during the course of 
treatment. A high percentage of the tamoxifen resistant tumors still express ER, either in 
form of ERα or ERβ. Additionally, in tumors that are ER negative, ER expression can be 
stimulated by using HDACi as an adjuvant therapy [42].  
I have identified tamoxifen-derived dual-acting SERM-HDACi that displayed 
enhanced potency and improved IVTI. Unlike tamoxifen that exhibits no selectivity for 
ER positive and ER negative breast cancer cells, these compounds are more potent and 
cytotoxic toward ER positive breast cancer cells (MCF-7). Furthermore, compared to the 
FDA approved HDACiSAHA which is significantly toxic to VERO cells, these SERM-
HDACi are less cytotoxic toward healthy cells. The improvement in potency and IVTI 
could potentially be due cell to ER expression status dependent cell uptake and/or 
intracellular retention of these SERM-HDACi.  
4.7. Experimental 
4.7.1. Materials and methods 
Tamoxifen was purchased from Cayman chemical company. 4-ethynylbenzyl 
alcohol and 1-chloroethyl chloroformate were purchased from Sigma-Aldrich. All 
commercially available starting materials were used without purification. Reaction 
solvents were high performance liquid chromatography (HPLC) grade or American 
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Chemical Society (ACS) grade and used without purification. Analtech silica gel plates 
(60 F254) were used for analytical TLC, and Analtech preparative TLC plates (UV 254, 
2000 µm) were used for purification.  UV light and anisaldehyde/iodine stain were used 
to visualize the spots.  200-400 Mesh silica gel was used in column chromatography. 
Nuclear magnetic resonance (NMR) spectra were recorded on a Varian-Gemini 400 MHz 
or Bruker 500 MHz magnetic resonance spectrometer.  1H NMR Spectra were recorded 
in parts per million (ppm) relative to the residual peaks of CHCl3 (7.24 ppm) in CDCl3 or 
CHD2OD (4.78 ppm) in CD3OD or DMSO-d5 (2.49 ppm) in DMSO-d6. 
13C spectra were 
recorded relative to the central peak of the CDCl3 triplet (77.0 ppm) or CD3OD septet 
(49.3 ppm) or DMSO-d6 septet (39.7 ppm) and were recorded with complete hetero-
decoupling. Original ‘fid’ files were processed using MestReNova LITE (version 5.2.5-
5780) program. High-resolution mass spectra were recorded at the Georgia Institute of 
Technology mass spectrometry facility in Atlanta. Compounds 3, 5, 7a-b, 9a-b, and 10a 
were synthesized as it was discussed before [24], [28], [30], [31], [43]. Compounds 4, 
20a-c were synthesized as described in chapter 2 and 3.  
 
4.7.1.1. N-Desmethyltamoxifen (3)  
Tamoxifen 1 (2.3 g, 6.2 mmol) was dissolved in DCM (10 mL). The reaction 
mixture was purged for 15 minutes, then cooled to 0 °C, and then 1-chloroethyl 
chloroformate 2 (2.7 mL, 24.8 mmol) was added dropwise and stirred for another 15 
minutes. Then it was refluxed overnight. Solvent was evaporated. Then reaction mixture 
was quenched with NaHCO3 (10 mL) and brine (10 mL). The organic layer was separated 
and dried over Na2SO4.  The crude product was purified by column chromatography 
(Silica gel, 3:2:0.1 EtOAc: Hex: NEt3) to give the product (2.1 g, 98%) as a white solid. 
1H NMR (400 MHz, CDCl3) δ 7.41 – 7.32 (m, 2H), 7.32 – 7.24 (m, 3H), 7.23 – 7.19 (m, 
1H), 7.17 – 7.08 (m, 3H), 7.04 – 6.96 (m, 1H), 6.95 – 6.90 (m, 1H), 6.86 – 6.79 (m, 2H), 
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6.62 – 6.54 (m, 2H), 3.94 (t, J = 5.1 Hz, 2H), 2.90 (dd, J = 6.8, 3.1 Hz, 2H), 2.51 (dd, J = 
12.3, 4.8 Hz, 2H), 2.47 (d, J = 8.2 Hz, 3H), 0.98 (dd, J = 11.8, 4.4 Hz, 3H). 
4.7.1.2. 4-(4-Ethynylbenzyl)−Tamoxifen (5)  
To a stirring solution of desmethyl tamoxifen 3 (572.2 mg, 1.28 mmol) in DMSO 
(5 mL), compound 4 (350 mg, 1.7 mmol) and Hunig’s base (0.7 mL, 4.1 mmol) were 
added. The reaction mixture was heated for 4 h at 85 °C. Then reaction mixture was 
washed with water (3×10 mL) EtOAc (5 mL) and quenched with NaHCO3 (5 mL) and 
brine (5 mL). The organic layer was separated and dried over Na2SO4.  The crude product 
was purified by column chromatography (Silica gel, 1:3:0.1 EtOAc: Hex: NEt3) to give 
the product (373 mg, 62%) as a pale yellow solid. 1H NMR (400 MHz, CD3OD) δ 7.36 
(dt, J = 7.3, 3.7 Hz, 2H), 7.32 – 7.29 (m, 2H), 7.27 – 7.14 (m, 5H), 7.15 – 7.01 (m, 5H), 
6.73 (dt, J = 4.9, 2.2 Hz, 2H), 6.56 – 6.46 (m, 2H), 4.91 (t, J = 1.1 Hz, 1H), 3.90 (dd, J = 
7.2, 3.9 Hz, 2H), 3.50 (d, J = 17.8 Hz, 2H), 2.67 (t, J = 5.5 Hz, 2H), 2.42 (q, J = 7.4 Hz, 
2H), 2.21 (d, J = 1.8 Hz, 3H), 0.95 – 0.82 (m, 3H). 
4.7.1.3. 7-Azido heptanoic acid (7b)  
Sodium azide (1.95 g, 30 mmol) was added to a stirring solutioin of 7-bromo 
heptanoic acid 6b (3.1 g, 15 mmol) in DMF (10 mL). Reaction stirred overnight. After 
TLC indicated the complete consumption of the starting material, DMF was evaporated 
off, and then reaction mixture was dissolved in EtOAc (10 mL) and acidify to pH=3. 
Then it was washed with brine (5 mL) and organic layer was separated and dried over 
Na2SO4. It yielded product (2.5 g, 97%) as a light brown oil. 
1H NMR (400 MHz, CDCl3) 
δ 11.86 (s, 1H), 3.26 – 3.10 (m, 2H), 2.27 (t, J = 7.0 Hz, 2H), 1.61 – 1.42 (m, 4H), 1.32 
(d, J = 2.5 Hz, 4H). 
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4.7.1.4. 4-Azido-N-(trityloxy)heptanamide (9b) 
7-Azido heptanoic acid 7b (2.5 g, 14.5 mmol) was dissolved in anhydrous THF 
(15 mL). N-methyl morpholine (1.6 ml, 14.5 mmol) was added to the solution. The 
reaction mixture was then cooled to -15 °C and stirred for 5 min. Isobutyl chloroformate 
(1.9 mL, 14.5 mmol) was added and the mixture stirred for another 10 min at -15°C. O-
Tritylhydroxyl amine (4.0 g, 14.5 mmol) was added followed by additional 2 eq of N-
methyl morpholine (3.2 mL, 29 mmol). Stirring continued for another 15 min at -15°C 
and 2 h at room temperature.  Reaction mixture was acidified with 1N HCl to pH=3 to 
neutralize excess amine, followed by work up. The organic layer was separated and dried 
over Na2SO4.  The crude product was purified by column chromatography (Silica gel, 1:2 
EtOAc: Hex) to give the product (3.3 mg, 53%) as a white solid. 1H NMR (400 MHz, 
CDCl3) δ 7.46 (d, J = 26.8 Hz, 3H), 7.29 (dd, J = 38.2, 18.5 Hz, 13H), 3.17 (s, 2H), 1.57 
(d, J = 27.1 Hz, 1H), 1.54 – 1.33 (m, 3H), 1.22 (tt, J = 35.4, 17.9 Hz, 4H), 1.07 (s, 2H). 
4.7.1.5. Tamoxifen−N-(4-triazolylbenzyl)-N-heptanoic Acid (8)  
4-(4-Ethynylbenzyl)−Tamoxifen 5 (92.5 mg, 0.2 mmol) and 7-azido heptanoic 
acid 7b (36.9 mg, 0.2 mmol) were dissolved in degassed anhydrous THF (5 mL). CuI 
(18.6 mg, 0.1 mmol) and Hünig’s base (0.07 mL, 0.4 mmol) were added to the reaction 
and the resulting reaction was stirred at room temperature overnight. Then, the reaction 
mixture was diluted with excess ethyl acetate (30 mL) and was transferred to a separatory 
funnel and then the ethyl acetate layer was washed with a solution (20 mL) of 4:1 mixture 
of saturated aqueous NH4Cl solution /NH4OH solution, water (10 mL), brine (10 mL), 
dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude was purified 
by preparative chromatography (Silica gel, 10:2:0.5 EtOAc/Hex/NEt3) to give the title 
compound 8 (31.8 mg, 25%) as a light yellow solid. 1H NMR (400 MHz, CDCl3) δ 7.88 – 
7.70 (m, 3H), 7.47 – 7.36 (m, 2H), 7.33 (t, J = 7.2 Hz, 2H), 7.24 (dt, J = 8.0, 6.0 Hz, 3H), 
7.13 (dq, J = 14.7, 7.4 Hz, 5H), 6.77 (d, J = 8.7 Hz, 2H), 6.53 (d, J = 8.6 Hz, 2H), 4.37 (t, 
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J = 7.1 Hz, 2H), 4.06 (s, 2H), 3.80 (s, 2H), 3.01 (d, J = 37.8 Hz, 2H), 2.47 (dd, J = 15.8, 
8.7 Hz, 2H), 2.41 (d, J = 6.5 Hz, 3H), 2.25 (d, J = 22.6 Hz, 2H), 1.93 (s, 2H), 1.37 (s, 
3H), 1.25 (s, 3H), 0.90 (dd, J = 14.5, 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 177.8, 
156.3, 147.3, 143.8, 143.2, 142.4, 141.5, 138.2, 136.0, 132.0, 130.8, 130.6, 130.4, 129.7, 
129.5, 128.1, 127.9, 127.8, 127.3, 126.5, 126.1, 125.8, 119.7, 114.1, 113.4, 64.8, 61.4, 
56.0, 54.9, 50.4, 41.6, 31.9, 30.2, 29.7, 29.0, 28.5, 26.3, 24.8, 22.7, 14.2, 13.6. HRMS 
(ESI) m/z Calcd. for C41 H47 O3 N4 [M+H
+]: 643.3643, found for 643.3637. 
4.7.1.6. Tamoxifen−N-(4-triazolylbenzyl)-N-hydroxyhexanamide (10a)  
4-(4-Ethynylbenzyl)−tamoxifen 5 (264.5 mg, 0.5 mmol) and 6-azido-N-
(trityloxy)hexanamide 9a (279.0 mg, 0.7 mmol) were dissolved in degassed anhydrous 
THF (5 mL). CuI (53.3 mg, 0.3 mmol) and Hünig’s base (0.2 mL, 1.1 mmol) were added 
to the reaction and the resulting reaction was stirred at room temperature overnight. Then, 
the reaction mixture was diluted with excess ethyl acetate (30 mL) and was transferred to 
a separatory funnel and then the ethyl acetate layer was washed with a solution (20 mL) 
of 4:1 mixture of saturated aqueous NH4Cl solution /NH4OH solution, water (10 mL), 
brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The 
crude was then dissolved in DCM: TFA (1: 0.2 mL) solution. Triisopropyl silane was 
added dropwise until the color transformed from dark yellow to pale yellow. TLC 
indicated the complete consumption of the starting material after 1 h. Solvent and TFA 
were evaporated off, then reaction mixture was quenched with NaHCO3 followed by 
work up and dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude 
was purified by preparative chromatography (Silica gel, 12:1:0.1 DCM/MeOH/NH4OH) 
to give the title compound 10a (196.0 mg, 61%) as a white solid. 1H NMR (400 MHz, 
CD3OD) δ 8.22 (s, 1H), 7.77 (d, J = 7.3 Hz, 2H), 7.39 – 7.28 (m, 2H), 7.30 – 7.21 (m, 
2H), 7.17 (t, J = 7.3 Hz, 3H), 7.03 (dt, J = 14.1, 6.3 Hz, 5H), 6.72 (d, J = 8.5 Hz, 2H), 
6.49 (d, J = 8.4 Hz, 2H), 4.32 (s, 2H), 3.88 (s, 2H), 3.58 (s, 2H), 2.72 (s, 2H), 2.44 – 2.31 
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(m, 2H), 2.24 (s, 3H), 2.06 (s, 2H), 1.87 (s, 2H), 1.61 (s, 2H), 1.26 (d, J = 21.4 Hz, 2H), 
0.84 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, CD3OD) δ 156.6, 147.1, 143.6, 142.2, 
141.2, 138.3, 137.1, 135.5, 131.7, 129.9, 129.1, 128.0, 127.6, 126.7, 126.0, 125.5, 120.9, 
113.1, 64.9, 61.6, 55.2, 49.9, 41.5, 29.5, 28.6, 25.5, 24.7, 12.8. HRMS (ESI) m/z Calcd. 
for C40 H44 O3 N5 [M+H
+]: 642.3439, found for 642.3451. 
4.7.1.7. Tamoxifen−N-(4-triazolylbenzyl)-N-hydroxyheptanamide (10b)  
4-(4-Ethynylbenzyl)−Tamoxifen 5 (617.3 mg, 1.3 mmol) and 7-azido-N-
(trityloxy)hexanamide 9b (673.1 mg, 1.6 mmol) were dissolved in degassed anhydrous 
THF (5 mL). CuI (123.8 mg, 0.6 mmol) and Hünig’s base (0.5 mL, 2.6 mmol) were 
added to the reaction and the resulting reaction was stirred at room temperature 
overnight. Then, the reaction mixture was diluted with excess ethyl acetate (30 mL) and 
was transferred to a separatory funnel and then the ethyl acetate layer was washed with a 
solution (20 mL) of 4:1 mixture of saturated aqueous NH4Cl solution /NH4OH solution, 
water (10 mL), brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated in 
vacuo. The crude was then dissolved in DCM: TFA (1: 0.2 mL) solution. Triisopropyl 
silane was added dropwise until the color transformed from dark yellow to pale yellow. 
TLC indicated the complete consumption of the starting material after 1 h. Solvent and 
TFA were evaporated off, then reaction mixture was quenched with NaHCO3 followed 
by work up and dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The 
crude was purified by column chromatography (Silica gel, 12:1:0.1 
DCM/MeOH/NH4OH) to give the title compound 10b (60.0 mg, 70%) as a white solid. 
1H NMR (400 MHz, CD3OD) δ 8.19 (s, 1H), 7.76 (s, 2H), 7.40 – 7.18 (m, 4H), 7.12 (d, J 
= 28.3 Hz, 3H), 7.04 (s, 5H), 6.71 (d, J = 7.4 Hz, 2H), 6.47 (d, J = 6.6 Hz, 2H), 4.29 (s, 
2H), 3.83 (s, 2H), 3.49 (s, 2H), 2.64 (s, 2H), 2.37 (d, J = 5.8 Hz, 2H), 2.17 (s, 3H), 2.07 
(d, J = 14.9 Hz, 2H), 1.82 (s, 2H), 1.54 (s, 2H), 1.26 (s, 4H), 0.83 (s, 3H). 13C NMR (101 
MHz, CD3OD) δ 171.4, 156.7, 147.1, 143.6, 142.3, 141.1, 138.4, 137.8, 135.5, 131.7, 
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129.9, 129.5, 129.1, 128.0, 127.7, 126.4, 125.8, 125.3, 120.9, 113.3, 104.9, 65.2, 61.6, 
55.4, 49.9, 41.8, 32.4, 29.8, 28.6, 27.8, 25.7, 25.0, 12.8. HRMS (ESI) m/z Calcd. for C41 
H48 O3 N5 [M+H
+]: 658.3752, found for 658.3746. 
4.7.1.8. Tamoxifen−N-(4-triazolylbenzyl)-N-(2-amino-5-(thiophen-2-yl)phenyl) 
hexanamide (12a) 
4-(4-Ethynylbenzyl)−tamoxifen 5 (50 mg, 0.1 mmol) and N-(2-amino-5-
(thiophen-2-yl)phenyl)-4-azidohexanamide 9a (38.4 mg, 0.1 mmol) were dissolved in 
degassed anhydrous THF (5 mL). CuI (10 mg, 0.05 mmol) and Hünig’s base (0.04 mL, 
0.2 mmol) were added to the reaction and the resulting reaction was stirred at room 
temperature overnight. Then, the reaction mixture was diluted with excess ethyl acetate 
(30 mL) and was transferred to a separatory funnel and then the ethyl acetate layer was 
washed with a solution (20 mL) of 4:1 mixture of saturated aqueous NH4Cl solution 
/NH4OH solution, water (10 mL), brine (10 mL), dried over anhydrous Na2SO4, filtered, 
and concentrated in vacuo. The crude was purified by preparative TLC (Silica gel, 
12:1:0.1 DCM/MeOH/NH4OH) to give the title compound 12a (72.0 mg, 85%) as a 
yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.95 (s, 1H), 7.77 – 7.66 (m, 3H), 7.40 (dd, J = 
14.9, 4.1 Hz, 1H), 7.39 – 7.28 (m, 5H), 7.29 – 7.27 (m, 1H), 7.25 – 7.22 (m, 2H), 7.18 – 
7.08 (m, 7H), 7.02 – 6.93 (m, 1H), 6.80 – 6.72 (m, 2H), 6.59 – 6.51 (m, 2H), 4.33 (dd, J 
= 19.0, 12.1 Hz, 2H), 4.01 – 3.87 (m, 2H), 2.76 (t, J = 5.9 Hz, 2H), 2.51 – 2.39 (m, 2H), 
2.34 (dd, J = 9.3, 5.1 Hz, 2H), 2.26 (d, J = 10.5 Hz, 3H), 1.90 (td, J = 14.3, 7.0 Hz, 2H), 
1.77 – 1.62 (m, 2H), 1.30 (dt, J = 16.6, 5.0 Hz, 4H), 0.92 (t, J = 7.4 Hz, 3H). 13C NMR 
(101 MHz, CDCl3) δ 171.9, 156.7, 147.6, 144.3, 143.8, 142.4, 141.4, 140.6, 138.3, 135.6, 
131.9, 129.7, 129.6, 129.4, 128.1, 127.9, 127.7, 127.3, 126.5, 126.0, 125.8, 125.6, 124.8, 
124.6, 123.5, 123.0, 121.6, 119.8, 118.3, 113.2, 66.0, 62.2, 55.7, 50.0, 42.7, 36.2, 29.9, 
29.6, 29.1, 26.1, 25.0, 13.7. HRMS (ESI) m/z Calcd. for C50 H53 O2 N6 S [M+H
+]: 




4-(4-Ethynylbenzyl)−tamoxifen 5 (50 mg, 0.1 mmol) and N-(2-amino-5-
(thiophen-2-yl)phenyl)-4-azidoheptanamide 9b (36.4 mg, 0.1 mmol) were dissolved in 
degassed anhydrous THF (5 mL). CuI (10 mg, 0.05 mmol) and Hünig’s base (0.04 mL, 
0.2 mmol) were added to the reaction and the resulting reaction was stirred at room 
temperature overnight. Then, the reaction mixture was diluted with excess ethyl acetate 
(30 mL) and was transferred to a separatory funnel and then the ethyl acetate layer was 
washed with a solution (20 mL) of 4:1 mixture of saturated aqueous NH4Cl solution 
/NH4OH solution, water (10 mL), brine (10 mL), dried over anhydrous Na2SO4, filtered, 
and concentrated in vacuo. The crude was purified by preparative TLC (Silica gel, 
12:1:0.1 DCM/MeOH/NH4OH) to give the title compound 12b (80.0 mg, 93%) as a 
yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.81 – 7.67 (m, 3H), 7.47 – 7.39 (m, 1H), 7.39 
– 7.29 (m, 4H), 7.29 – 7.19 (m, 4H), 7.20 – 7.04 (m, 8H), 7.03 – 6.92 (m, 1H), 6.81 – 
6.74 (m, 2H), 6.55 (d, J = 8.8 Hz, 2H), 4.32 (dd, J = 8.8, 5.0 Hz, 2H), 3.96 (t, J = 5.8 Hz, 
2H), 2.76 (t, J = 5.8 Hz, 2H), 2.48 (dq, J = 14.8, 7.4 Hz, 2H), 2.40 – 2.30 (m, 2H), 2.27 
(d, J = 10.1 Hz, 3H), 1.87 (d, J = 7.0 Hz, 2H), 1.70 (t, J = 18.5 Hz, 2H), 1.30 (ddd, J = 
31.5, 16.0, 7.3 Hz, 6H), 0.99 – 0.87 (m, 3H). 13C NMR (101 MHz, MeOD) δ 174.9, 
158.0, 148.6, 145.5, 145.0, 143.7, 142.6, 139.7, 138.8, 137.0, 133.0, 131.2, 130.9, 130.4, 
129.2, 129.0, 128.9, 128.3, 127.7, 127.1, 126.7, 126.4, 125.8, 125.2, 124.3, 124.1, 122.7, 
122.5, 122.2, 118.7, 114.3, 66.5, 63.0, 56.6, 51.2, 43.3, 37.0, 31.3, 30.1, 29.4, 27.2, 26.7, 
14.3. HRMS (ESI) m/z Calcd. for C51 H55 O2 N6 S [M+H





4-(4-Ethynylbenzyl)−tamoxifen 5 (60 mg, 0.1 mmol) and N-(2-amino-5-
(thiophen-2-yl)phenyl)-4-azidooctananamide 9c (50 mg, 0.1 mmol) were dissolved in 
degassed anhydrous THF (5 mL). CuI (12 mg, 0.06 mmol) and Hünig’s base (0.04 mL, 
0.2 mmol) were added to the reaction and the resulting reaction was stirred at room 
temperature overnight. Then, the reaction mixture was diluted with excess ethyl acetate 
(30 mL) and was transferred to a separatory funnel and then the ethyl acetate layer was 
washed with a solution (20 mL) of 4:1 mixture of saturated aqueous NH4Cl solution 
/NH4OH solution, water (10 mL), brine (10 mL), dried over anhydrous Na2SO4, filtered, 
and concentrated in vacuo. The crude was purified by preparative TLC (Silica gel, 
12:1:0.1 DCM/MeOH/NH4OH) to give the title compound 12a (13.0 mg, 14%) as a 
yellow oil. 1H NMR (500 MHz, CDCl3) δ 7.84 – 7.67 (m, 3H), 7.46 – 7.33 (m, 6H), 7.26 
(d, J = 7.0 Hz, 3H), 7.21 (dd, J = 22.4, 14.8 Hz, 4H), 7.16 – 7.07 (m, 5H), 6.79 (d, J = 8.6 
Hz, 2H), 6.57 (d, J = 8.3 Hz, 2H), 4.02 (s, 2H), 3.66 (d, J = 5.8 Hz, 2H), 2.83 (s, 2H), 
2.46 (dt, J = 25.8, 13.0 Hz, 3H), 1.96 (s, 4H), 1.67 – 1.57 (m, 4H), 1.38 (s, 6H), 1.01 – 
0.90 (m, 5H). 13C NMR (126 MHz, CDCl3) δ 168.1, 143.8, 142.4, 138.2, 136.5, 131.9, 
131.8, 129.7, 129.5, 128.1, 127.9, 127.8, 126.5, 126.2, 126.0, 125.9, 125.6, 124.7, 119.4, 
115.7, 114.1, 113.9, 113.4, 100.0, 56.1, 51.5, 42.6, 32.0, 31.1, 31.0, 30.1, 29.7, 29.7, 29.4, 
29.0, 28.9, 28.8, 28.8, 26.6, 26.2, 25.3, 25.1, 22.6, 17.0, 16.8, 14.1, 13.6. HRMS (ESI) 
m/z Calcd. for C52 H55 O2 N6 S [M+H
+]: 827.4102, found for 827.4100. 
4.7.2. Cell viability assay 
All cell lines used in this study were maintained in phenol red free Dulbecco's 
Modified Eagle Medium (DMEM) and Eagles’s Minimum Essential Medium (EMEM) 
(Corning, VA), supplemented with 10% fetal bovine serum (FBS) (Atlanta Biologicals, 
Atlanta, GA) and 1% Penicillin-Streptomycin. Cells were incubated in 96 well plate 24 h 
prior to treatment and then treated with various drugs’ concentration for 72 h. Their anti-
proliferative activity was measured using the MTS assay (CellTiter 96 Aqueous One 
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Solution and CellTiter 96 Non-Radioactive Cell Proliferation Assays, Promega, Madison, 
WI) as described by the manufacturer. All drugs solution were made in DMEM and 
EMEM while DMSO concentration was maintained at 0.1%. 
4.7.3. SAMDI assay (In vitro HDAC inhibition, performed by Lindsey Szymczak at 
Northwestern University) 
HDAC1, 2, 3, 8 and 6 were purchased from BPS Biosciences. To obtain IC50 
values, in a 96-well microtiter plates (60 min, 37 °C), isoform- optimized substrates (50 
μM) were incubated with enzyme (250nM) and inhibitor (at concentrations ranging from 
.1 nM to 1.0 mM) in HDAC buffer (25.0 mM Tris-HCl, pH 8.0, 140 mM NaCl, 3.0 mM 
KCl, 1.0 mM MgCl
2
, and 0.1 mg/mL BSA). Solution-phase deacetylation reactions were 
quenched with trichostatin A (TSA) and transferred to SAMDI plates to immobilize the 
substrate components. SAMDI plates were consist of an array of self-assembled 
monolayers (SAMs) presenting maleimide in standard 384-well format for high-
throughput handling capability. Following immobilization, plates were washed to remove 
buffer constituents, enzyme, inhibitor, and any unbound substrate and analyzed by 
MALDI mass spectrometry using automated protocols. Deacetylation yields in each 
triplicate sample were obtained from the integrated peak intensities of the molecular ions 
for the substrate and the deacetylated product ion by taking the ratio of the former over 
the sum of both. Yields were plotted with respect to inhibitor concentration and fitted to 
obtain IC50 values for each isoform−inhibitor pair.  
Isoform-optimized substrates were prepared by traditional FMOC solid-phase 
peptide synthesis (Anaspec) and purified by semi-preparative HPLC on a reverse-phase 
C18 column (Waters). The peptide GRKacFGC was prepared for HDAC1 and HDAC8 
experiments, whereas the peptide GRKacYGC was prepared for HDAC6 experiments.  
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BIFUNCTIONAL STAT3/HISTONE DEACETYLASE 
INHIBITORS FOR TREATING STAT3 DEPENDENT TUMORS 
5.1. Introduction 
Pyrimethamine is an antifolate drug used as an antimalarial agent (Figure 5.1) [1] 
and has also been used in chemotherapy along with other drugs such as proguanil for few 
decades [2]. Its antimalarial activity originates from its ability to specifically bind and 
inhibit dihydrofolate reductase (DHFR, 5,6,7,8-tetrahydrofolate: NADP+ oxidoreductase, 
EC 1.5.1.3) in Plasmodium falciparum and some other protozoa [3], [4]. DHFR is critical 
for folate metabolism and has been a drug target for fungal, protozoal and bacterial 
infections and cancer. It facilitates an NADPH-dependent reduction of dihydrofolate to 
tetrahydrofolate, a cofactor necessary for the biosynthesis of thymidylate, purine 
nucleotides, and many other essential amino acids required for protein, RNA and DNA 
synthesis [5]. DHFR inhibition by antifolate compounds interferes with these pathways, 
resulting in cell cycle arrest and cell death [6]. 
 
                                     
Figure 5.1. Structure of pyrimethamine, an antifolate drug with antimalarial activity. 
Pyrimethamine is a STAT3 inhibitor and is currently in clinical trial for treating relapsed 
chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). 
 
Unfortunately, pyrimethamine’s use as a standalone antimalarial agent has been 
hampered by naturally occurrence of drug resistance in the parasite [1].  Mutations in the 
gene encoding dihydrofolate reductase-thymidylate synthesis are responsible for the 
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developed drug resistance [7], [8]. To overcome the developed resistance obstacle, 
pyrimethamine has been used in combination therapy with other drugs such as 
sulfadoxine to treat malaria. However, parasite mutations in DHFR conferred 
sulfadoxine- pyrimethamine- resistant as well [9]. 
However, despite the pyrimethamine failure in treating malaria recent years, 
studies have shown it inhibits proliferation of acute myeloid leukemia (AML) by 
targeting a protein in tumor cells called STAT3 (Signal transducer and activator of 
transcription 3) [10], [11], [12]. In fact, pyrimethamine is currently in phase I/II clinical 
trials for the treatment of relapsed chronic lymphocytic leukemia (CLL) and small 
lymphocytic lymphoma (SLL) (ClinicalTrials.gov Identifier: NCT01066663).  
STAT proteins, a family of seven members (STAT1, 2, 3, 4, 5a, 5b, 6), were 
discovered in 1993 by Shuai et al [13]. STAT3, an oncogenic transcription factor with 
critical role in the signaling of a number of cytokines and growth factors, confers 
resistance to apoptosis in various cell types [14] and is activated in many cancers [15], 
[11]. STAT3 activation through its tyrosine phosphorylation by JAK (Janus kinase) or 
IL-6 signaling cascade [16] enhances its dimerization and translocation from cytoplasm 
to nucleus where it can bind to certain DNA sequences and regulates genes expression 
involved in various cellular processes. Tyrosine phosphorylation is not the only way to 
activate STAT3. It can be activated through other processes such as serine 
phosphorylation, acetylation, methylation and glutathionylation [17], [18], [19]. Once 
STAT3 is activated it enhances various cell processes such as cell proliferation, 
differentiation, survival and angiogenesis that contribute to malignant transformation and 
progression in many cancers such as breast, ovary, and prostate [20]. Although STAT3 
has non-transcriptional responsibilities, such as regulation of mitochondrial function, 
most of its oncogenic activities is related to its gene regulation in nucleus [12]. 
Activation of STAT3 is tightly regulated in normal conditions, however in cancer, 
it is highly activated and leads to malignant cancer cells phenotype [21]. Therefore, 
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inhibiting STAT3 can be a promising strategy for cancer therapy as a wide variety of 
cancers depend on STAT3 for their survival. Additionally, there is less chance for 
developing resistance due to convergence of many cellular pathways on STAT3. STAT3 
inhibitors exhibit synergetic effect with other therapeutic agents in inhibiting tumor stem 
cells, leading to improved therapeutic indices for these agents.  
Histone deacetylase (HDAC) enzymes are a class of proteins that play an 
important role in regulating STAT3 activation [22]. HDACs along with histone acetyl 
transferase (HAT) control gene expression, chromatin condensation and play an essential 
role in transcriptional activation by regulating acetylation state of histone proteins [23]. 
In addition to histone proteins, several non-histone proteins, including transcription 
factors (E2F, STAT3, P53, NF-ҝB), estrogen receptor (ERα), androgen receptor (AR), α-
tubulin, and chaperons (HSP90) are regulated by HDAC and HAT activity [24]. Due to 
critical role of HDACs in regulating a wide range of cellular pathways such as cell 
survival, differentiation, cell cycle progression, angiogenesis and immunity, HDACs are 
considered as promising targets, and their inhibition has emerged as a potential strategy 
in treating various diseases like malaria, leishmania, and most importantly cancer [25], 
[26]. To date, there are four US FDA approved HDACis, namely, SAHA (suberoylanilide 
hydroxamic acid, vorinostat) approved in 2006 for relapsed and refractory cutaneous T-
cell lymphoma (CTCL) [27], romidepsin (FK228) approved in 2009 for 
relapsed/refractory peripheral T-cell lymphoma [28], belinostat (PXD101) approved in 
2014 for relapsed/refractory peripheral T-cell lymphoma [29], and lastly panobinostat 
(LBH589) in 2015 for treating acute myeloma (Figure 5.2) [30]. Chidamide (CS055) is 
another HDACi which is only approved in China for treating relapsed/ refractory 
peripheral T-cell lymphoma. Chidamide is in phase II clinical trials in US [31]. 
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   Figure 5.2. US FDA approved HDACi. 
 
Inhibition and knockdown of class I HDAC, specifically HDAC3, has been 
shown to result in upregulated STAT3Lys685 acetylation, attenuated STAT3Tyr705 
phosphorylation and inhibition of survival of pSTAT3-positive diffuse large B-cell 
lymphoma (DLBCL) cells. The DLBCL cytotoxicity is linked to downregulation of the 
direct STAT3 target myeloid leukemia cell differentiation protein (Mcl-1), a pro-cell 
survival protein encoded by MCL1 gene [32]. Therefore, targeting STAT3-positive 
DLBCL cells with HDACi is another potentially viable therapeutic option for managing 
CLL and DLBCL tumors. We hypothesized that designed multiple ligands comprising 
pyrimethamine and HDAC inhibition chemotype will integrate direct stat3- and HDAC-
inhibition, and downregulation of Mcl-1 within a single molecular template. These 
pyrimethamine-HDACi conjugates are anticipated to be more efficient inhibitors of 
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proliferation of CLL, DLBCL and possibly other tumors which are exquisitely dependent 
on STAT3 signaling pathway.  
5.2. Design of Pyrimethamine-HDACi Conjugates 
The three-motif HDACi pharmacophoric model consists of a recognition cap 
group, linker group, and zinc binding group (ZBG) (Figure 5.3) [33]. Pyrimethamine 
structure closely resembles HDACi aryl-derived cap group. Moreover, substitution of the 
pyrimithamine halogen group with alkyl, aryl and ring systems have been shown to be 
compatible with DHFR inhibition. Based on these observations, I designed two classes of 
pyrimethamine-HDACi conjugates using pyrimethamine as a surrogate for HDACi cap 
group.                                          
 




For aryl triazolyl HDACi, we had previously shown that five and six methylenes 
are ideal length of for linker group to ensure optimal zinc chelation [25].  Therefore, I 
limited the linker length to five and six methylene groups in my design.  
5.3. Chemistry and synthesis 
To synthesizethe the class I pyrimethamine-HDACi conjugates, 4-bromophenyl 
acetonitrile 1 was reacted with ethyl propanioate 2 under basic condition to yield β-
ketonitrile 3 [34] the keto group of which was then converted to methoxy 5 using 
trimethyl orthoformate 4 [35]. Pyrimidine ring was formed through cyclization reaction 
with guanidine hydrochloride [36]. Boc protection of amine groups [37], [38] followed 
by sonogashira reaction with trimethylsilylacetylene 8 resulted in compound 9 [39]. 
Trimethylsilyl group was removed using potasium carbonate to afford alkyne 10. 
Subsequently,  copper (I) catalyzed azide-alkyne-cycloaddition (AAC) reaction [40] 
between alkyne 10 and compounds 11a-b, followed by removal of trityl- protecting 
group resulted the final product 12a-b. Compounds 11a-b were synthesized as described 
in chapter 4 [41] (Scheme 5.1). 
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Scheme 5.1. (a) KOtBu Amyl 25% toluene,THF, rt, 20 min, 90%; (b) 6 h, 107 °C, 
33%; (c) Guanidine hydrochloride, NaHCO3, DMSO, 100 °C, 6 h, 72%; (d) Boc2O, THF, 
DMAP, 45 °C, THF, 86%; (e) Hunig’s base, Pd(PPh3)4, acetonitrile, CuI, 75 °C, 
overnight; (f) K2CO3, MeOH, 0 °C, 2 h, 36% (e and f); (g) CuI, Hunig's base, rt, 
overnight; (h) TFA, DCM, rt, 2 h, 84-88% (g and h). 
 
To synthesize the class II pyrimethamine-HDACi conjugates, a Heck reaction was 
performed on intermediate 6 with methyl acrylate 13 [42]. After the Boc protection, the 
ester group was converted to carboxylic acid 16 using sodium hydroxide [43]. The final 
hydroxamic acid derivative 18 was synthesized through coupling of carboxylic acid 16 




Scheme 5.2 . (a) Tri-O-tolyl phosphine, Pd(OAc)2, TEA, DMF, 120 °C, overnight, 55%; 
(b) Boc2O, THF, DMAP, 45 °C, THF, 56%; (c) NaOH, H2O, Dioxane, 20 °C, 12 h, 60%; 
(d) EDCI, HOBT, DCM, rt, 6 h; (e) TFA, DCM, rt, 2 h, 24% (d and e). 
5.4. HDAC inhibitory potency (Performed by BPS Bioscience) 
All three pyrimethamine conjugated HDACi were tested against HDAC isoforms 
1, 6 and 8. Compounds 12a and 12b showed both HDAC1 and HDAC6 inhibition 
activity while compound 18 exhibited HDAC inhibition potency more selectively toward 
HDAC6.   
 
Table 5.1. HDAC inhibition activities of pyrimethamine-HDACi conjugates (IC50 in 
µM). 
     Compound           HDAC1         HDAC6         HDAC8  
12a 0.26 0.046 2.8 
12b 0.045 0.017 0.78 
18 2.2 0.40 1.8 
SAHA 0.042 0.034 2.8 
 215 
5.5. Docking study  
Molecular docking analyses using AutoDock Vina confirmed that compounds 12a 
and 12b chelates the zinc ion in the active stie of both HDAC1 and HDAC6 while 
compound 18 only chelates the zinc ion in the pocket of HDAC6 and does not exhibit 

















   
Figure 5.4. Docking structures of various pyrimethamin conjugated HDACi. Grey sphere 
represents zinc ion in the active site of HDAC isoform. (A) 12b against HDAC1 (B) 12b 





5.6. Antiproliferative activity 
The pyrimethamine-HDACi conjugates were tested against four cell lines. Three 
transformed cell lines, lung (A549), ER positive (MCF-7), ER negative (MDA-MB231) 
cancer cell lines, and one healthy cell line (VERO- monkey kidney epithelial cell). 
SAHA, the FDA approved HDACi, was used as the control.  
As expected compound 18 did not show anti-proliferative activity towards 
transformed cell lines, since it did not exhibit HDAC inhibitory activity. Additionally, 
compound 12b was a more potent HDAC inhibitor compared to 12a, therefore it was 
more cytotoxic towards transformed cell lines than 12a.  
Furthermore, The data showed that pyrimethamine conjugated HDACi 12a and 
12b were most cytotoxic toward MDA-MB231 with STAT3 activity. STAT3 is not 
activated in other cell lines, therefore the pyrimethamine conjugated HDACi did not 
show porent anti-proliferative activity towards them. 
 
Table 5.2. Anti-proliferative activity of pyrimethamine-HDACi conjugates (IC50 values 
in µM).      
Compound A549 MCF-7 MDA-MB231 VERO Hs.505 T 
12a NI NI 38.38± 1.0 ND ND 
12b 26.27± 3.0 52.6 ± 6.2 1.11 ± 0.2 11.5 ± 2.7 ND 
18 NI NI NI ND ND 
SAHA 5.00±0.24 3.27±0.05 3.40±0.20 1.03±0.97 52± 2.2 
Each value is obtained from a duplicate of three simultaneous experiments. NI: No Inhibition. ND: Not Determined at maximum 




I designed and synthesized two classes of pyrimethamine conjugated HDACi. 
Compounds 12a and 12b inhibited both HDAC1 and HDAC6 activity while compound 
18 was a very weak HDAC inhibitor. Additionally, it was 5 fold more selective toward 
HDAC6 compared to HDAC1. Compound 18 did not show HDAC anti-proliferative 
activity due to lack of HDAC inhibition potency. 
These pyrimethamine HDACi conjugates were most cytotoxic toward STAT3 actived 
transformed cell line such as MDA-MB231.   
5.8. Experimental 
5.8.1. Materials and methods 
4-Bromophenyl acetonitrile, ethyl propionate, O-tritylhydroxylamine, methyl 
acrylate, were purchased from Sigma-Aldrich. Trimethylsilylacetylene was purchased 
from Alfa Aesar. All commercially available starting materials were used without 
purification. Reaction solvents were high performance liquid chromatography (HPLC) 
grade or American Chemical Society (ACS) grade and used without purification. 
Analtech silica gel plates (60 F254) were used for analytical TLC, and Analtech 
preparative TLC plates (UV 254, 2000 µm) were used for purification.  UV light and 
anisaldehyde/iodine stain were used to visualize the spots.  200-400 Mesh silica gel was 
used in column chromatography. Nuclear magnetic resonance (NMR) spectra were 
recorded on a Varian-Gemini 400 MHz or Bruker 500 MHz magnetic resonance 
spectrometer.  1H NMR Spectra were recorded in parts per million (ppm) relative to the 
residual peaks of CHCl3 (7.24 ppm) in CDCl3 or CHD2OD (4.78 ppm) in CD3OD or 
DMSO-d5 (2.49 ppm) in DMSO-d6. 
13C spectra were recorded relative to the central peak 
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of the CDCl3 triplet (77.0 ppm) or CD3OD septet (49.3 ppm) or DMSO-d6 septet (39.7 
ppm) and were recorded with complete hetero-decoupling. Original ‘fid’ files were 
processed using MestReNova LITE (version 5.2.5-5780) program. High-resolution mass 
spectra were recorded at the Georgia Institute of Technology mass spectrometry facility 
in Atlanta.  
5.8.1.1. 2-(4-Bromophenyl)-3-oxopentanenitrile (3)  
To a solution of 4-bromophenyl acetonitrile (1.4 g, 7 mmol) in THF (10 mL), 
potassium tert-pentylate (25% in toluene) (12.2 mL, 21 mmol) was added dropwise, 
followed by addition of ethyl proponiate. The reaction mixture stirred for 20 minutes, and 
then diluted with 1N HCl solution to pH=7, and water (5 mL) and EtOAc (10 mL). The 
organic layer was then washed with water (10 mL) and brine (10 mL) and dried over 
Na2SO4. Crude product was purified by column chromatography using (Silica gel, 4:1, 
Hex: EtOAc) and yielded the product (1.6 g, 90%) as yellow oil. 1H NMR (400 MHz, 
CD3OD) δ 7.62 – 7.53 (m, 2H), 7.49 – 7.41 (m, 2H), 2.71 – 2.55 (m, 2H), 1.31 – 1.23 (m, 
3H). 13C NMR (101 MHz, CD3OD) δ 173.5, 132.1, 131.9, 130.9, 130.0, 128.9, 120.0, 
119.4, 85.6, 28.8, 11.2. HRMS (ESI) m/z Calcd. for C11 H10 N O Br [M+H
+]: 250.9946, 
found for 250.9946.  
 
5.8.1.2. 2-(4-Bromophenyl)-3-methoxypent-2-enenitrile (5) 
Compound 3 (3.1 mg, 12.5 mmol) and trimethyl orthoacetate 4 (12.3 ml, 96.5 
mmol) were heated at 107 °C for 6 h. The reaction mixture was washed with water (15 
ml), NaHCO3 (15 ml), and brine (15 ml). The organic layer was dried over Na2SO4. 
Crude product was purified by column chromatography using (Silica gel, 3:1, Hex: 
EtOAc) and yielded the product (1.1 g, 33%) as yellow oil. 1H NMR (400 MHz, CDCl3) 
δ 7.57 – 7.35 (m, 4H), 2.77 (q, J = 7.6 Hz, 2H), 1.32 – 1.26 (m, 3H). 13C NMR (101 
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MHz, CDCl3) δ 173.1, 131.4, 130.8, 129.8, 120.7, 119.7, 91.5, 56.4, 24.1, 12.8. HRMS 
(ESI) m/z Calcd. for C12 H12 N O Br [M+H
+]: 265.0102, found for 265.0103.  
5.8.1.3. 5-(4-Bromophenyl)-6-ethylpyrimidine-2,4-diamine (6) 
A mixture of compound 5 (846 mg, 3.2 mmol), sodium hydrogen carbonate (588 
mg, 7mmol) and guanidine hydrochloride (668 mg, 7 mmol) in dry DMSO (10 mL) was 
heated at 100 °C for 5 h. The reaction mixture was washed with water (15×3 mL) and 
10% MeOH: DCM (15 mL). Organic layer was seperated and washed with brine (10 
mL), and dried over Na2SO4.  Crude product was purified by precipitation with EtOAc 
and yielded the product (670 mg, 72%) as a white powder. 1H NMR (400 MHz, CD3OD) 
δ 7.62 (d, J = 8.5 Hz, 2H), 7.16 (d, J = 8.5 Hz, 2H), 2.22 (q, J = 7.6 Hz, 2H), 1.03 (t, J = 
7.6 Hz, 3H). 13 C NMR (126 MHz, DMSO) δ 166.8, 162.6, 162.4, 135.9, 133.4, 132.3, 
121.0, 105.9, 49.1, 27.9, 13.7. HRMS (ESI) m/z Calcd. for C12 H14 N4 Br [M+H
+]: 
293.0396, found for 293.0399. 
5.8.1.4. Di-tert-butyl (5-(4-bromophenyl)-6-ethylpyrimidine-2,4-diyl)bis((tert-
butoxycarbonyl)carbamate) (7)  
 Compound 6 (104.4 mg, 0.3 mmol) and DMAP (4.3 mg, 0.03 mmol) were 
dissolved in THF (5 mL) and flushed with argon. Boc2O (622.7 mg, 2.8 mmol) was 
added to the solution. Reaction went overnight at 40 °C. The reaction mixture was 
washed with water (5 mL) and DCM (5 mL) and the organic layer was seperated and 
washed with brine (5 mL), and dried over Na2SO4.  The crude product was purified on 
preparative TLC using 4:1 (Hex: EtOAc) to yield the product (204 mg, 86% conversion) 
as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.56 – 7.48 (m, 2H), 7.14 – 7.03 (m, 2H), 
2.59 (q, J = 7.5 Hz, 2H), 1.42 (s, 18H), 1.31 (s, 18H), 1.13 (t, J = 7.5 Hz, 3H). 13C NMR 
(101 MHz, CDCl3) δ 173.9, 158.6, 157.4, 150.3, 149.8, 132.0, 131.7, 130.8, 128.3, 122.6, 
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83.5, 83.1, 28.4, 27.9, 13.0. HRMS (ESI) m/z Calcd. for C32 H46 O8 N4 Br [M+H
+]: 
693.2494, found for 693.2493. 
 5.8.1.5. Di-tert-butyl (6-ethyl-5-(4-((trimethylsilyl)ethynyl)phenyl)pyrimidine-2,4-
diyl)bis((tert-butoxycarbonyl)carbamate) (9). 
Compound 7 (315 mg, 0.4 mmol), Pd(PPh3)4 (26 mg, 0.02 mmol), and CuI (8.6 
mg, 0.04 mmol) were dissolved in acetonitrile (5 mL) under argon. 
Trimethylsilylacetylene (0.1 mL, 0.9 mmol) was added, followed by Hunig’s base (0.2 
mL, 0.9 mmol) . The reaction mixture was heated to 75 °C overnight.  The reaction 
mixture was washed with water (3 mL) and DCM (5 mL). The organic layer was 
seperated and washed with brine (5 mL), and dried over Na2SO4. Crude product was used 
in the next step without purification.  
5.8.1.6. Di-tert-butyl (6-ethyl-5-(4-ethynylphenyl)pyrimidine-2,4-diyl)bis((tert-
butoxycarbonyl)carbamate) (10) 
Potassium carbonate (74 mg, 0.5 mmol) was added to a solution of crude 
compound 9 (190 mg) in methanol (3 mL). The reaction mixture stirred for 2 h at rt. The 
reaction mixture was washed with water (1 mL) and DCM (3 mL). The organic layer was 
seperated and washed with brine (3 mL), and dried over Na2SO4. The crude product was 
purified on preparative TLC using 8:1:1 (Hex: EtOAc: Ether) and yielded the product (93 
mg, 36% overall yield of 9 and 10) as a white powder. 1H NMR (400 MHz, CDCl3) δ 
7.57 – 7.49 (m, 2H), 7.25 – 7.18 (m, 2H), 3.14 (s, 1H), 2.61 (dt, J = 7.5, 6.0 Hz, 2H), 1.45 
(s, 18H), 1.34 (s, 18H), 1.17 (q, J = 7.6 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 173.8, 
158.7, 157.1, 150.9, 150.0, 134.0, 132.3, 129.5, 128.8, 122.4, 83.8, 83.5, 83.1, 78.4, 28.5, 
27.7, 13.0. HRMS (ESI) m/z Calcd. for C34 H47 O8 N4 [M+H





Compound 10 (41 mg, 0.06 mmol) and 4-azido-N-(trityloxy)hexanamide 11a (32 
mg, 0.08 mmol) were dissolved in anhydrous THF (5 mL) and purged with argon for 15 
min. Copper (I) iodide (6 mg, 0.03 mmol) and Hunig’s base (0.02 mL, 0.1 mmol) were 
then added to the reaction mixture. The reaction mixture was purged with argon for 
additional 15 min and stirring continued for overnight 12 h. The crude was then dissolved 
in DCM: TFA (1: 0.2 mL) solution. Triisopropyl silane was added dropwise until the 
color transformed from dark yellow to pale yellow. TLC indicated the complete 
consumption of the starting material after 1 h. Solvent and TFA were evaporated off. The 
crude product was purified by precipitation in EtOAc to give the title compound (23 mg, 
88%) as a pale yellow solid. 1H NMR (500 MHz, MeOD) δ 8.46 (s, 1H), 8.02 (d, J = 7.7 
Hz, 2H), 7.40 (dd, J = 15.1, 8.0 Hz, 2H), 4.50 (d, J = 6.2 Hz, 2H), 2.42 (q, J = 7.2 Hz, 
2H), 2.21 – 2.04 (m, 2H), 2.02 (s, 2H), 1.71 (s, 2H), 1.41 (s, 2H), 1.21 – 1.12 (m, 3H). 
13C NMR (126 MHz, MeOD) δ 165.2, 155.5, 154.6, 146.9, 131.6, 130.9, 126.7, 121.4, 
108.8, 71.2, 50.1, 29.8, 29.2, 25.6, 24.6, 23.9, 17.3, 11.8. HRMS (ESI) m/z Calcd. for C20 
H27 O2 N8 [M+H
+]: 411.2251, found for 411.2246. 
5.8.1.8. 4-(4-(4-(2,4-Diamino-6-ethylpyrimidin-5-yl)phenyl)-1H-1,2,3-triazol-1-yl)-N-
hydroxyheptanamide (12b) 
Compound 10 (40 mg, 0.06 mmol) and 4-azido-N-(trityloxy)heptanamide 11b (32 
mg, 0.08 mmol) were dissolved in anhydrous THF (5 mL) and purged with argon for 15 
min. Copper (I) iodide (6 mg, 0.03 mmol) and Hunig’s base (0.02 mL, 0.1 mmol) were 
then added to the reaction mixture. The reaction mixture was purged with argon for 
additional 15 min and stirring continued for overnight 12 h. The crude was then dissolved 
in DCM: TFA (1: 0.2 mL) solution. Triisopropyl silane was added dropwise until the 
color transformed from dark yellow to pale yellow. TLC indicated the complete 
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consumption of the starting material after 1 h. Solvent and TFA were evaporated off. The 
crude product was purified by precipitation in EtOAc to give the title compound (22 mg, 
84%) as a pale yellow solid. 1H NMR (400 MHz, CD3OD) δ 8.43 (s, 1H), 7.99 (d, J = 6.4 
Hz, 2H), 7.37 (s, 2H), 4.47 (s, 2H), 2.39 (s, 2H), 2.19 (d, J = 31.3 Hz, 2H), 1.99 (d, J = 
11.8 Hz, 2H), 1.60 (s, 2H), 1.38 (s, 4H), 1.14 (d, J = 6.1 Hz, 3H). 13C NMR (126 MHz, 
MeOD) δ 164.9, 155.4, 154.8, 146.7, 131.4, 130.9, 130.6, 126.5, 121.4, 108.8, 50.1, 29.8, 
29.4, 28.1, 26.1, 25.0, 23.7, 23.0, 11.8. HRMS (ESI) m/z Calcd. for C21 H29 O2 N8 
[M+H+]: 425.2408, found for 425.2402. 
5.8.1.9. Methyl-3-(4-(2,4-diamino-6-ethylpyrimidin-5-yl)phenyl)acrylate (14) 
Compound 6 (90 mg, 0.3 mmol), methyl acrylate 13 (0.09 mL, 0.9 mmol), TEA 
(0.1 mL, 0.8 mmol), and tri-O-tolylphosphine (28 mg, 0.09 mmol) were dissolved in 
DMF (3 mL). The reaction mixture was purged with argon for 15 min, then Pd(OAc)2 
(10.3 mg, 0.05 mmol) was added, and then was heated at 120 °C overnight.  The reaction 
mixture was washed with water (10 mL) and DCM (10 mL). The organic layer was 
seperated and washed with brine (5 mL), and dried over Na2SO4. Crude product was 
purified on preparative TLC using 10:1:0.5 (EtOAc: Hex: NEt3) and yielded the product 
(50 mg, 55%) as a pale yellow powder. 1H NMR (400 MHz, CD3OD) δ 7.74 (d, J = 8.2 
Hz, 3H), 7.32 (d, J = 7.7 Hz, 2H), 6.60 (d, J = 16.2 Hz, 1H), 2.38 – 2.21 (m, 2H), 1.10 (t, 
J = 7.4 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 167.4, 164.1, 157.7, 144.1, 134.6, 134.2, 
130.9, 128.7, 118.6, 107.9, 70.3, 51.1, 31.8, 29.2, 25.4, 12.0. HRMS (ESI) m/z Calcd. C16 
H19 O2 N4 [M+H
+]: 299.1503, found for 299.1503. 
5.8.1.10. Methyl-3-(4-(2,4-bis(bis(tert-butoxycarbonyl)amino)-6-ethylpyrimidin-5-
yl)phenyl)acrylate (15) 
Compound 14 (27 mg, 0.09 mmol) and DMAP (1.1 mg, 0.009 mmol) were 
dissolved in THF (3 mL) and flushed with argon. Boc2O was added to the solution. 
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Reaction went overnight at 40 °C. The reaction mixture was washed with water (1 mL) 
and DCM (3 mL) and the organic layer was seperated and washed with brine (3 mL), and 
dried over Na2SO4.  The crude product was purified on preparative TLC using 3:1 (Hex: 
EtOAc) to yield the product (35 mg, 56%) as a white solid. 1H NMR (400 MHz, CD3OD) 
δ 7.77 (s, 1H), 7.74 (d, J = 7.0 Hz, 2H), 7.34 (dd, J = 17.5, 8.2 Hz, 2H), 6.63 (dd, J = 
16.1, 10.6 Hz, 1H), 3.80 (s, 3H), 2.80 – 2.57 (m, 2H), 1.48 (s, 18H), 1.35 (d, J = 4.3 Hz, 
18H), 1.19 (t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 173.8, 167.3, 158.6, 157.4, 
150.9, 149.8, 143.8, 135.3, 134.5, 129.8, 128.0, 118.7, 82.2, 81.3, 70.4, 51.9, 51.8, 29.7, 
29.0, 28.6, 28.2, 28.0, 27.9, 27.8, 27.7, 13.2, 12.9. HRMS (ESI) m/z Calcd. C36 H51 O10 
N4 [M+H
+]: 699.3600, found for 699.3595. 
5.8.1.11. 3-(4-(2,4-Bis(bis(tert-butoxycarbonyl)amino)-6-ethylpyrimidin-5-
yl)phenyl)acrylic acid (16) 
Compound 15 (60 mg, 0.08 mmol) was dissolved in 1,4-dioxane (3 mL) and 
added dropwise to an aqueous solution (3 mL) containing hydroxylamine (6 mg, 0.2 
mmol) and sodium hydroxide (10.2 mg, 0.2 mmol) at rt, and stirred for 12 h and 
concentrated under vaccume to remove organic solvent. The aquous solution was 
adjusted to pH=1 with 1N HCl. The resulting precipitate was collected by filteration and 
dried to give the product (35 mg, 60%) as a pale yellow solid. 1H NMR (400 MHz, 
CDCl3) δ 7.70 (s, 1H), 7.60 – 7.52 (m, 2H), 7.27 (d, J = 5.2 Hz, 1H), 7.22 (d, J = 8.1 Hz, 
1H), 6.54 (s, 1H), 2.62 (dq, J = 15.2, 7.5 Hz, 2H), 1.51 (d, J = 15.4 Hz, 6H), 1.50 – 1.44 
(m, 12H), 1.32 (s, 18H), 1.24 (d, J = 3.9 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 174.3, 
158.9, 158.2, 157.6, 156.7, 150.7, 150.5, 150.0, 130.0, 129.5, 128.8, 128.1, 125.5, 81.5, 
29.7, 29.0, 28.6, 28.3, 28.0, 27.8, 27.7, 13.1, 12.9. HRMS (ESI) m/z Calcd. C35 H49 O10 
N4 [M+H
+]: 685.3443, found for 685.3434. 
5.8.1.12. 3-(4-(2,4-Diamino-6-ethylpyrimidin-5-yl)phenyl)-N-hydroxyacrylamide (18) 
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Compound 16 (35 mg, 0.05 mmol), EDCI (9.5 mg, 0.05 mmol) and HOBT (6.9 
mg, 0.05 mmol) were dissolved in DCM (3 mL) at 0 °C. After stirring at 0 °C for 15 min, 
amine (20.6 mg, 0.07 mmol) and Hunig’s base (0.03 mL, 0.15 mmol) were added. And 
the reaction mixture stirred for 12 h at rt. The reaction mixture was washed with water (1 
mL) and DCM (3 mL) and the organic layer was seperated and washed with brine, and 
dried over Na2SO4.  The crude was then dissolved in DCM: TFA (1: 0.2 mL) solution. 
Triisopropyl silane was added dropwise until the color transformed from dark yellow to 
pale yellow. TLC indicated the complete consumption of the starting material after 1 h. 
Solvent and TFA were evaporated off. The crude product was purified by precipitation in 
EtOAc to give the title compound (3.6 mg, 24%) as a pale yellow solid.  1H NMR (500 
MHz, MeOD) δ 7.75 (d, J = 7.4 Hz, 2H), 7.66 (d, J = 15.6 Hz, 1H), 7.37 (d, J = 6.9 Hz, 
2H), 6.59 (d, J = 15.3 Hz, 1H), 2.38 (d, J = 7.4 Hz, 2H), 1.15 (t, J = 7.3 Hz, 3H). 13C 
NMR (126 MHz, MeOD) δ 171.8, 165.2, 158.0, 155.3, 144.8, 135.7, 130.7, 128.7, 120.4, 
29.6, 27.2, 23.9, 12.0. HRMS (ESI) m/z Calcd. C15 H18 O2 N5 [M+H
+]: 300.1455, found 
for 300.1451. 
5.8.2. Cell viability assay 
All cell lines used in this study were maintained in phenol red free Dulbecco’s 
Modified Eagle Medium (DMEM) (Corning, VA), supplemented with 10% fetal bovine 
serum (FBS) (Atlanta Biologicals, Atlanta, GA) and 1% Penicillin-Streptomycin. Cells 
were incubated in 96 well plate for 24 h prior to treatment and then treated with various 
drugs’ concentration for 72 h. Their anti-proliferative activity was measured using the 
MTS assay (CellTiter 96 Aqueous One Solution and CellTiter 96 Non-Radioactive Cell 
Proliferation Assays, Promega, Madison, WI) as described by the manufacturer. All 
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drugs solution were made in DMEM while DMSO concentration was maintained at 
0.1%. 
5.8.3. In vitro HDAC inhibition (Performed through contractual agreement with 
BPS Bioscience) 
HDAC inhibition was performed via Fluor de Lys assay. This assay is based on 
Fluorimetric Histone deAcetylaseLysyl substrate and developer combination. First the 
substrate with the acetylated lysine chain is incubated with HDAC enszymes. Then the 
developer is added which results in generating a fluorophore.  
To perform the in vitro HDAC inhibition assay, different concentration of HDACi 
with 10% DMSO in HDAC assay buffer were prepared and added to the enzymatic 
reaction containing HDAC assay buffer, BSA, substrate and enzyme (HDAC1, HDAC6 
and HDAC8) in 96 well plate. Developer was then added to each well and the plate was 
incubated at room tempretaure for 15 minutes. Fluorescent intensity at the certain 
wavelengths was measured using Bioteck Synergy microplate reader. Fluorescent 
intensities were measured in the absence and presence of the compounds as well as in the 
absence of HDAC , and the data was analyzed using Graphpad Prism. IC50 value for each 
compound was determined by the concentration leading to a half-maximal percent 
inhibition.   
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CONCLUSION AND FUTURE STUDIES 
 
6.1. Conclusion 
Cancer is one of the leading causes of death worldwide [1]. Genetic and 
epigenetic alterations are involved in tumorigenesis, therefore, epigenetic regulations 
have become a new promising therapeutic strategy over the past few decades. Epigenetic 
regulation has various ways to modify DNA and histone state through processes such as 
DNA methylation, histone modification and remodeling via histone acetylation and 
deacetylation. Histone acetyl transferase (HAT) and histone deacetylase (HDAC) are able 
to add or remove acetyl group, respectively, from histone core tail, leading to an open or 
restricted chromatin. Histone modification impacts DNA access to transcription factors 
and, consequently, gene expressions [2].      
Development of HDAC inhibitors (HDACi) that impede HDAC enzyme function 
and result in expression of tumor suppressor proteins such as p53 has emerged as an 
encouraging anticancer therapeutic approach [3]. To date, there are four US FDA 
approved HDACi for treating CTCL, PTCL and myeloma  with many others being 
investigated in different phases of clinical trials [4]. Chidamide is another HDACi that is  
approved only in china for treating relapsed and refractory peripheral T-cell lymphoma 
and currently in phase II clinical trials in US [5]. Despite the promising results of these 
HDACi, they mostly suffer from poor bioavailability, lack of accumulation in solid 
tumors and side effects including severe cardiotoxicity [6]. Thus, there is an unmet 
medical need to develop a new class of HDACi that are more potent towards solid tumors 
and less cytotoxic to healthy cells. 
This thesis focused on two approaches to overcome the common limitations of 
HDACi: 1) Design and development of isoform-selective HDACi. 2) Targeted delivery 
of HDACi to the site of tumor through their conjugation to FDA approved drugs that are 
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known to accumulate in certain tissues or target certain receptors overexpressed on tumor 
cells.  
In chapter 2 and 3, I showed that HDACi that are conjugated to azithromycin, an 
FDA approved antibiotic, has the potential to target lung tissues, possibly due to 
azithromycin accumulation in macrophage cells [7], [8]. I described the designed and 
synthesis of pan HDACi and isoform selective HDACi conjugated to azithromycin for 
delivery to lung tissues, and evaluated their HDAC inhibitory potency and anti-
proliferative activity. Interestingly, despite the lower HDAC potency of isoform selective 
HDACi they exhibited more potent anti-proliferative activity towards transformed cell 
lines. Additionally, data from in vivo efficacy study on a lead pan HDACi and isoform 
selective HDACi in mouse model strongly suggest that these azithromycin conjugated 
HDACi have the potential to accumulate in lung tissue and protect it from metastasis. 
Furthermore, the in vivo study also confirmed the general hypothesis that isoform 
selective HDACi have better efficacy and therapeutic outcome compared to pan HDACi. 
Animal model showed greater tomur regression as well as less number of lung nodules in 
the mice that were treated with the isoform selective HDACi compared to the ones that 
were treated with pan HDACi.  
In chapter 4, a series of dual functioning compounds with both selective estrogen 
receptor modulator (SERM) and HDAC inhibition activities having various zinc binding 
groups was synthesized and tested against both ERα positive (MCF-7) and ERα negative 
(MDA-MB231) cell lines. In this project, tamoxifen, a SERM that is the most common 
and the first line therapy in treating ERα positive breast cancer [9], was used as the 
HDACi cap group. Conjugating tamoxifen to the HDACi resulted in their better uptake 
by ERα positive breast cancer cell line compared to ERα negative breast cancer cell line 
possibly due to tamoxifen’s binding to ERα [10], [11]. The lead tamoxifen conjugated 
HDACi exhibited more selectivity and cytotoxicity toward ERα positive (MCF-7) rather 
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than ERα negative (MDA-MB231) compared to tamoxifen itself [12]. Leads compounds 
are currently being investigated in animal models.  
The last chapter focused on design and synthesis of bifunctional STA3/ HDAC 
inhibitors, where pyrimethamine, a known STAT3 selective inhibitor [13] was used as 
the cap group. We hypothesized that multiple ligand compounds comprising of 
pyrimethamine and HDAC inhibitors will result in both STAT3 and HDAC inhibition. 
The anti-proliferative activity of these compounds were evaluated against three 
transformed cell lines, lung (A549), ERα positive (MCF-7), ERα negative (MDA-
MB231) with activated STAT3 and one normal cell line (VERO). These compounds anti-
proliferative activity was in correlation with their HDAC1 inhibition potency. The lead 
compound with the nanomolar range HDAC1 and HDAC6 inhibitory potency had the 
most potent anti-proliferative activity whereas the one with low HDAC inhibition 
potency (macromolar range) was not cytotoxic against cancer cells. Additionally, the lead 
compound exhibited the most cytotoxicity toward ERα negative (MDA-MB231) where 
STAT3 is activated. This data shows that pyrimethamine HDACi conjugates have the 
potential to inhibit proliferation of other tumors which are dependent on STAT3 signaling 
pathway including myeloma cell lines, INA6, and U266, and prostate cancer cell line 
DU145. 
Pyrimethamine is currently in clinical trials for treating relapsed chronic 
lymphocytic leukemia and small lymphocytic lymphoma due to STAT3 activation in 
these cancers [14].  
Furthermore, pyrimethamine is an FDA approved anti-folate and anti-malarial 
drug. However, its use as an anti-malarial therapeutic agent is hampered due to naturally 
developed resistance in the parasite [15], [16]. It has been shown that HDACi are 
associated with anti-parasitic activity, therefore, pyrimethamine conjugated HDACi have 
the potential to overcome the developed resistance to pyrimethamine in treating malarial. 
 258 
Hence, these compounds anti-malarial activity is another important factor that needs to be 
evaluated.  
Finally, to complete this project and SAR study, more pyrimethamine conjugated 
HDACi with different zinc binding groups need to be synthesized. 
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A.1. Introduction         
Cancer is one of the leading causes of death worldwide. According to American 
Cancer Society, cancer is the second deadliest disease, after cardiovascular diseases [1], 
[2]. Mutations or damages to the genes, which occur due to genetic disposition or 
environmental factors, are the main cause of cancer. Cancer cells are prone to rapid 
division, metastasis and are resistant to cell death [3]. Available treatments - like surgery, 
chemotherapy, hormone therapy, or radiotherapy - have terrible side effects. Most 
chemotherapeutic agents are hampered by narrow therapeutic indices, poor 
pharmacokinetics and non-selective distribution in the body, leading to off-target toxicity.  
To date, one of the main obstacles in cancer treatment has been selective delivery of 
drugs to tumor site, a feat which holds great promise at enhancing drug therapeutic 
efficacy and lowering off-target toxicities [4]. Nanoparticles (NP) have emerged as a 
promising therapeutic agents in recent years as they facilitate increased uptake and 
accumulation of drugs at the tumor sites [5]. Among all classes of nanoparticles, 
liposomal drug delivery system has received the most attention over the past few decades 
[6]. 
The idea of a liposome as a delivery vehicle goes back to 1965. It was first 
introduced by Alec Bangham and colleagues [7]. Liposomes are self-assembled small and 
spherical vesicles consisting of an aqueous core which is surrounded by one or more 
 262 
phospholipid bilayers. Because of their amphiphilic nature, liposomes are able to carry 
both hydrophobic and hydrophilic compounds [8] (Figure 1.A). Various types of small 
molecules including antifungal and anticancer drugs as well as macromolecules such as 
hormones, enzymes and different varieties of peptides have been incorporated into 
liposomes [9]. Liposomes’ biocompatibility, bioavailability and site specific drug 
delivery properties have stimulated intense interest in them as unique drug carrier 
systems for delivery and release of therapeutic drugs at the site of a tumor to  potentially 
enhance drug potency efficacy and minimize side effects [10]. Liposomes’ 
pharmacokinetic properties depend greatly on size, surface charge, number of bilayers 
and fluidity [11]. They can be classified in multiple categories such as: conventional (first 
generation of liposomes), stealth (PEG grafted liposomes), long release, triggered release 
or ligand targeted [8], [12]. In some liposome conjugates, a drug molecule is linked to the 
carrier through covalent bonds that are usually acid cleavable or redox sensitive [13]. In 
other liposome systems, the therapeutic drug is encapsulated by the carrier, without a 
need for a covalent bond. These designs allow liposomes to carry multiple drugs 
simultaneously [14].    
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Figure A.1. Liposomes as carriers in drug delivery systems. They can be used to 
encapsulate one or several hydrophobic and hydrophilic therapeutic agents [15]. A) 
Conventional liposomes (The first generation of liposomes). B) Stealth liposomes (PEG 
grafted liposomes) - PEG conjugated lipids impede the liposome clearance by RES and 
enhance circulation time in bloodstream, increasing concentration at the tumor site. (C) 
Some drugs can be conjugated directly to the surface of the liposome. (D) Targeted 
liposomes - a ligand (proteins, antibodies, small molecule, etc.) is coupled to the surface 
of the liposome to increase selectivity toward tumors and reduces its off-target toxicity.   
In 1986 Matsumura and Maeda suggested that the liposome facilitated tumor drug 
delivery is largely mediated through the enhanced permeability and retention (EPR) 
effect [16], [17] as solid tumors are made of vascular fenestrate that helps liposomes to 
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penetrate through tumor tissue [18].  It is becoming clear that the tumor vascular 
endothelial linings are usually more permeable than the vascular endothelial linings in 
healthy tissues. EPR relies on the permeability of tumor vasculature to sequester 
nanoparticles and therapeutic agents within its interstitial space. EPR also depends on 
tumor cell deficient lymphatic drainage to allow drugs to remain in the interstitial fluid 
compartment after being released from their carrier [19]. EPR is not effective for 
metastatic tumors or the ones with larger size. In vivo studies have revealed that these 
type of tumors suffer from low accumulation of pharmaceutical macromolecules, due to 
being hypovascular in the central area and consequently having less vascular leakage 
which results in a poor EPR effect and low drug accumulation within tumor tissue [17], 
[20], [21]. 
Tumor properties are not the only factors that determine EPR effect success. 
Liposome and pharmaceutical agent features are determining factors as well. Only 
liposomes with sizes as large as 200nm can penetrate tumor endothelia and are 
commonly used as drug delivery vehicles. These liposomes are being excluded from 
healthy tissues since they are limited to species smaller than 2nm [22]. Furthermore, 
circulation time of these liposomes needs to be long enough for the liposome to reach an 
effective concentration within the tumor interstitial space, and then accumulate in tumor 
tissue through EPR effect [23]. Therefore, optimization of tumor targeting and clearance 
mechanism is considered the next pressing step toward improved NP-based drug delivery 
systems [24]. In addition,  pharmaceutical agent size  influences EPR effect as very low 
molecular weight drugs diffuse back into blood stream and do not retain in the tumor 
interstitial fluid [19], [23]. 
Doxil®, the first US Food and Drug Administration (FDA) approved liposome, 
encapsulates Doxorubicin. It received FDA approval in 1995 for treating refractory 
ovarian cancer and Kaposi sarcoma in AIDS.  Since Doxil® approval, the scope of 
research into liposome facilitated drug delivery has widened. To date, twelve FDA 
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approved liposomes are available on the market (Table 1) and many more are in different 
phases of clinical trials.  
          
Table A.1. FDA approved liposomal and lipid based formulations [7], [10], [12], [25], 
[26]. 
    Platform        Drug         Indication      Marketed by 
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Table A.1. FDA approved liposomal and lipid based formulations (continued) 
Lipo-dox Doxorubicin 
Kaposi’s sarcoma, 









































A.2. Liposome properties 
Liposomes are made from cholesterol and non-toxic phospholipids. Their 
properties greatly depend on their size, surface charge, surface hydration and their lipid 
bilayer. Liposomes size ranges from 30 nm to several micrometers and this size variation 
influences circulation times and RES uptake rates. Liposomes of well-defined size are 
prepared by extrusion of lipids through filters containing pores having the desired size. 
However, liposomes that are made this way are about 20-50 % larger than the pore size 
[27]. Medium size liposomes (150nm <d< 200nm) have the highest circulation time. 
Liposomes with size greater than 300nm or smaller than 70nm commonly accumulate in 
liver and spleen [28] and cleared out from the blood circulation.  
Liposomes may compose of one (uni-lamellar) or multiple (multi-lamellar) lipid bilayers 
surrounding an aqueous layer. Polar and hydrophilic head groups are oriented towards the 



















Figure A.2. General structure of phospholipid constituent of liposomes with the head and 
fatty acid tail groups [12].  
Tail group (R2, R3) of liposome (Figure A.2) is a fatty acid chain with a carbon 
length between C14 and C18. When R2 and R3 are saturated chains, rigidity is higher and 
fluidity is lower. When the fatty acid chain is unsaturated the bilayer is less stable and 
more permeable. Furthermore, longer chains lead to a thicker bilayer. The saturation 
status and length of fatty acid chains affect the degree of liposome membrane leakiness 
and the lipid phase transition temperature. 
(R1) represents the head group. The identity of the head group has a direct impact 
on surface hydration. Some head groups like Choline and ethanolamine are positively 
charged and make the overall charge of liposome neutral, while others such as serine, 
PEG amide of ethanolamine, and glycerol are neutral and thus result in a negatively 
charged liposome (Table A.2). A charge free liposome with ethanolamine as its head 
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group has a minimal degree of surface hydration whereas a negatively charged liposome 
with PEG (ethanolamine) as the head group has an enhanced surface hydration [12].   
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A.2.1. Liposome surface charge and hydration 
Liposomes’ lipid head groups and surface charge have a significant influence on 
liposome cell binding and endocytosis. Head group charge determines in large part 
liposome stability and bio-distribution. Due to the negative charge of DNA backbone, 
cationic or neutral liposomes are used for intracellular DNA delivery, while anionic 
liposomes are used for transporting other macromolecules to other targets [30]. Liposome 
surface charge is one of the most important factors which dictate how liposome will 
interact with cells and how fast it will be cleared by macrophages or cells of the 
reticuloendothelial system (RES). Neutral liposomes have a high tendency to aggregate 
and the least tendency to be cleared out by RES. In negatively charged liposomes, 
aggregation is reduced and they are more stable in suspensions. However, the negative 
charge can be recognized by receptors on the surface of many cells including 
macrophages [31], resulting in faster endocytosis and up take by RES and MPS [12]. The 
rapid clearance of negative liposomes limits their use compared to neutral liposomes. 
Positively charged liposomes are up taken faster than negatively charged or neutral 
liposomes. Their interaction with serum proteins increases endocytotic uptake and 
clearance by the lung, liver and spleen. The positively charged liposomes faster clearance 
results in a low in vivo transfection efficiency [12]. In general, the interaction of specific 
opsonizing proteins with phospholipid head groups is a major factor in liposome 
clearance. Both positively and negatively charged phospholipid head groups enhance 
opsonization. One common solution to preventing opsonization, consequently reducing 
liposome clearance rate, is to use poly ethylene glycol (PEG). The flexible polymeric 
chains of PEG form a shield that can mask the liposome’s surface charge. An aqueous 
layer forms around the surface of liposome once PEG is installed onto its surface. 
Formation of this aqueous layer prevents liposome recognition by opsonins, resulting in 
longer circulation time and evading rapid uptake by RES [32]. PEG grafted liposomes are 
called “stealth” liposomes [23].   
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Additionally, in order to reduce aggregation and cellular uptake of liposomes by 
macrophages, the surface of the liposomes can be modified using hydrophilic polymers 
such as PEG to increase liposome thermodynamic stability. PEG addition to the surface 
of liposome prevents its recognition by macrophages and extends its blood circulation 
time [33]. This process is called surface hydration or steric modification [12], [34].    
A.2.2. Fluidity of lipid bilayer 
The fluidity of liposome membrane plays an important role in liposome mobility 
and morphology [35]. A liposome membrane can exist in both fluid and gel phases, 
which vary below and above Tc, the lipid phase transition temperature, where a liposome 
has maximum leakiness and both phases exist. Below Tc liposome is in gel phase and 
above Tc, it is in fluid phase. The lower membrane fluidity corresponds to a highly 
ordered structure [12]. The composition, length of phospholipid and the amount of 
cholesterol used in liposome formation has a direct impact on Tc and consequently 
liposome penetration [36]. Cholesterol content is a very vital factor in effectively 
delivering therapeutic agents to the site of a tumor [37]. Higher cholesterol content in the 
liposome formulation results in a lower drug encapsulation efficacy due to its possible 
effect on disruption of membrane linear structure [38]. 
A.2.3. Liposome bio-distribution in vivo 
Liposome bio-distribution in vivo highly depends on lipid bilayer size, 
composition, charge, surface hydration and degree of saturation. For instance, liposomes 
with saturated fatty acyl chains have an improved bio-distribution compared to ones that 
contain unsaturated chains. The phase transition state of phospholipids is also another 
important factor. Liposomes with phospholipids of different transition phase such as PG 
and DSPC are retained less in the body and eliminated faster due to leakage and phase 
separation [39]. Additionally, PEG coated liposomes gain a longer circulation time and 
improved bio-distribution by introducing steric hindrance to the phagocyte system [40].    
 272 
Liposomes can be injected via three routes: subcutaneous (sc), intravenous (iv) or 
intraperitoneal (ip). Each route results in a different bio-distribution pattern [37], thereby 
having a great influence on the delivery of an encapsulated drug to the site of a tumor. 
Liposome injection via a subcutaneous route results in a higher level of drug in the 
bloodstream. In such injections, smaller liposomes have the highest concentration and 
remain in the body 12 to 24 hours post injection, whereas larger liposomes do not 
circulate well and remain at the site of injection [41]. Intravenous and intraperitoneal 
injections of liposomes result in a lower half-life compared to subcutaneous injections 
[42].  
Liposome’s surface hydration and charge as well as size have direct impacts on 
bio-distribution, pathway and rate of cellular uptake [43] by affecting liposome’s 
interaction with cells and thus its penetration through tumor tissue [44], [45]. For 
Liposome to maintain long circulation time in the body its size has to fit within a certain 
range. Liposomes smaller or larger than this size range are removed rapidly from blood 
stream. Positively and negatively charged liposomes are recognized and uptaken by RES 
faster compared to the charge free liposomes. Installing PEG on the surface of liposome 
prevents opsonization and liposome uptake by macrophages. To obtain a liposome that is 
optimal for drug delivery these factors have to be considered and be optimum. A neutral 
stealth liposome with a size range of 70-150 nm is one of the ideal candidates for drug 
delivery system.  
A.3. Liposomes enhance delivery via triggered release 
In spite of their versatility as drug delivery vehicles, liposomes suffer from key 
limitations.  In particular, the rate of drug release once the liposomes are internalized in 
the tumor endosomal compartment can be slow. Also, liposomes internalized by tumor 
cells through endocytosis are eventually transferred to the lysosome, where the 
encapsulated drugs may be degraded if they are unable to escape the harsh lysosomal 
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environment. [46]. Various triggers mechanisms, which facilitate drug release, have been 
incorporated into liposome design. Therefore, applicable strategies should be developed 
to release the drug at the site of a tumor prior to degradation. The commonly used 
triggers for liposome cargo release rely on pH [47], [48], [49], light [50], [51], heat or 
temperature difference [52], [53], [54], specific enzymes, ultrasound, or magnetic field 
[55].  These triggers induce changes in the carrier assembly which leads to destabilization 
and release of the encapsulated drug.  The logic behind the triggered release is not only to 
control the place and time the drug is released but also to decrease the injected dose and 
minimize side effects.  
A.3.1. Acid triggered release 
Acid triggered release was first suggested by Yatvin et al. in 1980 [48]. Since then 
extensive studies have been done on pH-sensitive liposomes [56], [57]. They are 
designed to introduce macromolecules or hydrophilic molecules to the cytoplasm of 
tumor cells and are generally made from phosphatidylethanolamine (PE) or its 
derivatives and a compound with an acidic group such as a carboxylic acid moiety which 
plays a stabilizing role at neutral pH [58]. Several acid sensitive liposomes contain 
dioleoylphosphatidylethanolamine (DOPE) in combination with Cholesteryl 
hemisuccinate (CHEMS) because of the fusogenic potential of these lipids, making them 
stable at physiological pH [59], [60], [61]. DOPE by itself does not form a liposome, but 
it can be stabilized and used to make liposomes by mixing with other PEG-coated lipids 
[46]. CHEMS gets protonated under acidic conditions and it loses its ability to stabilize 
the charged bilayer. The ensuing electrostatic repulsion causes liposome destabilization 
[62]. DOPE and CHEMS or a combination in the formulation of pH-sensitive liposomes 
have been used for encapsulating several anticancer and antibacterial agents such as 
doxorubicin, staurosporin, methotrexate, and  gentamicin [60]. Acid triggered release 
liposomes are also grafted with a low molar ratio PEG to extend circulation time as 
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discussed earlier. Liposomes shielded with PEG-lipids have reduced sensitivity to acidic 
conditions and slower cargo release compared to conventional liposomes. Acid sensitive 
liposomes are stable at physiological pH (pH= 7.4), but undergo quick destabilization and 
degradation upon entering the acidic condition in the late endosomal environment (5 
<pH< 6.3) [61], [63]. Once liposome is endocytosed by tumor cells, upon exposure to an 
acidic environment and cleavage of PEG lipids, it fuses the endosome membrane and 
releases the drug into the cytoplasm of the tumor cells [61]. It must be noted that the 
encapsulated drug has to be released from its carrier once it is in the late endosomal 
environment, and before liposome entrance to the harsh acidic environment of lysosome 
which degrades both carrier and cargo [64]. 
A.3.2. Light triggered release 
Light activation is another approach for triggering the release of liposome cargoes 
that has been extensively studied. Light-dependent techniques that have been used to 
elicit cargo include photoisomerization, photocrosslinking, photosensitization-induced 
oxidation, surface plasmon absorption, and photothermal effects [65].  In 
photoisomerization, the part of the lipid components used to make the liposome has a 
double bond which changes configuration from trans to cis upon exposure to light [66]. 
Azobenzenes, moieties with a nitrogen-nitrogen double bond to which benzene rings are 
attached on each side, are the most commonly used compounds for photoisomerization. 
Once the compound is exposed to light, it changes its configuration from planar trans 
isomer to the less hydrophobic cis isomer which is less favorable for forming micelles 
[67]. Consequently, light radiation results in destabilization of the assembly and triggers 
release of the liposome encapsulated drug(s).   
Photocrosslinking-mediated liposome cargo release was first introduced by Regen 
et al. [68]. Liposomes designed for photocrosslinking are made by doping the lipids with 
photocrosslinkable lipids such as 1, 2 bis-(tricosa-10, 12-dinoyl)-sn-glycero-3-
 275 
phosphocholine) (DC8,9PC) or gelatin methacryloyl (GelMA) which have polymerizable 
triple and double bonds respectively [69], [70]. Photo irradiation of liposomes containing 
these polymerizable bonds results in polymers which disrupt the uniformity of the 
bilayer, creates pores, release the liposome encased drug(s).  
Photosensitization-induced oxidation, which was first introduced by Anderson et. 
al in 1992 [71], utilizes lipids which are prone to photo-oxidation [72]. 
Photosensitization-induced oxidation occurs when oxidizing agents such as singlet 
oxygen are formed upon light exposure. These oxidizing agents cause damage to the 
liposome bio-membrane by oxidizing the plasmogenic lipids and inducing a transition 
from laminar to hexagonal phase which results in the leakage of cargo from the carrier 
[73]. Tissue is irradiated when the liposome is uptaken by tumor cells and has entered the 
endosome. Once the tissue is irradiated, the photosensitizer reagent contained in the 
liposome acts on the endosomal membrane, resulting in releasing the drug into the tumor 
cytosol.   
Near infrared radiation (NIR) is the ideal light- triggered release mechanism since 
it can penetrate through blood and tissues up to 10 cm [74]. Upon irradiation with NIR 
light, liposomes convert the absorbed light into a thermal energy which increases the 
regional energy and temperature and leads to the cargo release [75]. However this method 
suffers from a lack of organic compounds which are capable of converting NIR light 
(700- 950nm) energy to a chemical response to trigger drug release. Gold nanoparticles 
are among the few agents that can absorb NIR light well, making them useful in photo-
thermal therapy [76]. The first gold nanoparticle was introduced by Radt et al. [65] and 
since then extensive studies have been done on utilizing gold nanoparticles in surface 
plasmon absorption triggered release [75]. Wu et al. [77] showed that irradiating gold 
nanoshells can lead to almost complete release of an encapsulated drug.     
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A.3.3. Heat triggered release 
Thermosensitive liposomes (TSL) respond to heat stimulus, such as IR lasers or 
microwave, to release the encapsulated drug. Most thermosensitive liposomes release 
their encapsulated drug at about 35-45 °C in a span of 30 minutes [78].  When TSLs are 
exposed to heat stimulation, their phase status changes from gel to liquid, making their 
bilayers become more permeable and releasing an encapsulated drug [79]. As mentioned 
earlier, melting temperature (Tm) depends on the character of the phospholipid used in 
forming the liposome [80]. However, for PEG grafted liposomes, the concentration of 
lipid-PEG applied on the liposome surface (in most cases 1, 2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-PEG2000 “DSPE2000”) matters as well since PEG can 
influence the permeability of the liposome bilayer [81]. Also, heat triggered release 
depends on tumor microvasculature features. Exposure to heat can influence tumor vessel 
leakiness and enhances tumor perfusion [82], leading to higher accumulation and 
concentration of liposome in the tumor endosome [83]. Cisplatin, doxorubicin, and 
methotrexate are some examples of anticancer drugs that have been encapsulated in heat 
sensitive liposomes [84], [85]. This method is generally combined with chemotherapy or 
radiation therapy to improve the treatment outcome. Improved survival rate has been 
noted in cohort of patients who undergo combination of chemotherapy and hyperthermia 
compared to the patients who receive only chemotherapy [86].  
A.4. In-vivo liposomal drug delivery 
Liposome mediated drug delivery in vivo occurs through two different targeting 
modes - passive and active targeting. Active targeting delivery development of liposomes 
is hindered by many barriers (discussed below) and hence is less advanced compared to 
passive targeting delivery [87].  In passive targeting, the liposome complex diffuses into 
leaky microvasculature such as tumors or inflamed tissues and shows selectivity toward 
any tissues with permeable endothelium cells. In active targeting, the liposome complex 
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incorporates a ligand that is specific for the epitope of a certain tissue or a distinct 
receptor that is overexpressed by cancer cells. Active targeting of liposomes has the 
potential to result in the delivery of elevated levels of drugs at disease sites with 
concomitant increase in drug efficacy [88].  
 
A.4.1. Passive Targeting 
Passive targeting of liposome is a means of delivery and transportation of the 
encapsulated drug into tumor cells through convection or passive diffusion. Convection is 
the movement of molecules within the fluid whereas diffusion is the transport of 
molecules across the membrane based on their concentration gradient (Figure A.3). Small 
molecules with low molecular weights mainly rely on diffusion for tissue distribution, 
while convection occurs when a large molecule is being transported through the large 
pores. [89]. However, since convection through the tumor interstitium is deficient, due to 
interstitial hypertension of tumors, diffusion is the main means for drug delivery in 
passive targeting. Following injection, liposome enters the tumor cytoplasm through the 
EPR effect. Maximum EPR effect is reached when a liposome has a longer circulation 
time in the body and it is not up-taken by RES organs quickly. To provide liposomes with 
longer blood circulation, they are often grafted with PEG to diminish their rapid 
clearance rate by RES.  
Passive targeting relies on liposome size and tumor vasculature, and varies for different 
types of tumors based on their extravasation, angiogenesis, and vascularization. In solid 
tumors, passive targeting is not very efficient because of the interstitial fluid pressure. 
Tumor interstitial fluid pressure has a nonlinear correlation to its lymphatic drainage [90]. 
As the interstitial fluid pressure for a tumor gets higher, its lymphatic drainage decreases 
[91]. Tumor interstitial fluid pressure is a barrier in cancer therapy that results in 
inefficient therapeutic agents uptake [92]. 
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Liposome size plays an important role in extraversion into tumor cells. As the 
liposome size gets larger, its clearance by RES or phagocyte systems (MPS) becomes 
more rapid. Liposomes of size below 400nm have enough circulation time in the 
bloodstream to extravasate into tumors, however, extraversion is more effective if 
liposomes have diameters lower than 200nm [23]. 
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Figure A.3. Passive liposomal delivery. Liposomes reach the tumor site through 
diffusion and accumulate in tumor tissue via EPR effect.   
 
Passive targeting through the EPR effect is applicable for targeting all tumor cells 
except prostate and pancreatic cancer cells [93], [94]. To date, there are many passive 
targeting liposomes that are FDA approved and there are many more currently in clinical 
trials. Liposomal encapsulated Doxorubicin, Vincristine, and cisplatin are examples of 
liposome formulated drugs in the market that function through passive targeting. The first 
two are conventional liposomes whereas the latter is categorized as a PEG grafted one.  
While conventional liposomes are uptaken rapidly by RES or macrophages in liver and 
spleen, PEGylated liposomes have longer half lives in the body, which in some cases can 
reach a couple of days [23].   
A.4.2. Active Targeting/ Ligand Targeting Liposomes (LTL) 
New strategies that may improve the tumor selective delivery of liposome 
encapsulated drugs are currently under active investigation. So far, ligand- targeting 
liposomes (LTL) have emerged as the most promising drug delivery tools [95], [96], [97]. 
In ligand targeting liposomes (LTLs) (Figure A.4), a ligand that selectively targets a 
specific receptor is coupled to the surface of the liposome. After EPR effect mediated 
selective accumulation within tumor interstitum, the attached ligand promotes tumor cell 
uptake of the [98]. Active targeting has been noted to enhance liposome delivery to 
diseased organs, tissues, or subcellular domains [99] and elevate therapeutic efficacy 
[100].  The ideal ligand is that for a receptor that is overexpressed by tumor cells relative 
to normal cells (Figure A.5) [101], [102]. The interaction between the ligand on liposome 
surface and the receptor overexpressed on cancer cells must be sufficiently strong and 
capable of receptor mediated endocytosis to enable efficient delivery of liposomes to the 
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site of a tumor and within the tumor cells. [103]. Receptors overexpressed on the tumor 
surface are more accessible, and therefore are better targets, compared to receptors 
overexpressed within the cancer cell nucleus or cytoplasm. For LTLs to reach the 
intracellular receptors, they have to be able to penetrate tumor cell membranes [104]. 
These non-selective targeted liposomes may enter the cytoplasm of healthy cells leading 
to unwanted side effects caused by damage to healthy cells along with cancer cells [105].  
Figure A.4. Ligand targeted liposome. Liposome is conjugated to a targeting ligand that 
specifically interacts with a certain receptor which is overexpressed only by tumor cells.  
 
Active targeting highly depends on the physicochemical properties of the ligand 
such as size, charge, orientation, and physical adsorption [106], [107]. The type of ligand, 
as well as its conjugation chemistry to the nanoparticle surface, has a great impact on the 
liposome’s overall targeting efficacy. Nonspecific binding of the ligand to other proteins 
in the bloodstream is another important factor that should be taken into consideration 
[108], [109]. By far, covalent attachment is the most preferred approach for conjugating 







Figure A.5. Liposomal active targeting. A variety of targeting moieties can be coupled 
on the surface of liposome to enhance selective delivery to the site of tumor [110]. 
Ligand conjugated liposomes interact with the receptors overexpressed on the surface of 
tumor cells. In addition to increasing drug concentration at tumor site, this phenomena 
also decreases drug toxicity to healthy cells [111].  
The targeting ligand can vary from proteins to a nucleic acids, peptides, small 
molecules, sugars or antibodies in order to target a sugar, protein, or nucleic acid existing 
in diseased tissues and organs [112], [113].  Using antibodies or antibody fragments as a 
targeting moiety is one of the more promising approaches to active targeting due to their 
high affinity and selectivity for target receptors. However, some studies revealed that 
using antibodies does not help tumor localization but instead helps with internalization in 
tumor tissue in animal models [103]. Peptides are another encouraging targeting ligand 
that are easy to prepare at low cost and can be modified to minimize potential enzyme 
degradation [22].   
There are a few criteria that need to be considered in choosing the targeting 
ligand. Key among these criteria is target specificity. It is beneficial if the targeting ligand 
can recognize a receptor which is specific to tumor cells, to avoid targeting healthy cells 
that are expressing another isoform of targeted receptor [114]. The binding affinity 
between the targeting ligand and the tumor receptor is of importance as well. There is an 
inverse correlation between binding affinity and the concentration of liposome needed to 
reach tumor receptor binding saturation. When the targeting ligand has a high affinity to 
bind to the tumor receptor, a lower concentration of the liposome is needed [115].  Using 
ligands with a strong affinity for the tumor receptor reduces the liposome interaction with 
healthy cells and thus diminish its off-target toxicity. However, if a ligand with low 
affinity can be at higher concentration or  a combination of various ligands can be used to 
compensate for not having a  ligand with a strong affinity for tumor receptor [111], [116].  
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The size of the targeting ligand affects the overall size of liposome and hence influences 
the drug delivery via different mechanisms. When a liposome gets bigger it is cleared 
faster from the bloodstream by RES or MPS while smaller liposomes have a greater 
retention time. Additionally, smaller liposomes can extravasate better into the tumor 
interstitium. The ideal liposome size for tumor uptake is less than 200nm [117].  
The point of ligand attachment impacts liposome drug delivery as well [107]. It is 
better to use functional groups such as amine, carboxylic acid, etc. that can be coupled to 
the liposome directly or indirect through as spacer group. However, it is possible that 
attaching the ligand to the liposome through these functional groups may compromise 
ligand’s ability to interact with the tumor expressed receptor [111]. To forestall an 
attenuation of ligand-receptor interaction, regions of the ligand that will not hinder its 
affinity for tumor receptor should be identified prior to considering liposome conjugation.  
Although active targeting is more efficient than free drug release in the blood 
circulation or even passive targeting, only a small fraction of the drug is uptaken by 
tumor cells. In active targeting, two factors are competing against each other: liposome 
clearance by RES and binding to the target site. One of the challenges in ligand-mediated 
liposomes is that for it to be recognized by the target tissue or cell, the liposome has to be 
in the locality of the target site [118]. To overcome this problem, the bloodstream 
circulation time must be extended [119]. As mentioned earlier, liposome uptake by RES 
can be avoided or delayed by using PEG grafted liposomes, elevating the drug 
concentration at the tumor site and consequently enhancing target binding of the 
liposome [120]. Presence of free PEG does not generally interfere with the liposome 
target binding.  
Thus far, no targeted liposome has received FDA approval and there are few in 
clinical trials. Several reasons are responsible for this clinical failure. First, when 
liposomes are introduced in bloodstream they experience a rapid formation of a protein 
corona around them which hampers surface functionality. Protein corona was first 
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described by Dawson et.al in 2007 as involving an adsorption layer or atmosphere formed 
around nanoparticles by the proteins that are interacting with nanoparticles [121, 122]. 
Secondly, tumors grow quickly around endothelial barriers. When liposomes with 
targeting moieties get to the tumor site, they bind to the first receptor they see and may 
not even penetrate into the rest of tumor to bind other receptors [123]. Additionally, once 
inside tumor vasculature, there may be other barriers the liposomes have to cross. Finally, 
the existence of targeting moieties on the surface of the liposome can influence their 
uptake by RES, lowering circulation time in bloodstream. These drawbacks make 
targeted liposomal delivery essentially equal in efficiency to non-targeted delivery in vivo 
studies [124]. Despite their shortcomings, several clinical trials on targeted liposomes are 
currently underway. Doxorubicin and oxaliplatin liposomal formulations are examples of 
targeted liposomal delivery in clinical trials under the names MM302 (I) and MBP-426 
(I), respectively. The former targets HER2 using an anti-ErbB2-scFv formulation for 
treating breast cancer [125] while the latter targets transferrin to treat gastroesophageal 
and esophageal adenocarcinoma [126].  
Ligands for targeted liposomal drug delivery applications are divided into two 
groups of small molecule and macromolecule targeting ligands. Each group itself is 
further divided into subgroups. Small molecule targeting moieties are ligands with low 
molecular weight and smaller size.  One example of small molecule targeting ligands is 
folic acid which shows affinity for folate receptor overexpressed on tumor cells. Unlike 
small molecule ligands, macromolecule targeting ligands such as proteins, antibodies and 
their fragments have larger size and higher molecular weight. In general, macromolecule 
targeting ligands have lower tumor cell permeability and are of limited applications 




A.4.2.1. Small molecules as targeting ligands 
Many anticancer drugs are known to be toxic toward healthy cells by restricting 
proliferation or inducing apoptosis. To minimize anticancer agent toxicities to healthy 
cells, several strategies have been developed to selectively target cancer cells through 
conjugation of anticancer agents to ligands selective for receptors overexpressed in 
tumors. The type of tumor targeting ligand has a significant impact on the efficiency of 
LTLs. Therefore, ligand selection should be done very carefully.  Among natural and 
synthetic ligands, folic acid, ACUPA (S,S-2-[3-[5-amino-1-carboxypentyl]-ureido]-
pentanedioic acid), and TPP (triphenylphosphonium) are common examples of small 
molecule ligands that have shown promise in liposomal active targeting [107].  
Carbohydrates like mannose, glucose, and galactose and their derivatives are other small 
molecule targeting ligands that have been widely used [116].    
A.4.2.1.1. Folic acid-drug conjugates 
Folic acid (folate) (Figure A.6) has been widely used as a small molecule ligand 
to selectively target folic receptors (FR) [127]. FR are membrane proteins with molecular 
weight of 38-40 kDa, with two distinct isoforms (α and β) in humans [128], [129]. 
Isoform β has been found on CD34+ cells [130] and does not show affinity for folic acid 
or any folate derivatives. On the other hand, Isoform α is frequently overexpressed on the 




Figure A.6. Folic acid structure. High affinity for folate receptor is generally retained 
when folic acid is conjugated to folate receptor by the γ carboxylic acid [128]. 
Folic acid has several advantages that make it a better targeting moiety compared 
to many other targeting ligands. First, folic acid displays a high affinity (KD = ~ 10
− 9 M) 
and selectivity for tumor surface expressed FR. Second, folate is very stable and does not 
succumb to denaturation. Third, folate is readily available and its conjugation chemistry 
to the surface of liposome has been worked out. Furthermore, FR overexpression in some 
cancer cells exceeds 106 per cell. However, folate affinity can be compromised after 
conjugation to a drug molecule. The solution to this obstacle is to load more drug per 
folate carrier in order to compensate for its low affinity, or to replace the payload with 
much more potent drugs.  Although conjugating more concentration of the same drug 
molecule to the targeting ligand seems appealing, it is simpler and more convenient to 
have one warhead that has a greater potency compared to installing many of the low 
potency drug on the same carrier. Additionally, in order for folate to be effective as a 
liposome tumor targeting ligand, it is coupled to the liposome surface via a PEG linker to 
overcome the steric hindrance at the interface of contact between the cell and the 
liposomes. Folate-conjugated liposomes designed in this way have shown a high affinity 
for tumors overexpressing FR [131].  
Folate-conjugated liposome drug release after endocytosis and drug delivery 
capacity depends on environmental pH. Studies have shown folates are internalized into 
tumors with a low pH endosomal environment. Therefore, utilizing pH sensitive lipids in 
making the liposomes enhances folate conjugated liposome efficiency. One example of 
folate-targeted pH-sensitive liposomes is folate-LPDII, which is synthesized by mixing 
dioleoylphosphatidylethanolamine (DOPE)/cholesteryl hemisuccinate (CHEMS)/folate-
PEG-DOPE (60:40:0.1, m/m) and the cationic DNA/poylysine (1:0.75, w/w) complexes. 
The first folate mediated targeted drugs that entered clinic, EC17, was designed to elevate 
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the immunogenicity of FR positive tumors (Figure A.6) [132]. And the first folate 
conjugated drug to be tested on humans was 111In-DTPA-folate, a chelator of 111In. 111In-
DTPA-folate binds to FR with 1 nM affinity [133] and mostly targets cancer cells but it is 
also found in kidney tissue [134]. Paclitaxel-liposome is another example of folate 
conjugated liposomes. Paclitaxel is an anticancer drug mainly used for treatment of breast 
and ovarian cancers. Paclitaxel and yttrium-90 conjugation with folic acid in liposomal 
active targeting has been shown to improve survival in a mouse xenograft model of 
ovarian cancer [135].   Additionally, recent studies have shown folic acid can be used to 
deliver imaging and therapeutic agents in both xenograft models as well as human cancer 
cells [136].  
 
Figure A.7. Structure of EC17, the first folate ligand mediated targeting liposome in 
clinical trial. 
 
Folate mediated cancer targeting does have its share of limitations. In addition to 
tumor cells, many healthy cells in different organs express FR on their surface. FR 
expression in normal cells mostly occurs in activated macrophages or monocytes, and 
tubules of the kidneys, lung, and thyroid [137], [138], [139]. This reduces folate 
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conjugated liposome selectivity toward cancer cells as well as increasing the chance of 
off-target toxicity. Activated macrophages often accumulate at the site of inflammation 
and have been most observed in inflammatory diseases such as, rheumatoid arthritis, 
osteoarthritis, and Crohn's disease or organ transplantation and infection [140].  
Furthermore, FR overexpression varies for different patients and depends on the type of 
cancer. Although FR is overexpressed in about 40% of cancer patients, this 
overexpression varies widely from as low as 17% in case of testicular cancer to as high as 
90% for breast, ovarian and uterus cancers [136].  
A.4.2.1.2. TPP- drug conjugates 
Many disorders in humans such as cancer, neurodegenerative diseases, Alzheimer 
disease, diabetes, or aging are characterized by mitochondria dysfunctions [141]. Some of 
the features associated with mitochondria diseases could be respiratory (respiratory 
failure, apnea), cardiac (heart failure), neurological or endocrinal [142].   The 
mitochondrion is an organelle located in the cytosol which functions to maintain energy 
producing oxidative metabolism as well as cellular mortality management. Unfortunately, 
there are currently no available treatments for mitochondrial related diseases other than 
treating symptoms.  In recent years, targeting mitochondria has emerged as a promising 
approach to control many types of mitochondria related diseases. One of the obstacles in 
treating mitochondrial related diseases is to find a way to get the therapeutic drug inside 
the mitochondria of cells with a reasonable bio-distribution. This is hard to accomplish 
due to the controlled impermeability of the mitochondrial inner membrane. Clinical trials 
on several mitochondria-acting drugs failed due to the lack of an effective drug delivery 
approach to the mitochondria [143]. Many drugs will eventually reach mitochondrial 
vicinity through interaction with subcellular compartments but the main challenge to 
enter mitochondria still remains. Triphenylphosphonium (TPP) and its derivatives (Figure 
A.7) are examples of small molecule targeting ligand that are being used in liposomal 
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delivery for targeting mitochondria [144]. TPP is a hydrophobic molecule that can easily 
penetrate the cell membrane and accumulate inside cells. Studies have shown that the 
positive charge on TPP is responsible for its high accumulation within mitochondria, an 
attribute that is vital to its in vitro performance. However, TPP positive charge adversely 
affects in vivo blood exposure [144], [145]. One of the mitochondria targeting liposomes 
conjugated to TPP is stearyl TPP (STPP) bromide (Figure A.8). It is synthesized by 
ultrasonication after film rehydration [146]. STPP targeting liposomes have been widely 
used to deliver various therapeutic agents inside mitochondria. Recently, DOX and PTX 
were loaded inside STPP-derived targeting liposomes for delivery inside mitochondria 
[146].  Loading DOX inside a STPP-derived liposome enhanced its targeted delivery to 
the site of tumor. Additionally the liposome was further modified by adding folic acid on 
the surface, to increase its efficiency and potency by transforming it to a dual targeting 
motif. Similarly, utilizing ligand targeted liposome to deliver PTX to tumor tissue 
resulted in PTX greater bio-distribution and thus lower IC50. To date, only a few 
liposomes are known to deliver mitochondrial-acting therapeutics, however none of them 
have been approved by FDA due to limited bioavailability and biocompatibility.    
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Figure A.8. A. Triphenylphosphonium (TPP) structure. Different groups can be added to 
the phosphonium ion to synthesize more potent targeting groups that have a higher 
affinity for entering mitochondria. B. Structure of stearyl TPP (STPP) bromide. STPP has 
been used widely as a small molecule targeting group in ligand-mediated liposomal 
delivery. 
A.4.2.1.3. ACUPA- drug conjugates 
Another very promising small molecule targeting ligands is S,S-2-[3-[5-amino-1-
carboxypentyl]-ureido]-pentanedioic acid (ACUPA). ACUPA mediates molecular 
interaction between prostate specific membrane antigen (PSMA) and liposomes [6]. 
PSMA is overexpressed in prostate cancer cells as well as in non-prostate solid tumor 
neovasculature [147] and was first used as prostate cancer imaging agent [148]. One of 
the ACUPA mediated liposomes that has entered phase II clinical trial is ACUPA 
docetaxel-loaded PEG-PLGA, a pH sensitive liposome that effectively delivers the 
payload drug to the site of tumor [149]. Mice xerograph studies revealed that it enhances 
tumor accumulation and promotes prolonged growth suppression in vivo [6]. 
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Furthermore, clinical studies in patients with advance solid tumor showed a lower dose 
tumor shrinkage compared to free docetaxel [150].  
A.4.2.2. Macromolecules as targeting ligands 
Utilizing macromolecule-derived targeting ligands, such as nucleic acid, peptides, 
proteins, and antibodies, in liposomal drug delivery has shown promising results in 
cancer therapy due largely to ligand related enhancements in efficacy, prolonged 
circulation time and targeted delivery to tumor sites. However, unlike small molecule 
ligand mediated targeting liposomes, macromolecule ligand use is limited by lower 
permeability through tumor vasculature due to the larger size [151]. Antibodies were the 
first macromolecule to be used as a targeting ligand and since then more macromolecules 
have been introduced [152]. This section focuses on a variety of macromolecules as 
targeting ligands and their properties such as size or molecular weight as well as their 
benefits and limitations in liposomal delivery systems.  
A.4.2.2.1. Nucleic acid based- drug conjugates: 
Nucleic acid aptamers are composed of oligonucleotides which fold by 
intramolecular interaction and form distinct three-dimensional conformations [153]. 
Nucleic acid aptamers have strong affinity and specificity for their substrate due to a 
distinctive structure that originated from Watson-Crick and non-Watson-Crick 
interactions. Because of their small size, ease of isolation and favorable immunogenicity 
profile, aptamer conjugated liposomes have emerged as promising drug delivery vehicles 
in targeted cancer therapy [154]. They are also being used in imaging and cell sorting 
applications. In addition to their strong affinity for cognate receptors, aptamers also 
benefit from ease and replicability of synthesis or chemical derivation. Additionally, 
aptamer conjugated liposomes have conformational flexibility and nuclease stability. 
Aptamer binding affinity depends on secondary and tertiary structures, which in turn 
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relies on target environment conditions such as pH and temperature. This can affect and 
reduce liposomal therapy efficiency in vivo experiments.  
Nucleic acid aptamers are usually 75-100 nucleotides. This length provides an 
opportunity for vast variation in sequence, resulting in different confirmations and 
different binding affinity. However, the negative charge associated with the 
phosphodiester backbone aptamers contributes to increase in liposome clearance rate by 
the spleen and kidney, thereby reducing circulation time in blood stream. The negative 
charge on liposomes also elevates non-specific interactions as well, leading to a reduction 
in substrate affinity. Additionally, long aptamers generate steric hindrance which leads to 
a barrier in conjugation to the liposome surface [155].  To overcome this obstacle, 
positively charged PEG linkers can be used to conjugate the aptamers to the liposome 
surface, this approach neutralizes both the liposome negative charge as well as decreases 
steric hindrance.  
The first in vitro aptamer conjugated nanoparticle to target PSMA was reported in 
2004. Following that research was conducted in vivo, which showed a reduction in tumor 
growth in comparison to  non-targeted nanoparticles [154]. Despite the promising results 
of aptamer conjugated liposomes in vitro, they show limitations in vivo. Nucleic acids are 
easily degraded, which makes them unstable in biological environment. To overcome this 
problem and avoid ligand degradation on the surface of liposome, nucleic acids can be 
modified with fluoro, amine, or methoxy groups. Besides in vivo limitations, the high 
manufacturing cost of aptamers is one of the major reasons hampering their development.     
A.4.2.2.2. Peptide- drug conjugates 
Peptides, composed of up to 50 amino acids, have simpler three dimensional 
structures relative to proteins. Therefore, their conjugation to liposomal surfaces is easier. 
To increase drug efficacy by enhancing cellular uptake and maintaining liposomes within 
tumor tissue, many cell penetrating peptides have been designed and synthesized [100].  
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RGD (arginine–glycine–aspartic acid), which targets αvβ3 integrin with a strong 
affinity, is the most commonly used peptide [156]. RGD with various linkers facilitating 
liposomal conjugation are commercially available. RGDs can be in both linear and cyclic 
forms, and studies have shown that cyclic RGD is more potent [157]. However, the use of 
RGD as a targeting ligand is being hampered by the fact that αvβ3 integrin expression 
can be found on healthy cells in addition to tumor cells. 
Another peptide targeting ligand that has been widely used for delivering 
anticancer drugs to the tumor site is NGR (asparagine-glycine-arginine). Like RGD, 
NGR has linear and cyclic forms, with the cyclic structure being more potent. NGR 
specifically binds to CD13/aminopeptidase N, which is overexpressed in tumor 
vasculature [158].  
A.4.2.2.3. Protein- drug conjugates 
Proteins have been widely used as targeting ligands due to their strong substrate 
binding and well defined three dimensional structures. Transferrin (Tf), a glycoprotein 
which binds to the transferrin receptor (Tf-R) with a high affinity and triggers 
endocytosis by taking advantage of clathrin-dependent pathway, is a commonly used 
targeting ligand. After internalization, Tf and TfR are recycled to the cellular surface 
through recycling pathway.  Transferrin function is transportation and regulation of 
intracellular iron concentration. The transferrin receptor has been extensively used for 
drug targeting to tumors. Tf-R is overexpressed on cancer cells because of the need of 
iron for energy production, cell proliferation and heme synthesis [159]. Luckily, 
transferrin does not induce any immune response in patients [160], therefore using 
liposomes that are conjugated with Tf can be beneficial to deliver encapsulated drugs to 
the tumor site.  Research has shown that transferrin can affect the efficacy of the 
encapsulated drug at cellular levels in addition to affecting targeting ability. In some 
studies, there was an increase in gene transfection and tumor size shrinkage [161]. MBP-
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426 is a Tf conjugated liposome in clinical trials that encapsulates oxaliplatin. It is 
currently under investigation in phase II clinical trial for treating colorectal cancer. 
In addition to naturally occurring proteins, there are variety of synthetic proteins 
such as affibodies and ankyrin repeat proteins which are being investigated for targeted 
delivery of anticancer therapeutic agents. Affibodies are polypeptide ligands of 
approximately 15kDa that are used for tissue-specific targeting and controlled release of 
encapsulated drugs in ligand conjugated nanoparticles. Their small size provides a high 
ratio of binding site to ligand size, which improves endocytosis by tumor cells. For 
instance, some affibodies selectively bind to extracellular domain of the human epidermal 
growth factor receptor 2 (HER-2) in tumors that overexpress HER-2 antigen [162], [163].  
In addition to affibodies’ selective targeting ability, their high stability in both in vitro 
and in vivo studies have made them a promising targeting ligand of choice in liposomal 
drug delivery [162].  
Designed ankyrin repeat proteins (DARPin) are non-immunoglubins binding 
proteins. The Ankyrin motif is composed of 33 amino acids which form a secondary 
structure consisting of 1 β turn and two antiparallel α-helices. Their small size, high 
stability, and high affinity against soluble or membrane bound antigens have made them 
excellent binders for tumor targeting. Winkler et al [164] designed DARPins that are 
specific for epithelial cell adhesion molecules (EpCAM) as a drug delivery vehicle for 
small interfering RNA (siRNA) complementary to the bcl-2 mRNA. DARPin dimers 
were utilized as fusionproteins to deliver siRNA into cells. EpCAM is transmembrane 
glycoprotein responsible for cell proliferation, differentiation and signaling [165].   
EpCAM is overexpressed in solid tumors, with a low expression in normal cells. Its 
overexpression is more common in breast, prostate, colon, and pancreas carcinomas. 
EpCAM is easily internalized by tumor cells and is suitable for the delivery of anticancer 
agents to tumor tissue [164].  
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Unfortunately, proteins suffer from several limitations. In some cases their size 
affects the efficiency of their installation on liposomal surfaces. The complexity of their 
amino acid residues makes conjugation chemistry difficult. Moreover, the chemistry used 
for protein conjugation to liposomal surfaces can significantly influence their 
secondary/tertiary structures which may affect antigen affinity.           
A.4.2.2.4. Antibody- drug conjugates  
Antibodies or immunoglobulin (Ig) are Y-shaped glycoproteins that [152] bind 
and interact with antigens through the binding site which is located at the tip of the 
antibody. The binding site, which is also called “hypervariable region (HVR)” or “F(ab′)2 
fragment”, can have various structures in order to interact with different antigens. The 
antibody protein recognition part “Fc fragment” is located at the bottom of Y-shaped 
antibody (Figure A.9). It helps mononuclear phagocyte system and immune system to 
recognize proteins. [107]. The first evidence for their specific binding to tumor cells 
antigen was seen in 1975 [166]. 
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Figure A.9. Antibody Y-shaped structure. Protein recognition part (Fc) is located at the 
base, while antigen binding site (Fab) is positioned at the tip of antibody structure.  
 
To date, several antibody targeted cancer treatment modalities have been 
approved by the US FDA [167]. Retoximab (Rituxan®) is anti-CD20 antibody being 
used for treating CD-20 positive B-call non-Hodgkin's lymphoma. It was approved in 
1997 and manufactured by IDEC pharmaceuticals. Ibritumomab tiuxetan (Zevalin®) is 
another anti-CD20 antibody manufactured by IDEC pharmaceuticals. It obtained FDA 
approval in 2002 and since then has been used for Rituximab-failed non-Hodgkins 
lymphoma [168].  Gemtuzumabozogamicin (Mylotarg®) is an anti-CD33 antibody 
manufactured by Wyeth Pharmaceuticals. It has been in the market since FDA approval 
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in 2000, for treating relapsed and refractory acute myelogenous leukemia [169]. These 
are only a few examples of antibody use for targeted cancer treatments. Studies have 
shown that using antibodies as targeting ligands is beneficial in delivery systems such as 
liposomes due to high affinity and selectivity for the target. Antibody conjugated 
liposomes can enhance the selective toxicity of therapeutic agents to cancer cells [170].  
Unfortunately, even though antibody conjugated liposomes showed favorable 
results in vitro, their use in in vivo studies have been hampered by several limiting 
factors. Antibodies are very sensitive to environmental changes such as temperature, 
enzyme or salt concentration changes and are not stable in the presence of organic 
solvents. These factors, along with large size (150 kDa), make conjugation of antibodies 
to liposome surfaces complex. Furthermore, antibodies’ large size increases the overall 
liposome size after conjugation and resulting antibody-conjugated liposomes have 
enhanced clearance rates by RES or MPS leading to low blood circulation time [171].  
The main function of antibodies is to recognize antigens and induce clearance by MPS 
and the immune system. Decorating liposomes with antibodies inadvertently leads to 
faster clearance from the bloodstream, although, removal of Fc fragment slightly 
improves circulation time [172]. Newer coupling methods, where an antibody or its 
fragment is attached to the terminal end of a PEG linker and engrafted to the liposome 
surface, have been developed to minimize blood clearance [7], [131].  
Despite all these limitations, several antibody conjugated liposomes have made 
their way to pre-clinical or clinical trials. For example, SGT-53 is a wildtype p53 
sequence encapsulating cationic liposome with anti-transferrin receptor antibody. It is 
under investigation in phase II clinical trials for treating glioblastoma, solid tumors and 
pancreatic cancer. SGT-94 is another anti-transferrin receptor antibody liposome 
incorporating RB94 plasmid DNA. It is in phase I clinical trials for treating solid tumors 
[173].  MM-302 is an anti-Her-2 antibody conjugated liposome that encapsulates 
doxorubicin. It is in clinical trials for the treatment HER-2 positive breast cancer. Upon 
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administration, MM-302 binds to HER-2 overexpressing tumor cells and doxorubicin 
gets released upon endocytosis of the conjugated liposome into the tumor cell. The 
released doxorubicin then impedes topoisomerase II activity, inhibition of RNA synthesis 
and DNA replication; leading to retardation of tumor growth [174]. MCC-465 is another 
example of antibody conjugated liposome that encapsulates doxorubicin. It is in clinical 
trials for treating gastric cancer. It is conjugated to F(ab')2 fragment of human 
monoclonal antibody GAH, which targets more than 90% of cancerous stomach tissue 
[175].        
A.5. Future perspective and conclusion   
With the FDA approval and success of several liposomes in recent years, 
liposomal drug delivery has become a promising targeted delivery system for cancer 
therapy. Liposomal drug delivery occurs through passive and active targeting. Active 
targeting can revolutionize cancer therapy and increase patient’s life quality and survival 
by delivering anticancer drugs specifically to tumor sites, consequently diminishing 
cytotoxicity and minimizing side effects. However, despite all the research and efforts 
dedicated in active targeting liposomes studies, progress in the clinic has been so slow. 
Although active targeting liposomes enhance drug efficiency and efficacy by improving 
delivery to the target site as well as increasing tissue distribution and cellular uptake by 
tumor cells, their use in in vivo studies has been hampered by low penetration through 
tumor tissues and their quick recognition by the immune and reticuloendothelial systems 
due to formation of protein corona around liposome surface.  
Additionally, some of the targeting ligands are not stable and soluble in organic 
solvents, a situation which makes their scale up synthesis very difficult.  
Therefore, there is an unmet need to improve the design and stability of active targeting 
liposomes as therapeutic delivery systems. Factors such as liposome size, charge, PEG 
coating, and ligand size, charge, length and density cause formation and composition of 
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protein corona [176]. These factors should be optimized to obtain ligand targeted 
liposomes with higher potency and efficacy for cancer therapy. 
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AZITHROMYCIN FUNCTIONALIZED LIPOSOMES 
 
B.1. Introduction 
Despite intensive research towards development of new therapies for treating 
cancer, it is still among the leading causes of death worldwide [1], [2].   Every year over 
10 million people are diagnosed with cancer which results in thousands of death [3]. 
Cancer cells originate from normal healthy cells and because of their similarity to normal 
cell, it has proven very difficult to selectively target them [4]. The utility of most of the 
current cancer therapeutic agents is hampered by dose-limiting side effects and off-target 
toxicities [3]. One approach to solve this problem is the use of carriers, such as 
liposomes, to deliver anticancer drugs selectively to target tissues. Liposomal drug 
delivery method facilitates selective targeting of the cancerous tissues while reducing the 
off-target toxicities and increasing the drug’s blood circulation time. Additionally, 
liposomal drug delivery formulation could be used to deliver multiple drugs, which target 
pathways, to various cancer types [5], [6].      
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Liposomes are lipid bilayers vesicles, designed to enhance the drug bioavailability and 
accumulation at the target site [7]. In some cases in order to increase the liposome blood 
circulation, they are coated with Poly Ethylene Glycol (PEG). These are called “stealth” 
liposomes and prevents liposome’s rapid uptake by immune system [3], [7].  Once the 
liposome is made and decorated with PEG and other ligands the anticancer drug can be 
inserted inside or it can be attached outside to the lipid bilayer based on the drug 
lipophilicity (Figure B.1). If the anticancer drug is hydrophilic it will be encapsulated into 
the liposome, since the interior part is surrounded by hydrophilic head groups. On the 
other hand, if it is hydrophobic it will be inserted in or attached to hydrophobic bilayer 




Figure B.1. Liposomal drug delivery system. Various therapeutic drugs can be 
encapsulated inside the liposome, within its bilayers or conjugated to its surface 
depending on their hydrophobicity. Installing PEG on the surface of liposome delays its 
recognition by reticulum endothelial system (RES) and macrophages.  
B.2. Ligand functionalized liposome design 
Liposomes function as drug delivery vehicles by encapsulating the therapeutic 
drug in the interior, within their bilayers or attaching it on the bilayer membrane [8], [9], 
[10]. Liposomes can be made based on three models. In the first model the ligand is 
directly attached to phospholipid head group. But the problem with this model is the 
liposome will be uptaken by immune system easily and rapidly. Hence, the circulation 
time of such liposome is short [11]. The second model is similar to the first one except 
that PEGylated phospholipids are incorporated into the liposome to increase the liposome 
blood circulation time. However, steric occlusion could prevent the accessibility of the 
targeting ligand by the receptors expressed in the target tissue. In the third model, the 
ligand is attached to the distal end of PEG coating. This model is called “post insertion” 
















Figure B.2. Three different design of functionalized liposome. A) Ligands conjugated 
directly on phspholipid head group of non-PEGylated liposome. B) Ligands conjugated 
directly on phspholipid head group of PEGylated liposome. C) Ligands are conjugated on 
the free terminus of PEGylated chain [12]. 
In this project, I designed azithromycin decorated liposomes for lung tissue 
selective delivery of therapeutic agents (Figure B.3). Three phospholipid functionalized 
azithromycin analogues were synthesized to construct liposome in which targeting 
ligands are embedded in the PEG layer.  
A B C 
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Figure B.3. Three different designs of azithromycin functionalized phospholipid. 
 
Azithromycin is a 15 membered macrolide (Figure B.4). Which has been used 
widely for respiratory tract infection treatment, middle ear infection, sexually transmitted 
diseases and trachoma [13], [14], [15]. Compared to the 14 membered ring erythromycin, 
a macrolide originally isolated from Streptomyces Species [16], azithromycin is more 
chemically stable and better tolerated. Its high accumulation in cells and tissues 
specifically lung tissue results in 10-100 fold higher concentration compared to plasma.  
The high intracellular accumulation results in prolonged half-life, and more favorable 
regimen and shorter dosage schedule. Azithromycin, contains two basic amine groups, 
and relative to erythromycin, it has greater tissue penetration as well as higher potency 
against gram negative bacteria [17]. The anti-bacterial property of erythromycin class of 
macrolides is due to their reversible binding to the 50s subunit of the bacterial ribosome 
which results in inhibiting translocation and transpeptidation reaction [14], [18].   
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Figure B.4. Azithromycin structure, a FDA approved antibiotic for treating bacterial 
infection. 
Based on its lung tissue accumulation property, azithromycin could serve as 
ligand for lung targeted delivery of therapeutic agents.  It is therefore conceivable that 
liposomal formulations incorporating liposome-forming macrolides, derived from 
azithromycin (AZM) will generate a new class of nanocarriers that are selectively 
accumulated in the lung tissues [19].  
B.3. Chemistry and synthesis 
Toward obtaining liposomal formulation for lung tissue selective delivery of 
therapeutic agents, three different phospholipid functionalized azithromycins were 
synthesized. The short chain phospholipid functionalized azithromycin 5 was synthesized 
through conversion of amine group to azide by performing a diazotransfer reaction [13] 
followed by Cu (I) cycloaddition with N-ethynyl benzyl azithromycin 4 [14] (Scheme 
B.1).   
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Scheme B.1. (a) TEA, CuSO4, MeOH: H2O, rt, overnigh, 51%; (c) CuI, Hunig’s base, 
THF, rt, overnight, 39%.  
 
To synthesize the middle length liposome 7, a click reaction was performed 
between N-ehynyl benzyl azithromycin 4 and PEGylated phospholipid 6 (provided by 
Idris Raji) (Scheme B.2).  
 
 
Scheme B.2. CuI, Hunig’s base, THF, rt, overnight, 50%. 
 
To synthesize the long chain of azithromycin functionalized liposome, N-ehynyl 
benzyl azithromycin 4 was reacted with amine azide PEG 8 through CuI (I) cyclization 
reaction followed by nucleophilic reaction with commercially available NHS PEG 2000 
derivative 11 (Scheme B.3). 
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Scheme B.3. (a) CuI, Hunig’s base, THF, rt, Overnight, 30% ; (b) CH3Cl, rt, 24 h, 81%. 
B.4. Discussion and future studies  
The liposome-forming capability and macrophage uptake potential of these AZM 
–derived liposome-forming macrolides will be investigated in the future by another lab 
member. 
  
B.5. Material and Synthesis 
Azithromycin was purchased from Greenfield chemical. 4-ethynylbenzyl alcohol 
was purchased from Sigma-Aldrich. All commercially available starting materials were 
used without purification. Reaction solvents were high performance liquid 
chromatography (HPLC) grade or American Chemical Society (ACS) grade and used 
without purification. Analtech silica gel plates (60 F254) were used for analytical TLC, 
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and Analtech preparative TLC plates (UV 254, 2000 µm) were used for purification.  UV 
light and anisaldehyde/iodine stain were used to visualize the spots.  200-400 Mesh silica 
gel was used in column chromatography. Nuclear magnetic resonance (NMR) spectra 
were recorded on a Varian-Gemini 400 MHz or Bruker 500 MHz magnetic resonance 
spectrometer.  1H NMR Spectra were recorded in parts per million (ppm) relative to the 
residual peaks of CHCl3 (7.24 ppm) in CDCl3 or CHD2OD (4.78 ppm) in CD3OD or 
DMSO-d5 (2.49 ppm) in DMSO-d6. 
13C spectra were recorded relative to the central peak 
of the CDCl3 triplet (77.0 ppm) or CD3OD septet (49.3 ppm) or DMSO-d6 septet (39.7 
ppm) and were recorded with complete hetero-decoupling. Original ‘fid’ files were 
processed using MestReNova LITE (version 5.2.5-5780) program. High-resolution mass 
spectra were recorded at the Georgia Institute of Technology mass spectrometry facility 
in Atlanta.  
Compounds 4, and 8 were synthesized as described before [22], [23], [24], [25].  
B.5.1. 3-(((2-azidoethoxy)(hydroxy)phosphoryl)oxy)propane-1,2-diyl distearate (3) 
Triethyl amine (2 mL, 14.2 mmol) and catalytic amount of CuSO4. 5H2O were 
added to a suspension of compound 1 (218 mg, 0.3 mmol) in MeOH: H2O (4:1 mL). 
Freshly made trifluoromethanesulfonyl azide 2 (152.2 mg, 0.9 mmol) was added. The 
reaction mixture was allowed to stir overnight. The reaction mixture was concentrated 
and dissolved in EtOAc (60 mL) and organic layer was washed with 5% KHSO4 (5 mL) 
and brine (2×5 mL) brine solution and dried over Na2SO4. Crude product was purified 
sing preparative TLC (Silica gel, 4:1:0.1 DCM: MeOH: NH4OH) to yield product 3 (114 
mg, 51%). 1H NMR (400 MHz, CDCl3) δ 3.99 (s, 2H), 3.66 (s, 1H), 3.47 (s, 2H), 2.31 (d, 
J = 7.6 Hz, 2H), 1.59 (s, 2H), 1.25 (s, 64H), 0.87 (t, J = 6.7 Hz, 6H). 31P NMR (162 
MHz, CDCl3) δ -4.47.  
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B.5.2. (Azithromycin-4-(methylamino)-N(methyl)(4-benzyltriazolyl))- 
ethoxy)(hydroxy)phosphoryl)oxy)propane-1,2-diyl distearate (5) 
Compound 4 (113.8 mg, 0.1 mmol) and phospholipid 3 (114 mg, 0.1 mmol) were 
dissolved in anhydrous THF (10 mL) and stirred under argon at room temperature. 
Copper (I) iodide (12.8 mg, 0.07 mmol) and Hunig’s base (0.05 mL, 0.3 mmol) were 
added to the mixture and stirring continued for overnight.  A solution of 4:1 saturated 
NH4Cl/NH4OH (10 mL) was added to the reaction mixture and extracted with 20% 
MeOH/ CH2Cl2 (3×10 mL). The organic layer was dried over Na2SO4 and concentrated 
in vacuo. The crude product was purified by preparative chromatography (Silica gel, 
12:2:0.5 CHCl3: MeOH: NH4OH) to give the product (84.4 mg, 39%) as white solid. 
1H 
NMR (400 MHz, CDCl3) δ 8.55 (s, 1H), 7.91 – 7.68 (m, 2H), 7.30 – 7.08 (m, 2H), 4.45 – 
3.83 (m, 6H), 3.86 – 3.57 (m, 3H), 3.49 (dd, J = 27.0, 20.3 Hz, 2H), 2.88 (s, 3H), 2.44 – 
2.19 (m, 5H), 2.05 – 1.82 (m, 3H), 1.72 (d, J = 9.6 Hz, 3H), 1.63 – 1.50 (m, 5H), 1.48 – 
1.41 (m, 3H), 1.42 – 1.14 (m, 81H), 1.09 (d, J = 5.8 Hz, 6H), 1.06 – 0.95 (m, 5H), 0.97 – 
0.80 (m, 16H), 0.72 (dt, J = 15.0, 7.6 Hz, 3H). 31P NMR (162 MHz, CDCl3) δ -2.34. 
HRMS (MALDI) m/z Calcd. for C87 H156 O20 N5 P [M]: 12624.1.  
 
B.5.3. (Azithromycin-4-(methylamino)-N(methyl)(4-benzyltriazolyl))- octa ethylene 
glycol)(hydroxy)phosphoryl)oxy)propane-1,2-diyl distearate (7) 
Compound 4 (145.2 mg, 0.2 mmol) and phospholipid 6 (200 mg, 0.2 mmol) were 
dissolved in anhydrous THF (10 mL) and stirred under argon at room temperature. 
Copper (I) iodide (16 mg, 0.08 mmol) and Hunig’s base (0.06 mL, 0.3 mmol) were added 
to the mixture and stirring continued for overnight.  A solution of 4:1 saturated 
NH4Cl/NH4OH (10 mL) was added to the reaction mixture and extracted with 20% 
MeOH/ CH2Cl2 (3×10 mL). The organic layer was dried over Na2SO4 and concentrated 
in vacuo. The crude product was purified by preparative chromatography (Silica gel, 
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15:2:0.3 DCM: MeOH: NH4OH) to give the product (142 mg, 50%) as white solid. 
1H 
NMR (400 MHz, CDCl3) δ 8.04 (s, 1H), 7.81 (d, J = 6.9 Hz, 2H), 7.36 (s, 2H), 5.20 (s, 
1H), 4.96 (s, 1H), 4.74 (d, J = 6.7 Hz, 1H), 4.59 (t, J = 4.7 Hz, 2H), 4.43 – 4.26 (m, 2H), 
4.23 – 4.04 (m, 4H), 4.03 – 3.83 (m, 7H), 3.76 (s, 1H), 3.69 – 3.48 (m, 29H), 3.44 (d, J = 
27.0 Hz, 4H), 3.03 (s, 2H), 2.90 (d, J = 30.4 Hz, 6H), 2.65 (s, 2H), 2.24 (ddd, J = 33.5, 
18.2, 9.2 Hz, 9H), 1.80 (t, J = 24.1 Hz, 3H), 1.55 (s, 5H), 1.49 – 1.35 (m, 5H), 1.36 – 
1.15 (m, 67H), 1.15 – 1.05 (m, 6H), 0.98 (dd, J = 20.3, 7.2 Hz, 8H), 0.91 – 0.76 (m, 9H). 
31P NMR (162 MHz, MeOH) δ 0.08.  
 
B.5.4. (Azithromycin-4-(methylamino)-N(methyl)(4-benzyltriazolyl))- octa ethylene 
glycol amine (9) 
 Compound 4 (183.945.2 mg, 0.01 mmol) and azido octa ethylene glycol amine 8 (39 mg, 
0.01 mmol) were dissolved in anhydrous THF (5 mL) and stirred under argon at room 
temperature. Copper (I) iodide (9.4 mg, 0.05 mmol) and Hunig’s base (0.03 mL, 0.2 
mmol) were added to the mixture and stirring continued for overnight.  A solution of 4:1 
saturated NH4Cl/NH4OH (10 mL) was added to the reaction mixture and extracted with 
20% MeOH/ CH2Cl2 (3×10 mL). The organic layer was dried over Na2SO4 and 
concentrated in vacuo. The crude product was purified by preparative chromatography 
(Silica gel, 20:2:0.5 EtOAc: MeOH: NH4OH) to give the product (37 mg, 30%) as white 
solid. 1H NMR (400 MHz, cd3od) δ 7.77 (t, J = 10.2 Hz, 1H), 7.47 (d, J = 6.3 Hz, 2H), 
7.39 (s, 2H), 5.03 (d, J = 4.7 Hz, 2H), 4.88 (s, 28H), 4.58 – 4.48 (m, 3H), 4.18 (ddd, J = 
21.5, 13.9, 4.3 Hz, 5H), 3.89 – 3.76 (m, 7H), 3.36 – 3.26 (m, 7H), 3.22 (d, J = 5.6 Hz, 
5H), 3.01 (t, J = 7.9 Hz, 3H), 2.87 – 2.67 (m, 7H), 2.55 (d, J = 11.5 Hz, 2H), 2.35 – 2.27 
(m, 8H), 2.28 – 2.21 (m, 8H), 2.09 – 1.89 (m, 14H), 1.89 – 1.70 (m, 19H), 1.70 – 1.46 
(m, 26H), 1.38 – 1.31 (m, 9H), 1.30 – 1.21 (m, 18H), 1.22 – 1.15 (m, 15H), 1.13 – 1.02 
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(m, 19H), 0.96 – 0.87 (m, 13H). HRMS (ESI) m/z Calcd. C62 H111 O19 N6 [M+H
+]: 
1243.7899, found for 1243.7890. 
B.5.5. (Azithromycin-4-(methylamino)-N(methyl)(4-benzyltriazolyl)) PEG 2000 
phosphoryl)oxy)butane-1,2-diyl distearate (11) 
PEG 2000 10 (167.1 mg, 0.05 mmol) and compound 9 (76 mg, 0.06 mmol) were 
dissolved in chloroform (10 mL). The reaction was allowed to stir at rt for 24 h. The 
reaction mixture was then washed with brine (5 mL) and dried over Na2SO4. The crude 
product was purified on preparative TLC (10:1.2:0.5 DCM:MeOH:NH4OH) to yield the 
product as a white solid (185 mg, 81%). 1H NMR (400 MHz, MeOH) δ 8.42 (s, 1H), 7.83 
(d, J = 8.0 Hz, 2H), 7.49 (d, J = 8.0 Hz, 2H), 5.02 (d, J = 4.8 Hz, 1H), 4.64 (t, J = 4.9 Hz, 
2H), 4.54 (d, J = 7.1 Hz, 1H), 4.44 (dd, J = 11.9, 3.1 Hz, 1H), 4.20 – 4.08 (m, 4H), 3.96 
(dt, J = 7.8, 5.3 Hz, 4H), 3.87 (q, J = 5.4 Hz, 1H), 3.68 – 3.58 (m, 175H), 3.47 (ddd, J = 
20.6, 13.8, 8.6 Hz, 7H), 3.33 (ddd, J = 10.0, 6.5, 4.9 Hz, 7H), 3.23 (dd, J = 14.8, 7.9 Hz, 
2H), 3.19 (s, 3H), 3.03 (d, J = 9.4 Hz, 2H), 2.72 (s, 3H), 2.34 (dt, J = 15.1, 11.0 Hz, 7H), 
2.21 (dd, J = 14.5, 7.0 Hz, 4H), 1.86 (dt, J = 21.2, 10.8 Hz, 4H), 1.81 – 1.70 (m, 2H), 
1.57 (dd, J = 21.3, 6.4 Hz, 6H), 1.43 (s, 3H), 1.29 (s, 57H), 1.25 – 1.18 (m, 8H), 1.16 (d, 
J = 10.8 Hz, 6H), 1.08 (d, J = 7.4 Hz, 2H), 1.02 (d, J = 6.7 Hz, 3H), 0.90 (t, J = 6.8 Hz, 
8H). 
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